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malaria (moqeorio) n. an infectious disease characterized by recur­
ring attacks of chills and fever, caused by the bite of an anopheles 
mosquito infected with any of four protozoans of the genus Plasma- 
dium (P. vivax, P. falciparum, P. malariae, or P. ovale), [€18; from 
Italian mala aria bad air, from the belief that the disease was 
caused by the unwholesome a ir in swampy districts] —ma'Iarial, 
m a’larian , or m a’Iarious adj.
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Summary
Plasmodium species is transmitted between humans by the female 
anopheles mosquito. It kills 1.5-2.7 million people every year and 40% of 
humanity lives in an endemic area. Throughout time numerous attempts 
have been made to control the disease through natural remedies such as 
quinine (A) and artemisinin (B), synthetic drugs e.g. chloroquine (C), and 
also by the use of bed nets and insect repellents.
Polyamines such as putrescine (D), spermidine (E) and spermine (F) 
are naturally occurring and are widespread in nature. They have been 
shown to be important in fundamental processes such as cell proliferation 
and differentiation. The study of these compounds has led to the 
development of polyamine analogues to treat a wide range of diseases from 
cancer and parasitic diseases through to their use as anti-fungal agents.
We started work in this area when a simple putrescine analogue (G) 
was shown to have promising antimalarial activity and became the "lead" 
compound for this project.
Initially we synthesized a number of analogues of (G) varying the 
carbon chain and the substitution patterns on the nitrogens. We did not see 
any improvement in activity until a A/,/V-bisbenzyl compound was prepared; 
however in vivo results were disappointing. We decided to investigate 
analogues of higher polyamines as these had shown better activity than 
putrescine analogues by workers in the cancer field.
Surprisingly the spermidine analogues that were prepared showed 
little antimalarial activity, although separate tests showed them to have 
excellent anti-fungal properties. The spermine analogues synthesized were 
more promising with the bisbenzyl analogue (H) the most active in vitro so 
far.
It was known that the genome of P. falciparum is rich in adenine and 
thymine base pairs compared to the human host so we decided to study 
some AT specific binding agents to see if this improved the activity. We 
decided to incorporate the A/,A/-dimethylaminoethyl (I) and propioamidino (J) 
moieties into spermine analogues to see if antimalarial activity increased. 
These functional groups had been used previously in AT binding agents. No 
test data is available on these compounds.
A number of compounds were prepared and we observed increased 
activity as we added hydrophobic benzyl groups and also as we increased 
the number of nitrogens present to four, as in spermine analogues. This is in 
agreement with the hypothesis that DNA binding is related to the activity of 
the compounds which itself is controlled by the increased number of 
nitrogens in the compound. A number of compounds are still awaiting 
testing.
We have prepared a range of polyamines, both known and novel, and 
examined their antimalarial activity. Antimalarial testing was carried out by 
Prof. Stephen Phillips and Fiona McMonagle in the Division of infection and 
Immunity and antifungal tests by Dr Dale Walters and Caroline Macintosh at 
the Scottish Agricultural College, Auchincruive.
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1 Malaria
1.1 Public Enemy No1
The sun sets - the hunt for human blood begins.
Throughout the dark night the female Anopheles mosquito searches 
for a host. Blood is a necessity. She needs the protein for the development 
of her eggs which she will lay in a suitable warm, damp place. She enters as 
quiet as a burglar attracted by your warm body and the carbon dioxide you 
exhale. Only she is potentially deadly - she carries the malaria parasite and 
passes this cargo between victims infecting 300-500 million people each 
year.
Two needle like objects pierce your skin and a local anaesthetic is 
quickly applied by her saliva. As she searches for a vein two blades saw at 
your skin until the feed tube sucks your blood and she flies away laden with 
twice her weight in blood.
Behind her she leaves a deadly legacy. It kills 1.5-2.7 million people 
every year and 40% of humanity lives in an endemic area. This is by far the 
world's most important parasitic disease killing more people than any other 
communicable disease except tuberculosis.
Malaria kills one person every 12 seconds but what is it, how does it 
survive, what does it do and how may we combat it?
1.2 Malaria - A Potted History
Although it was a long time before the cause of malaria was 
understood its characteristic symptoms have been documented as far back 
as the ancient Egyptians followed by Hypocrates who first described the 
disease in detail. Herodotus (485-425 BC) noticed that in the swampy
regions of Egypt people often slept on raised platforms or under nets out of 
reach of the mosquitos and from these early times "miasma" or bad air ("mal 
aria") that emanated from these marshes became associated with this 
disease.1
Many ancient treatments for malaria have proven highly effective 
including an infusion of qinghaosu (Artemisia annua) used in China for over 
2000 years and recently the subject of much research since the active 
component Artemisinin was identified. An extract from the cinchona tree was 
first used successfully in Peru during the fifteenth century and its use was 
established in India, Ceylon and the East Indies during the nineteenth 
century. The active ingredient, quinine, was isolated in 1820 by the French 
chemist Pelletier and was thereafter widely used.
So for many years the disease was described and even treated but no 
one knew what caused it and how it was transmitted.
The crucial step came on 6th November 1880 when a French army 
surgeon Charles Louis Alphonse Laveran identified the malaria parasite in 
the blood of a patient infected with P. falciparum2 Unfortunately this was the 
world of Louis Pasteur, the "germ" was seen as the cause of all disease, and 
Laveran's observations were not readily accepted.
Throughout the last two decades of the nineteenth century came great 
advances in this field. An Italian Camillo Golgi identified two human 
malarias, P. vivax and P. malariae, and described the asexual multiplication 
of the parasite in the red blood cell. The recurrent fevers associated with 
malaria were also linked to this asexual reproductive stage.
The transmission of the disease still remained a mystery.
Patrick Manson, an eminent English physician, and the founder of 
tropical medicine in England, had discovered that mosquitos could suck up 
small threadlike worms and believed that maybe they could draw the malaria 
parasites from human blood. He began an association with Ronald Ross, a 
doctor in the Indian medical service, and together they planned a series of 
experiments. Ross was a lone and dedicated researcher despite his wish to 
be a poet or playwright rather than working in the army. He dissected 
mosquitos for two years under difficult circumstances; however he was 
unaware it was only the Anopheles mosquitos that transmitted the disease. 
At last, and by luck, the right mosquitos arrived and after feeding them on an 
infected patient he saw evidence of the parasite developing in the mosquito 
on 20th August 1897.2 This was the first link between the mosquito and 
transmission of malaria. On moving to Calcutta he started work on avian 
malaria parasites and proved that the infective stages of the parasite appear
in the salivary gland of the mosquito and were passed on when the mosquito 
bit its next victim. Ross was later awarded the second Nobel Prize for 
medicine. Throughout this time he continued to write poems, one of which 
he wrote soon after his discovery:
This day relenting God 
Hath placed within my hand 
A wondrous thing; and God 
Be praised. At His command’,
Seeking His secret deeds 
With tears and toiling breath,
I find thy cunning seeds,
O million-murdering death.
I know this little thing 
A myriad men will save.
O Death, where is thy sting?
Thy victory, O Grave?
A group of Italians were working on the same puzzle and this led to 
years of controversy between Ross and Giovanni, Battista and Grassi over 
who first traced the development of the malaria parasite in man. Discovery 
was rapid and by 1948 elucidation of the life cycle of the malaria parasite in 
man was complete (1.5). Unfortunately a number of speculations arose. For 
example it had been noted that Africans were often immune to malaria and in 
the Journal of Tropical Medicine, 1900, George Nuttal suggested it was "the 
offensive smell" of Africans that discouraged the mosquitos from 
approaching and biting them!
1.3 Transmission of Malaria
The malaria parasites are protozoa of the genus Plasmodium and 
these parasites are transmitted by the female Anopheles mosquito (Figure 
1). "The female of the species is more deadly than the male" and this is 
certainly true in this case as the humble male feeds only on plant juices and 
does not spread malaria. Out of a total of 380 species of anopheles 
mosquito only 60 can transmit malaria between human hosts and there are 
four generally recognized species of malaria parasite of humans: P. 
falciparum, P. vivax, P. ovale and P. malariae.2>3
4Figure 1 Anopheles gambiae - one of the most important vectors for the 
malaria parasite.
P. falciparum  is by far .the most lethal form of the parasite and 
accounts for the majority of fatalities. It is confined to the tropics and sub­
tropics as development of the parasite in the mosquito is retarded at 
temperatures less than 20°C. It kills more people in Africa alone than 
anything else.
P. v/Vaxw as once common in temperate countries, e.g. South 
England, but it is now found only in the sub-tropics. This leads to a form of 
malaria where relapses can occur months after initial infection. In some 
cases there are no symptoms associated with the primary infection and the 
first clinical symptoms are seen months after initial infection.
P. malariae is now relatively uncommon since its eradication from 
temperate climates. This parasite develops relatively slowly in both mosquito 
and human host, and has long persistence even though the level of 
parasitaemia is often low The main threat is the recrudescences which can 
occur up to 50 years later!
P. ovale is now found only in West Africa and is a rare form of the 
disease. It is similar to P. vivax, but with less chance of relapses and milder 
symptoms.
Malaria can also be transmitted by blood transfusions, contaminated 
needles and syringes and very occasionally from mother to baby during 
pregnancy.
1.4 Prevalence of Malaria
Systematic control of the disease started after the discoveries of 
Laveran and Ross and led to the idea of total eradication. This gained 
popularity after World War II when Malaria epidemics had ravaged areas of 
Southern Europe and the insecticide DDT (1) had proven effective in 
controlling them. Inexpensive and readily available chloroquine-based drugs 
were also synthesised in this period (1.7) 4>5
1955-1969 saw the launch of the WHO Global Eradication 
Programme aimed at spraying the inside of homes with this insecticide and 
led to success in large areas of North America, Southern Europe, the former 
Soviet Union and some areas of Asia and South America. Unfortunately 
results often varied and in most Asian countries, Latin America and Africa 
eradication on such a scale was never attempted. Epidemics occurred, 
notably in Sri Lanka in 1968 where malaria was thought to be eradicated, 
and the hope for global eradication was abandoned in 1969.3
Control is becoming more difficult as the spread of the disease is 
linked to activities such as road building, mining, new agricultural projects 
and logging particularly in regions such as the Amazon. Conditions where 
the mosquito eggs are laid such as swampy ground should be avoided. In 
other regions deteriorating social conditions, economic and political 
pressures lead to migration from non-endemic areas into endemic areas and 
the loss of health services only worsen the problem.
A Global Malaria Control Strategy was adopted in 1992 by the 
Ministerial Conference on Malaria in Amsterdam and its plans were updated 
in 1995.4 The overall goal is: "the prevention of mortality and the reduction 
of morbidity and social and economic loss due to malaria, through the 
progressive improvement and strengthening of focal and national capabilities 
for malaria control at national, district and community levels."
Within this stategy two main objectives are listed as: "that by the year 1997 
at least 90 % of the countries affected by malaria implement appropriate 
malaria control programmes."
Cl
1
"that by the year 2000 malaria mortality has been reduced by at least 20 % 
compared to 1995 in at least 75 % of affected countries."
Nowadays malaria is a health problem in 91 countries inhabited by 40 
% of the world's population. It kills one person every 12 seconds, mostly 
children under five years old. Eighty per cent of cases occur in tropical Africa 
and it is estimated that a bout of malaria costs the equivalent of ten working 
days-an estimated total of $1,800 million in 1995.
1.5 Life Cycle of the Malaria Parasite in the Human Host
The malaria parasite is a protozoum (Gr: prot - primitive; zoon - 
animal) which is a single celled animal. Despite this apparent simplicity the 
parasite has a complicated life cycle composed of three stages (Figure 2).2*
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1.5.1 The Liver: The Hiding Place of the Parasite
Whilst probing for blood the female mosquito releases, into the human 
skin, saliva containing sporozoites (Gr: spora - sowing) which quickly find 
their way to the liver and invade some liver cells. The cell nucleus divides 
many times until it forms one large schizont (Gr: schizein - to divide; on, 
ontos - being) containing thousands of new parasites. Increased pressure in 
the cell causes it to burst and release all the new parasites, merozoites (Gr: 
meros - part), which leave the liver and enter the circulating blood stream, 
where red blood cells rich in nutrients wait. This stage, known as the primary 
liver stage, usually takes 1-2 weeks, and the human host is unaware there is 
any infection as no symptoms are associated with this stage of the disease.
1.5.2 The Red Blood Cell: Erythrocytic Stage
The released merozoites must survive this brief extracellular situation 
until they invade the circulating red blood cells where they feed. They digest 
the host cytoplasm, i.e. haemoglobin, and grow into ring shaped trophozoites 
(Gr: trophe - nourishment) which eventually enlarge and lose the vacuolar 
appearance until they fill the whole cell. A cluster of 8-24 new parasites form 
and, as before, the cell bursts under increased pressure releasing them into 
the blood strearp. This is the asexual stage in the parasites' life cycle and it
repeats every 2-3 days, depending on the species, resulting in an ever 
increasing number of parasites in the human's blood stream.
1.5.3 The Mosquito: Sexual Life of a Parasite
Some merozoites grow in the red blood cell without dividing and 
transform into sexual cells called male and female gametocytes (Gr: gamete 
- wife; gametes - husband; kutos - cell) which are necessary for perpetuation 
of the parasite. These cells can only mature outside the human body and 
leave with the help of the mosquito as it takes a blood meal. Evolution has 
come up with a remarkable way of helping both parasite and mosquito - 9the 
parasite needs a host to reproduce and the mosquito needs protein from the 
blood to lay her eggs. Mature gametocytes are taken into the mid gut of the 
mosquito where they lose the red cell membrane, undergo gametogenesis, 
and are ready for fertilisation. Fertilisation occurs quickly and the nuclei fuse 
to form a zygote which grows and eventually moves to the outside wall of the 
mosquito's gut and secretes a cyst wall around itself. This oocyst grows and 
gives rise to millions of new sporozoites which migrate to the salivary gland 
and the cycle starts again.
1.6 Do you have Malaria?
It is the parasites in the blood which cause the illness associated with 
malaria and the severity of the attack is usually proportional to the number of 
red blood cells destroyed by the parasites. Symptoms occur 10-16 days 
after infection and the classical course involves shaking chills which are 
followed by high fevers, sweating and muscular pain. This similarity with 'flu 
often leads to mis-diagnosis and is a particular problem with travellers 
returning home from endemic regions. The spleen becomes enlarged and 
tender and anaemia develops as red cells are destroyed. This is especially 
dangerous in children and pregnant women. Other side effects may include 
jaundice, renal dysfunction and hypoglycaemia among others. The cycle of 
fever symptoms are associated with the asexual erythrocytic stage in the life 
cycle of the parasite which releases an estimated quarter of a billion 
parasites into the blood stream every 1-2 days (Figure 3).2> 4>6
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Figure 2 Life cycle of malaria parasite in the Anopheles mosquito and 
human host, including the site of action of antimalarial drugs.3
In P. falciparum parasitised cells can block vessels leading to 
haemorrhages and when they invade the brain they can lead to convulsions 
and cerebral malaria which is often fatal. Most of the deaths are in children 
less than 5 years old.
Stage of life cycle
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released
Merozoites
released
105 Mature
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schizont103
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24001200 2400120024002400 1200
1800 0600 06001800 18000600
Time (h)
Figure 3 Temperature chart of a patient with P. vivax2
However if humans survive they may build up immunity and many 
adults who live in endemic areas no longer show symptoms of the disease. 
Unfortunately effective immunity is quickly lost if you stop living in the 
malarious area. It is P. falciparum which accounts for the high mortality rate 
of this disease due in part to the high reproduction of the asexual stage of 
the parasite. Other human malarias are rarely fatal. However with P. vivax 
and P. ovale parasites can persist in the liver as dormant stages and later 
can start new cycles of reproduction in the blood. This persistent infection is 
the source of recurrent fevers and relapses that may occur months or years 
after the initial infection. P. falciparum and P. malariae only have a primary 
liver phase so if a chemotherapeutic regime is followed which eliminates 
parasites from the blood stream the patient will be cured.
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1.7 Coping with Malaria
Malaria is on the move. Areas previously free of this terror are once 
again in the front line. Natural immunity is very effective but this only builds 
up as a result of high and prolonged exposure and does not address the 
problem of high morbidity and mortality in children under 5 years of age, the 
main risk group in Africa. A number of possible strategies can be 
considered:
1. Chemoprophylaxis
2. Affordable and effective treatment of the disease
3. Influencing the vector
4. Prevention of insect bites.7
Tropical disease has been hit badly in recent years by the 
pharmaceutical mergers. The fewer companies now competing concentrate 
on more profitable areas. Indeed the number of companies researching in 
tropical medicine can be counted on one hand. Spending on cancer 
research in the UK alone is twice that spent on malaria world-wide.5
1.7.1 Chemotherapy - Preventative and Curative
Chemotherapy has traditionally played an important role in the 
treatment of malaria, with many synthetic and naturally occurring compounds 
being used to treat infected patients. Prophylactic drugs reduce the 
incidence of malaria and if the patient does get an attack it is likely to be less 
severe. In most countries where P. falciparum is endemic there is a varying 
problem of resistance to a large number of well established and often-used 
drugs. A drug may be put to several uses both curative and prophylactic, 
with its efficacy determined by factors such as: species of parasite; drug 
sensitivity; partial immunity of the patient and side effects.8' 9>10
Anti-malarials are classed according to the stage in the parasites' life 
cycle which they attack.8 Although some have a specific mode of action 
many can be classed in more than one category (Figure 2).
1. Tissue schizontocides inhibit growth of the pre-erythrocytic stages of the 
parasite in the liver cell. The less toxic members of this family, e.g. 
proguanil, are used alone or in combination as prophylactics.
2. Hypnozoitocides kill the dormant liver stages, e.g. primaquine, and are 
used as anti-relapse drugs for P. vivax and P. ovale. It is only the 8- 
aminoquinolines which are effective in man.
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3. Blood schizontocides act rapidly on the erythrocytic stage and are 
generally used for treatment, e.g. chloroquine. The less toxic members of 
this family are also used as prophylactics.
4. Gametocytocides destroy sexual stages of parasite in the blood, e.g. 
primaquine.
5. Sporontocides inhibit development of the oocysts and therefore the 
formation of sporozoites in the mosquito, e.g. pyrimethamine and proguanil.
Chloroquine
Chloroquine (2) has been the most popular drug for chemotherapy 
and prophylaxis of malaria since it was introduced in the mid 1940s. It is 
cheap, safe, widely available and highly effective against all asexual blood 
stages of the four Plasmodium - the classic characteristics of a successful 
drug. It is used as a prophylactic and also for treatment; and is sold as the 
diphosphate salt of the racemic mixture. Unfortunately resistance (7.1.2) by 
P. falciparum to chloroquine has increased over the last 30 years and the 
effectiveness of this drug has diminished. In many areas, especially in Africa, 
other drugs are now recommended.
Chloroquine is a blood schizontocide and acts on the intraerythrocytic 
stage of the life cycle. Plasmodium multiplies by digesting haemoglobin 
which then discards haem. Haem is toxic to the parasite and is normally 
eliminated as haemozoin (an insoluble pigment) by oxidative polymerisation. 
Chloroquine and related antimalarials interrupt this process in some way to 
produce a toxic substance which kills the parasite (Figure 4).11»12
Proteins and DNA 
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Plasmodium 
within red blood cell
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toxic to Plasmodium Haeme polymerase
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Figure 4 Metabolism of haem by the malaria parasite.12
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Hoffmann-LaRoche have recently studied chloroquine analogues with 
shorter side chains that retain their activity against chloroquine resistant P. 
falciparum.13
Quinine. Quinidine
The use of quinine (3) is well established since its effectiveness was 
noted by colonials in India taking gin and tonic water, which contains quinine. 
Both quinine and its diastereoisomer quinidine (4) are members of the 
cinchona alkaloid family, derived from the bark of the cinchona tree of South 
America and have been used for centuries.14 Quinine is still regarded as 
one of the best drugs for termination of acute attacks in non-immune 
individuals with chloroquine-resistant malaria, but is not used for prophylactic 
use due to its high toxicity. Quinidine may be superior to quinine for drug 
resistant infections although both have their use limited due to their 
cardiotoxicity. Quinine and quinidine are blood schizontocides and inhibit 
haem polymerase in a manner similar to chloroquine.15
Mefloquine
Mefloquine (Lariam™) (5) was developed by the US Army to prevent 
chloroquine-resistant malaria encountered during the Vietnam War. 
Mefloquine is a 4-quinolinemethanol derivative that is extremely well 
absorbed by the gastrointestinal tract and acts as a blood schizontocide. It is 
usually sold as the 1RS, 2'SR erythro mixture; however studies have shown 
that the 1S, 2R is the most potent form.lt is active against chloroquine
8S, 9R 3 
8R, 9S 4 2
CF3
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resistant parasites and is used as a single entity or in combination with other 
drugs, although for prophylactic use it tends to be used on its own. In recent 
months controversy has surrounded the use of this drug due to reported 
undesirable side effects. Hoffman-LaRoche say side effects including 
psycho-neurotic disorders may occur in 1:10000 cases. However recent 
evidence suggests figures more like 1:140. WHO tried to restrict the use of 
mefloquine to treating multiresistant falciparum malaria. However the fact 
remains this is now the prophylactic drug of choice in a number of areas, e.g. 
Africa.16* 17. 18
Halofantrine
Halofantrine (6) is an orally administered blood schizontocide active 
against chloroquine-resistant and chloroquine-sensitive malaria, although it 
may not be effective on P. falciparum resistant to mefloquine. It is a 
phenanthrenemethanol derivative related to mefloquine and quinine and is 
sold as the racemic mixture of the hydrochloride salt. However it suffers 
from poor absorption from the gut and high cost as well as possible cardiac 
toxicity. It has no place as a prophylactic. Its use is limited to areas where 
resistance to chloroquine and sulfonamide-pyrimethamine combinations is 
established and hopefully this will extend the useful life of this drug.19- 20
Sulfonamide-pyrimethamine combinations
Combinations of such drugs act at different points along the folate 
metabolism pathway which increase their effectiveness. Pyrimethamine (7) is 
an inhibitor of dihydrofolate reductase (DHFR), the enzyme which catalyses 
the reduction of dihydrofolate to tetrahydrofolate. Unfortunately in P. 
falciparum the gene for DHFR mutates leading to resistance. Sulphadoxine 
(8) inhibits dihydropteroate synthase preventing the incorporation of p- 
aminobenzoic acid into a precursor to dihydrofolate. Marketed as 
Fansidar™ this combination is too slowly-acting to cure acute attacks and is 
often used intramuscularly with quinine to treat uncomplicated P.falciparum 
cases in chloroquine-resistant areas. It has the benefit of being cheap and is 
highly effective in much of Africa and Indochina.
Proguanil
Proguanil (Paludrine™) (9) is a prodrug and its active metabolite is a 
triazine, cycloguanil. It is an antifolate which inhibits DHFR. It was 
developed by the British and Australian scientists during World War II and
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when given in proper doses has no side effects. Although it rapidly lost its 
ability to be useful in treatment, due to resistance, it is still used as a 
prophylactic. It kills the liver stages of the parasite and therefore prevents 
blood infection from occurring and also acts as a slow schizontocide. 
Proguanil now tends to be used in combination with chloroquine for 
prophylaxis.21
Primaquine
Primaquine (10) is an 8-aminoquinoline and is currently the only 
available drug that kills the latent liver stages of P. vivax and P. ovate. It is 
sold as the diphosphate salt as a racemic mixture. It is believed to be 
converted into an active quinone metabolite in the liver and is also an active 
gametocytocidal drug for P. falciparum.22
Antibiotics
Tetracyclines were investigated in the 1950s as potential antimalarial 
drugs with little success, but due to the resistance to some drugs their use 
was reappraised. They are slow blood schizontocides and are administered 
with a faster acting blood schizontocide, e.g. quinine. Doxycycline (11) is 
used as a prophylactic in S. E. Asia. However it does have side effects 
including sun-sensitisation. It does not eliminate the hypnozoite phases of 
relapsing malaria and primaquine must be given to eradicate this.
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Artemisinin (Qinghaosu)
Artemisinin (12) is a 15-carbon lactone peroxide, which is naturally 
occurring, and structurally unrelated to all other antimalarials. It was isolated 
in 1972 from Artemisia annua, a plant used traditionally by the Chinese since 
340 AD for the treatment of fever.
Artemisinin shows no cross resistance with known anti-malarials and 
is used for treating severe malaria although it does need long treatment 
courses. It is available as the parent compound and also three semi­
synthetic derivatives: hemisuccinate salt (13) (water soluble), crystalline 10(3- 
artemether (14) (oil soluble) and crystalline 10p-arteether (15) (10a is an oil). 
All three are blood schizontocides and are metabolised to dihydroartemisinin 
which is believed to be an active metabolite. These derivatives have greater 
potency and stability but are more expensive. Artemisinin is used as a 
suppository, artemether is introduced by intramuscular injection and 
artesunate (13) is used both intramuscularly and intravenously. None of 
these compounds are licensed in Europe or the USA although there is 
intense interest in this area.12>23
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1.7.2 Drug Resistance
Drug resistance is a major problem. It is not restricted to chloroquine 
but has been described for inhibitors of folate biosynthesis and more recently 
other important antimalarials including quinine, mefloquine and amodiaquine. 
Cross resistance within all these aminoquinolines is particularly worrying as 
the world depends on them for prophylaxis and treatment.
There are at least two possible mechanisms of drug resistance in 
malaria. First, resistance to inhibitors of folate metabolism which results from 
specific point mutations of the active site on the dihydroreductase enzyme. 
This resistance has spread independently and arose quickly after the 
introduction of such drugs. The second form is resistance to chloroquine
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which is likely to involve more than one gene. It is known that chloroquine 
acts by inhibiting haem polymerase (1.7.1) and it is suggested that the 
mechanism of resistance is not associated with this, but rather alterations in 
drug transport.24- 25>26
As a weak base chloroquine accumulates rapidly in the acid food 
vacuole of the parasite and it appears that in chloroquine-resistant parasites 
less drug is accumulated and/or there is an increase in efflux of the drug out 
of the parasite. Verapamil, a calcium channel blocker, has been shown to 
reverse chloroquine resistance although quite how this works is not fully 
understood. One thing for sure is resistance to aminoquinolines is increasing 
and elucidating the mechanism of action is high on many biologists' 
agendas.27
1.7.3 Vaccines - Present and Future Prospects.
The issue of vaccine development is extremely wide ranging and 
complex and as such this thesis is not the place for a review; however a 
number of the key issues will be covered, in brief.
Residents of malaria endemic areas acquire protective immunity to 
malaria and the number of clinical episodes declines with increasing age. 
The idea is that a vaccine could mimic this process and in the 1960s the 
British scientists Sydney Cohen and Sir Ian McGregor discovered that 
antibodies from such individuals could reduce parasitaemia and clear the 
symptoms. Each stage of the life cycle has different antigens that lead to 
protective immunity. This area is extremely exciting and is generating a lot of 
financial support. Any vaccine must be easily incorporated into the health 
programme and give immunity of sufficient duration.28
One of the first approaches was injecting sporozoites from irradiated 
mosquitos into human volunteers. However this required long exposure 
times and was impractical. Instead sporozoite proteins were targeted hoping 
they would reproduce the effect of the whole sporozoite. In the 1980s a 
gene coding for a sporozoite protein was cloned although vaccines based on 
this failed in field trails. Pre-erythrocytic vaccines target the sporozoites or 
the forms in the liver cells. This is ideal as they remain in the cells for 
several days, although this approach has many problems with the actual 
vaccine design. All sporozoite vaccines which have undergone trials have 
had poor results although the latest offering from Smith Kline Beecham and 
the US Army is exciting as they are given together with compounds that 
stimulate the immune system.5
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Anti-asexual vaccines target antigens expressed on the surface of the 
red blood cell by the parasites inside. One of the most studied vaccines is 
based on a surface protein of merozoites and is promising as the protein 
sequence has no variations. Hopes for a vaccine in this area were raised by 
Manuel Patarroyo, a Colombian biochemist with trials of SPf66. Design of 
his trials has been criticised. There have been contradictory results including 
one that shows that the vaccine has no effect. Trials are still continuing.
Transmission-blocking vaccines interrupt development of the gametes 
in the mosquito and are aimed at reducing transmission rather than 
protecting individuals. A yeast-derived polypeptide is likely to undergo trials 
in the near future although in the long term it will probably be used together 
with erythrocytic or pre-erythrocytic stage vaccines.
One of the major controversies in the use of vaccines is that 
decreased transmission is likely to lead to decreasing natural immunity and 
any breakdown in the vaccines would lead the way for massive epidemics. 
Malaria parasites are also diverse and can evolve rapidly, especially if the 
vaccine is based on a single antigenic peptide.
1.7.4 Transgenic Mosquitos
Rather than eradication of the mosquito which has been proven in the 
past to be nearly impossible, why not influence the vector directly? The idea 
is to construct a transgenic which is incapable of transmitting the disease 
and as such can spread natural resistant genes through the wild population. 
Such genes are currently being studied and a number of scientists are 
collaborating to map the mosquito genome.
Another approach is to engineer the insects so that they carry foreign 
genes that confer protection against infection. One researcher at the 
Liverpool School of Tropical Medicine has cloned a mammalian antibody that 
attacks an antigen during the ookinete phase of the parasite in the mosquito. 
Researchers are optimistic that genetically engineered mosquitos will be 
released into the wild and will spread rapidly through the population.5' 29
1.7.5 Prevention of the Bite.
For many years people have known the benefits of protecting 
themselves from the mosquito. Amongst the most effective methods are the 
use of window and door screens made of small mesh and the mosquito bed- 
net. The netting should be stiff cotton to allow movement and rectangular to
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prevent the skin touching it. The Anopheles attack between dusk and dawn 
so adequate prevention is essential when you are asleep. Pyrethrin 
insecticides kill mosquitos instantly so soaking your bed-net and spraying the 
room with an appropriate solution also helps. Studies have shown this to 
reduce childhood mortality by 15-35%. Some scientists argue that the use of 
such methods will reduce the natural immunity of the population and lead to 
an eventual increase in mortality.4
The most basic precautions such as mosquito repellent will also help. 
Natural oils such as citronella and eucalyptus have been used; however 
these are short lived and have been replaced by synthetic compounds. N,N- 
Diethyl-m-toluamide (DEET) is one of the newer compounds that is an 
excellent repellent and is active for 10 hours. When pitching a tent choose 
an appropriate place away from possible breeding places, e.g. not near 
damp swampy areas. Wearing beige and yellow long-sleeved clothes and 
trousers after dark is highly effective but the scent of perfume attracts the 
mosquito.3
Different strategies are required for different situations, e.g. urban 
areas are not as high a risk as the African savanna. Altogether a number of 
simple and cheap options are available to help prevent "the bite". Control 
depends on elimination of the insect vector by destruction of its breeding 
areas, killing the larval stages and the adult mosquitos. This is not easy. 
What is now needed is political will and well-managed resources both at 
international level and also within the small communities where the risk is 
highest.
1.8 Summary
Malaria is obviously an extremely complex and problematic disease 
and for thousands of years people have treated it without knowing exactly 
what it was. Synthetic compounds and natural remedies have been used 
and in today's age of genetic engineering transgenic mosquitos are also a 
possibility to control this disease. Polyamines have been investigated as 
therapy for a number of diseases, including malaria. In the next chapter 
aspects of polyamines will be discussed including their biosynthesis and their 
many chemotherapeutic uses.
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2 Polyamines
2.1 Introduction
How can compounds so ubiquitous in nature merit so little attention? 
This was definitely true until the 1960s when research in this challenging 
area took off and an explosion of literature began to be published.
In 1677 Anton von Leeuwenhoek first observed an unknown 
crystalline substance, under his microscope, in a sample of human semen. It 
took a further 250 years to identify it as spermine phosphate and shortly 
afterwards spermidine was also identified. Putrescine (16) and cadaverine 
(17) were discovered in the carcasses of rotting animals and that completed 
this group of simple aliphatic structures.30
Putrescine, spemidine (18) and spermine (19) are all found in 
eukaryotic organisms and have been found to be essential for cell growth 
and differentiation. It is their importance in such fundamental processes that 
stimulated research in this area.31> 32 The pattern of changes of polyamine 
content in the cell were related to proliferative processes with a correlation 
between polyamines, protein synthesis and RNA content. Differentiation can 
be induced in certain systems by inhibition of polyamine biosynthesis;
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spermidine is an essential requirement for milk protein synthesis, a 
differentiated function.33
Conformationally mobile polyamines can associate with polyanionic 
molecules such as DNA, RNA and phospholipids.30- 34 This interaction can 
stabilise polynucleotides against denaturation and can also exert a strong 
influence on the secondary and tertiary structure of such molecules. Direct 
in vitro effects of polyamines have been studied and they can affect DNA, 
RNA and thus protein synthesis. The binding is electrostatic although some 
scientists believe that the polyamines interact in the minor groove of DNA by 
hydrogen bonding with the edges of the base pairs rather then the phosphate 
backbone (2.7).35
It is worth noting that not only do polyamines exist as these small 
simple compounds but they may often be found conjugated to sugars, 
phospholipids, peptides and plant alkaloids. This provides an array of 
compounds with wide-ranging uses and a staggering variety of complex 
carbon-nitrogen backbones. Kukoamine A (20) is a spermine derivative 
which exerts a powerful antihypertensive activity and oncinotine (21) is a 
macrocyclic lactam with a spermidine backbone. Cytotoxic agent (22) was 
extracted from coral reef Sinularia brongersmai in 1979 and was the first 
spermidine metabolite discovered in a marine organism.30
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2.2 Polyamines: Formation and Degradation
2.2.1 Biosynthesis
Polyamines are distinct from metal ions whose circulation depends on 
diffusion or transport to pass through cell membranes. Polyamine levels are 
controlled carefully and precisely according to cell needs. Collective effects 
from the biosynthetic pathway, a catabolic pathway and an uptake 
mechanism combine to keep the intracellular levels of these compounds 
within fairly tight restraints.36- 37
In mammalian cells, protozoa, and fungi, the first step in polyamine 
biosynthesis is decarboxylation of ornithine to putrescine, using an enzyme, 
ornithine decarboxylase (ODC).39 Higher polyamines such as spermidine 
and spermine are formed by the successive addition of aminopropyl groups 
and this is catalysed by the aminopropyl transferases. S - 
Adenosylmethionine (23) (AdoMet) is converted into decarboxylated S- 
adenosylmethionine, which contains the desired three carbon chain, by the 
enzyme S-adenosylmethionine decarboxylase (AdoMetDC) and the 
aminopropyl group is then transferred.31- 32- 34- 38 The other product of the 
aminopropyl transferase reaction is 5'-methylthioadenosine (MTA) produced 
in stoichiometric amounts with the polyamines. It is rapidly degraded to 
adenine and 5'-methylthioribose-1-phosphate by a phosphorylase enzyme. 
5'-Methylthioribose-1-phosphate is converted back into methionine and 
adenine goes to the nucleotide pool (Scheme 1).33
In plants and some fungi putrescine can also be formed indirectly from 
arginine. This route utilises arginine decarboxylase (ADC) to give agmatine 
which is converted into A/-carbamoylputrescine by agmatine 
iminohydrolase.40 The last stage is conversion into putrescine via the 
enzyme A/-carbamoylputrescine amidohydrolase. The simple diamine 
cadaverine is formed by decarboxylation of lysine which in plants is 
catalysed by lysine decarboxylase, but in animal cells ODC is used, albeit 
inefficiently.34- 38
ODC is an enzyme with a known turnover, t -|/2 15-20 min, which is the 
shortest t-1/2 of any mammalian enzyme studied so far.33 All ODC enzymes 
identified require pyridoxal-5'-phosphate (PLP) for activity and show high 
selectivity for /.-ornithine as a substrate 41 PLP is the co-factor for ODC and 
probably sits in a "pocket" of the enzyme where ornithine can approach and 
be decarboxylated.
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It is worth noting that PLP cofactor decarboxylates ornithine with retention of 
configuration, i.e. the new hydrogen atom Hz has the same stereochemical 
orientation as the leaving carboxyl group. PLP is shown here linked to a 
lysine residue of the apoenzyme (24).
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Scheme 2 Decarboxylation of ornithine to putrescine
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As soon as a substrate appears the lysine detaches and leaves an 
aldehyde which quickly forms a Schiff base adduct with the a-amino group of 
ornithine (25) and the carboxyl group leaves in an irreversible reaction. The 
intermediate is stabilised by conjugation and protonation occurs to form an 
imine which hydrolyses to the product putrescine. The original PLP-lysine 
apoenzyme is regenerated (Scheme 2).32» 38 Mammalian AdoMetDC has a 
pyruvate residue covalently linked to the enzyme as a prosthetic group.33
2.2.2 Catabolism
The main enzymes critical to the breakdown of polyamines in 
mammalian cells are A/1-acetyltransferases and polyamine oxidases. 
Spermine and spermidine are converted into A/1-acetylspermine and N1- 
acetylspermidine respectively by spermine/spermidine-A/1 -acetyl transferase 
(SSAT) in the presence of acetyl-CoA and the products are excellent 
substrates for polyamine oxidase (PAO). The PAO breaks down the 
substrates into A/-acetylpropionaldehyde and spermidine or putrescine 
depending on the substrate. Putrescine is degraded in two ways: oxidative 
deamination catalysed by PAO or via A/-acetylputrescine. The final product 
is y-aminobutyraldehyde which is cyclised to A1-pyrroline (Scheme 3).33
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2.2.3 Polyamine Transport Apparatus
If the biosynthetic pathway to polyamines breaks down or is inhibited 
by chemotherapy how will the cell sustain normal growth? The cell has a 
mechanism it can start up which will ensure polyamine pools are maintained 
by scavenging exogenous polyamines and bringing them into the cell. To 
avoid toxicity it is also possible to down-regulate this mechanism in response 
to a flood of extra polyamines.36
The mammalian transport system is believed to be protein in nature 
and highly specific for polyamines and it can be affected by a variety of 
agents including protein kinase C inhibitors. As well as moving polyamines 
the system can also carry synthetic compounds such as the herbicide 
paraquat and polyamine analogues. It has also been utilised to transport 
established therapeutic moieties into the cell where their site of action is and 
hence increase their potency (2.5.3).
Recent work on regulation of the polyamine transport system has 
shown that lowering polyamine pools through biosynthesis inhibition will lead 
to an increase in polyamine uptake. This occurs rather slowly and in 
conjunction with polyamine depletion. Exogeneously supplied polyamines 
and/or polyamine analogues are capable of down-regulating the transport 
system. In contrast to the above response this is very sensitive and occurs 
rapidly resulting in only minor changes in the intracellular polyamine pools.36
2.3 Polyamine Inhibitors
The ubiquitous occurrence of polyamines and their association with 
nucleic acids heralded a considerable amount of research into specific 
inhibition of polyamine biosynthetic enzymes. A decrease in the polyamine 
pool causes a response from the two main controlling enzymes in the 
biosynthetic pathway: ODC and AdoMetDC. A brief consideration of early 
developments in this field will be considered, followed by advances made in 
individual therapeutic areas.
2.3.1 Ornithine Decarboxylase (ODC) Inhibitors
ODC is one of the most highly regulated enzymes in eukaryotic 
organisms.34 The first paper dealing with ODC inhibition appeared in 197242
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and since then three main approaches for the development of inhibitors have 
been considered.
1. Synthesis of ornithine and putrescine analogues as competitive 
inhibitors.
2. Synthesis of compounds capable of interacting with the PLP co­
factor.
3. Design of enzyme activated inhibitors.
The first two approaches are concerned with competitive/reversible 
inhibition of the enzyme and in the third approach irreversible inhibitors are 
designed.38
1. Analogues of ornithine and putrescine.
a-Methylornithine (26) was one of the first reversible inhibitors 
reported. Decarboxylation occurred 6000 times slower than ornithine and a 
gradual decrease in activity of ODC was observed.43- 44 (E)- 
Dehydroputrescine analogues, a-hydrazinoornithine (27) and 1-aminooxy-4- 
aminobutane (28a) all had inhibitory effects but were not potent enough to 
decrease intracellular spemidine significantly. These compounds often had 
problems with selectivity and increased the t i /2  of ODC when tested in 
wVo.31 > 34 >48
NHNH
28b n=2
2. Reversible inhibitors that interact with PLP.
The first step of interaction with the PLP co-factor is formation of the 
Schiff base. A variety of substrates could be envisaged that would replace 
the natural substrate and form a stable adduct with PLP hence inhibiting the 
enzyme. It is thought that the inhibitory effects of such compounds occur as 
they mimic transition states along the reaction pathway. 1-Aminooxy-3- 
aminopropane (28b) was shown to be an extremely potent inhibitor of mouse 
kidney ODC and rat liver ODC; however it also inactivated AdoMetDC and 
spemidine synthase showing a lack of the desired specificity. More recent 
work in this area by Khomutov et al. has looked at more analogues of (28).32 
a-Hydrazinoornithine as described above also had the same problems with 
selectivity.46-47
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A main problem with reversible inhibitors is lack of activity in vivo 
compared to promising in vitro results. They also appear to increase levels 
of ODC. When the inhibitor is metabolised and its concentration drops the 
enzyme is reactivated and putrescine production goes through the roof. The 
focus turned towards irreversible inhibitors.
3. Irreversible inhibition of ODC.
This area involves the design of a chemically inert pseudo-substrate 
that contains a functional group that will eventually be transformed to leave a 
species that inactivates the enzyme. PLP enzymes are good targets for this 
approach and should lead to selectivity in vivo. A huge amount of manpower 
was spent working in this area by scientists at Merrell Dow 43> 48 This led to 
the development of a-difluoromethylornithine (DFMO) (29) which became a 
drug tested on almost every disease. The chemotherapeutic uses of DFMO 
will be discussed in detail later (2.6). DFMO acts by binding to the enzyme 
and then decarboxylation occurrs. The enzyme is inactivated by alkylation of 
a postulated nucleophilic residue at or close to the active site.33 Both 
enantiomers of DFMO have been shown to inhibit mammalian ODC, 
although (-)-DFMO (33) is the more active enantiomer49
Although DFMO is nontoxic it needs to be given in large doses and 
more longer acting and potent inhibitors were sought. Numerous ornithine 
and putrescine analogues were prepared. To summarise a lot of work in this 
area, for ornithine analogues an increase in the size of the leaving group on 
the a-methyl substituent reduced activity and the most active analogues 
contained an a-fluorinated methyl or acetylenic group. The vinylic analogue 
was inactive in vitro. Introduction of a 3,4-fra/is-double bond increased the 
activity of DFMO and a-fluoromethylornithine (MFMO) (30) and this led to 
two new compounds (Ej-3,4-dehydro-(a-difluoromethyl)-ornithine (31) and 
(Ej-3,4-dehydro-(a-fluoromethyl)-ornithine (32). Similar results were found 
with comparable putrescine analogues although when tested in vivo they 
were converted into y-aminobutyric acid (GABA) analogues, hence blocking 
GABA transaminase, which was undesirable. One problem of such 
analogues was oxidation of the terminal amino group by amine oxidases. 
This was overcome by synthesising analogues with 6-methyl substituents 
such as 6-methylacetylenicputrescine (MAP). MAP is a mixture of four 
diastereoisomers but studies showed that the R,E-isomer (34) was  
responsible for most of the a c t i v i t y . 3 1 ' 50
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In vivo studies showed that none of the new analogues was superior 
to DFMO but A-MFMO when given as its methyl ester (which is inactive in 
vitro) has promising activity against parasites and is also being
investigated.
2.3.2 S-Adenosylmethionine Inhibition
Due to the rapid turnover of this enzyme effective inhibition is not a 
simple task. Almost all inhibitors of AdoMetDC contain a 
bis(guanylhydrazone) moiety and methylglyoxalbis(guanylhydrazone) MGBG 
(35) was the first inhibitor of polyamine biosynthesis to be discovered. It is 
an extremely potent inhibitor, however it causes massive damage to 
mitochondria and inhibits respiration.34 Substitution at C-4 has a major 
effect on the inhibition of AdoMetDC with an ethyl substituent producing a 
more potent analogue (EGBG). Figure 5 shows the structure-activity 
relationship for MGBG. The length of the molecule (A) is critical for utilisation 
of the polyamine carrier system and the aminoguanidine portions (B) are 
responsible for inhibiting the action of diamine oxidase. These analogues 
also stimulate ODC, maybe due to stabilisation of the enzyme protein against 
intracellular degradation. This is a problem with all these types of inhibition 
as deactivating one enzyme sets off compensatory measures in another.51
NH Me
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Figure 5 Structure-activity relationships of MGBG
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One compound which has proven successful in inhibiting only 
AdoMetDC is 6-spermyne. Initial activity of both ODC and AdometDc 
decreased over 2 hours then the level of ODC activity recovered to normal 
levels over 48 hours. The AdoMetDC enzyme remained suppressed, 
presumably acting through a regulatory mechanism inherent to the 
biosynthetic pathway. This result suggests that the two enzymes, so closely 
related, are regulated through two distinct mechanisms.52
2.3.3 Inhibitors of the Spermidine/Spermine A/1-Acetyltransferases 
(SSAT)
Cyclohexylamine is one of the most powerful inhibitors of spermidine 
synthase in mammals, trypanosomes, plants and some bacteria. 
Cyclohexylamine is rapidly taken up by mammalian cells and leads to rapid 
depletion in spermidine levels, although no information is available on its 
affect on other biosynthetic enzymes. Further investigations led to S- 
adenosyl-1,8-diamino-3-thiooctane being identified as a powerful inhibitor.34 
It is extremely effective on spermidine synthase from many sources but has 
no effect on spermine synthase. The structural requirements for the active 
site of SSAT have not been examined in detail; however a free aminopropyl 
is essential for a compound to be a substrate. This is easily proven as 
spermidine and spermine are substrates whereas A/1-acetylspermidine and 
A/1-acetylspermine are not.53 It has also been shown that SSAT has a 
greater affinity for H2 N(CH2 )3 NH(CH2 )3 NH(CH2 )3 NH2 (denoted 3,3,3) and 
H2 N(CH2 )3 NH(CH2 )4 NH(CH2 )3 NH2 (denoted 3,4,3) carbon chains than 
H2N(CH2)3 NH(CH2)4 N H 2 (denoted 3,4) or H2 N(CH2 )3 NH(CH2)3 NH2 
(denoted 3,3).54 It is thought that in some cases the ability to superinduce 
SSAT leads to the growth inhibitory properties of a compound (2.4)
2.3.4 Arginine Decarboxylase (ADC) Inhibitors.
Due to the related mechanism of PLP dependent decarboxylases a 
similar approach to ODC inhibition was used for ADC. A range of a- 
fluoromethyl analogues of arginine were prepared and were excellent 
inhibitors of bacterial ADC. One inhibitor, a-difluoromethylarginine (DFMA), 
was used in studies of putrescine biosynthesis. It was discovered that DFMA 
is metabolised to DFMO by arginase and it is DFMO that is thought to be the 
active inhibitor.34
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2.4 Polyamines as Potential Anti-fungal Agents
Plants are attacked by a wide range of fungi which cause 
considerable loss of crops and the economic consequences that go with this. 
There is constant need for the development of novel fungicides with new 
modes of action and in today's world they must be environmentally friendly!
In fungi the major polyamine is spermidine with putrescine and 
spermine present in less than 10% the quantities of spermidine. Little was 
known about the role of polyamines in pathogenic fungi; however research 
was sparked off as the realisation dawned that a specific inhibitor of 
polyamine biosynthesis can lead to powerful fungicidal effects.34
Polyamines varying slightly in structure might be capable of reducing 
cell growth by the following.
1 Inhibition of polyamine biosynthesis.
2. Regulation of polyamine biosynthetic enzymes.
3. Competing for polyamine binding sites.
4. Binding at polyamine sites and therefore disrupting the structure 
and/or function.
Initial studies in this area really began with the design of ornithine and 
putrescine analogues as described previously. In 1985 it was shown that 
DFMO inhibited several fungi on artificial media and this was extended to the 
control of rust infection of pinto beans. It was shown to be active if applied 
before or after inoculation with the fungus and systemic action was also 
observed. 1,4-Diaminobutan-2-one (36) has been shown to control a 
number of important plant fungi and interestingly A/-acetylputrescine (37) was 
inactive, probably due to the deacetylases present.55
Research workers in our group investigated a number of putrescine 
analogues as potential fungicidal agents.56- 57> 58> 38 Synthetic routes were 
investigated and a number of unsaturated analogues, both alicyclic and 
cyclic, were investigated and (38), (39) and (40) were particularly active. 
(38) and (39) controlled five important plant pathogens and also powdery 
mildew on spring barley. (38) reduced ODC and AdoMetDC levels; however 
levels of putrescine increased seven fold, spermine increased 60% and 
spermidine decreased by only 32%. (39) reduced putrescine by 58%, 
spermidine by 35% and increased ODC. The powerful anti-fungal activity of 
these analogues is undoubted but their reduction of polyamine pools is not 
enough to account for their activity. These compounds do increase AdoMet 
levels and it is speculated that this might account for their activity. The work 
of Byers et al. suggests that the increase in AdoMet levels may account for
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the activity of DFMO. The excess of AdoMet may lead to aberrant 
methylation which would disrupt cell growth.34- 59
O O
R=Et, 39
More recent work in our group has looked at spermidine analogues 
and their activity and this will be discussed later.
2.5 Evaluation of Polyamines as Anti-cancer Agents
2.5.1 Introduction
The level of polyamine biosynthesis is very high in transformed and 
rapidly dividing cells. This is reflected in higher activity of the polyamine 
enzymes and also increased concentrations of polyamines in extracellular 
fluids. Urinary excretion of polyamines was greater in patients suffering from 
leukaemia or lymphoma and in patients with solid tumours when compared 
to patients with non-malignant diseases.59 The association of polyamines 
with nucleic acids and their accumulation stimulated research into the use of 
biosynthetic inhibitors to treat proliferative diseases such as cancer.33- 60> 61
2.5.2 Cancer Chemotherapy
Unsurprisingly DFMO and MGBG were among the first inhibitors to be 
tested both in vitro and in vivo against tumours and both were found to be 
effective. MGBG inhibits AdoMetDC and SSAT; however it is not clear which 
of these roles is important in inhibiting the cell growth. Clinical trials were not 
as good as hoped, MGBG was too toxic and DFMO didn't show significant 
impact on tumours. This maybe due to the short ti /2  of these enzymes which 
means patients have to be exposed for long periods of time.60- 62
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Polyamine analogues were designed which are enough like the 
natural polyamine to shut down the enzymes when cells are exposed to 
exogenous spermine. They will be transported into the cell via the transport 
apparatus, find their way to the same subcellular sites as natural polyamines 
and hopefully be unable to be further metabolised. A polyamine analogue 
which can regulate the activities of the biosynthetic enzymes and can't 
substitute for the natural polyamines in cell growth may be a good 
antiproliferative agent.60
Initial studies by Bergeron and co-workers63 looked at spermidine 
analogues which were substituted on A/1, A/8- or A/4-. Their ability to compete 
with [3H]spermidine for cellular uptake, inhibit cell growth, affect polyamine 
biosynthesis and suppress enzyme activity were assessed.
R 4
H I 4
n h
R - i
R1=H, R4=Me, R8=H 
R1=H, R4=Et, R8=H 
r 1=H, R4=acetyl, R8=H 
Ri=H, R4=hexyl, R8=H 
R-i=H, R4=hexanoyl, R8=H 
R1=H, R4=benzyl, R8=H 
Ri=H, R4=benzoyl, R8=H
The diethyl (41) and dipropyl (42) derivatives had reasonable antiproliferative 
properties. The A^-derivatives were generally inactive and this is surprising 
as they have better uptake but are less effective at inhibiting ODC. Growth 
inhibition would be expected when the analogue is incapable of substituting 
for spermidine. The A/1,A/8- derivative (41) inhibits spermidine uptake, 
inhibits growth, decreases all polyamine pools, suppresses ODC and does 
not substitute for spermidine. This is in contrast to DMFO which depletes 
only putrescine and spermidine as (41) also depletes spermine by 50%. The 
terminal nitrogens are critical for cellular uptake and cell proliferation and the 
central nitrogen seems more involved in regulatory activities.
Further work by Bergeron and co-workers62 established that (43) had 
improved anti-proliferative activity when compared to (41), testing on cultured 
L1210 cells. In vitro results suggested that mono-alkylation of the terminal 
nitrogens gave the best activity as (43) was more active than either the tetra- 
alkylated analogue (44) or the internally alkylated analogue (45). In vitro 
structure-activity results showed activity decreased as alkyl substitution went
R-i=Et, R4=H, R8=Et, 41 
R^acetyl, R4=H, R8=acetyl 
R-,=propyl, R4=H, R8=propyl, 42 
R^propionyl, R4=H, R8=propionyl
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ethyl-propyl-methyl and also decreased if the internal nitrogens were 
incorporated in a 1,4-piperazine system (46). It is clear that spermine 
analogues were more active than spermidine analogues and this agrees with 
the studies by Porter et al.64 They found that the order of activity for diethyl 
analogues was putrescine < spermidine < spermine.
H /  \  H
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(43) cleared putrescine and spermidine from within the cell and 
depleted spermine by 74%. In untreated cells it only affected ODC not 
AdoMetDC so its mechanism of action was due to some regulatory 
mechanism. More analogues were prepared to establish definitive structure- 
activity relationships.
1. Symmetrical methylene backbones, same alkyl substituent.
2. Symmetrical methylene backbones, different alkyl substituent.
3. Unsymmetrical methylene backbones, same alkyl substituent.
4. Unsymmetrical methylene backbones, different alkyl substituent.
This gave a range of analogues based on norspermine (3,3,3), spermine 
(3,4,3), homospermine (4,4,4) and other homospermine homologues. All 
were then tested to evaluate IC50  values on a murine L1210 cell line, plus 
affects on ODC, AdoMetDC and SSAT and on polyamine pools. For those 
tetraamines that showed IC5o<25|liM structural parameters were established 
for activity (Figure 6).65
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Figure 6 Structure-activity relationship for polyamines
di is the number of chain atoms between a terminal nitrogen and the 
nitrogen second closest to it and it must be greater than or equal to eight. 62 
is the distance from the terminal carbon to the second nitrogen (including 
terminal carbon) and this must be greater than or equal to seven. Bulky 
substituents decrease activity and this may be due to the ability of the 
molecule to interact with e.g. nucleic acids, as although the molecule is a 
tetracation the bulkiness could compromise electrostatic interaction. (47) 
was the most active analogue, superinducing SSAT. The level of 
accumulation of the analogues did not reflect their activity and neither did the 
ability of an analogue to deplete the polyamine pools. These results 
suggested that the analogues owe their activity to something other than just 
affecting polyamine metabolism, e.g. protein synthesis.
The role of charge in polyamine recognition was also studied by the 
very prolific Bergeron and co-workers60 as extremely similar compounds 
often behaved very differently. (43), (47) and (48) all suppress ODC and 
AdoMetDC to the same levels and yet (47) up-regulates SSAT by 1200 fold 
compared to 250 and 30 fold for (43) and (48) respectively.
All of those molecules are highly protonated at physiological pH and 
compare well with spermine and homospermine. Compounds were prepared 
that would appear to the cell as differently charged molecules and the ability 
to impact on cell growth was measured. Those such as (47) (50) and (51) 
which would appear as tetracations competed well with spermidine for 
uptake and were effective at controlling cell growth. Those that would 
appear as dications such as (52) and (53) competed poorly and were 
inactive when tested against LC1210 cell lines. The same results were
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observed when the analogues were tested on ODC, AdoMetDC and SSAT 
with the dications having little or no effect on the enzymes.
FoC
n= 1,50  
NH n=2,51
n= 1, 52 
n=2, 53
The induction of SSAT in two human lung cancer cell lines which 
respond differently to inhibitors of polyamine biosynthesis has been studied. 
The diethylspermine analogue (47) was cytotoxic against large cell lung 
carcinoma (LCLC) causing massive depletion of polyamines and ODC 
activity. However it minimally affected small cell lung carcinoma (SCLC). In 
the LCLC line SSAT was induced 1000 fold and Saab and co-workers 
suggested SSAT plays an important role in the specificity of such agents. 
The ability to superinduce SSAT is postulated to play a role in the toxic 
action of such drugs. To investigate SSAT further they prepared two 
unsymmetrically substituted polyamines (54) and (55) which were shown to 
have similar potency and activity on SSAT to (47).53
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Other work by Saab et al,54 looked at the evidence that (54) and (55) 
superinduce SSAT in LCLC cell lines. Reactions catalysed by SSAT have 
been shown to proceed by a bi-bi mechanism where the polyamine is the 
first to bind to the surface of the enzyme.66 They prepared 
phosphonamidate and phosphinate analogues which have been used in 
other work to mimic the tetrahedral transition state.67’ 68 (56) was too labile 
for their studies and (57) was ineffective as a growth inhibitor, maybe due to 
destabilization of SSAT.
Other research in this area by Edwards, Bitonti and co-workers69 had 
also concluded that spermine analogues were giving the best activity against 
tumours. They investigated the effect of increasing the carbon chain length 
between the central nitrogens and the most active analogue was attained 
when eight carbon atoms connected them (58). In vivo studies showed rapid 
metabolism of this compound so methyl groups were placed a - to the 
terminal nitrogen (60) or a- to the central nitrogen but this decreased activity. 
Alkyl groups were introduced on the terminal nitrogens also to inhibit amine 
oxidases (59) and results were similar to those of Bergeron as activity 
decreased as the alkyl group size increased. One analogue (61) was found 
to be a potent irreversible inhibitor of PAO. In vivo tests were carried out 
| against the L1210 model and the activity of the compounds was found to 
increase when co-administered with bisallene PAO inhibitor (61), suggesting 
these types of compounds are metabolised by PAO.
I
H
Two aziridine-containing spermidine analogues were prepared by 
Yuan and co-workers,70 containing the aziridine at AA- (62) or A/8- (63). An 
amino group was replaced with the ring strained alkylating aziridine ring that 
is known to react covalently with DNA causing massive damage. A/-(4-
ii
i
j
i
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Aminobutyl)aziridine has been shown to be cytotoxic against prostatic 
carcinoma cells and is a potent irreversible inhibitor of DAO. Both the new 
spermidine analogues were also shown to be cytotoxic against L1210 cells 
and the A/1-substituted compound was more active than the N8-. They also 
studied the incorporation of [3H]thymidine and [3H]uridine into DNA and RNA 
but from the results it was unclear whether DNA/RNA was the target of these 
compounds.
2.5.3 Transport of Therapeutic Moieties via Poiyamines
The site of many cytotoxic agents is intracellular so for a drug to be 
active it must pass many hurdles. Firstly it must cross the cell membrane 
and then recognise and interact selectively with cellular targets. If a drug can 
be helped to pass these hurdles it would probably improve on its cytotoxicity 
and activity. Cullis and co-workers hoped to exploit the polyamine uptake 
mechanism and the high affinity of polyamines for DNA by preparing a 
spermidine-chlorambucil conjugate. Chlorambucil (64) is a proven anti­
cancer drug used for treating lung and ovarian cancer. It is believed that this 
bifunctional alkylating agent owes its activity to its ability to crosslink DNA 
and it has been shown that cytotoxicity relates well to the ability to crosslink. 
By preparing this conjugate (65) it was hoped to improve on the activity of
chlorambucil.71- 72,73
NH
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Initial studies showed an increase in activity with naked DNA by a 
factor of 104. In vitro cytotoxicity of the conjugate in polyamine-depleted 
cells was increased 2 0 0  fold compared to chlorambucil but this fell to only 
four fold in vivo. The spermine conjugate (6 6 ) is even more active than the 
spermidine one (65) although they both show identical crosslinking 
specificities.
2.6 Polyamines to Fight Parasitic Diseases
The biosynthesis of polyamines has been a target for cancer 
chemotherapy and then moved on into parasitic diseases.74
The group of Edwards and co-workers has shown that parasitic 
protozoa are sensitive to inhibitors of polyamine biosynthesis, with DFMO 
effective against African trypanosomes both in the laboratory and in the 
clinic. DFMO also inhibits the blood stages of the human parasite P. 
falciparum in vitro and of P. berghei in mice (Figure 7).75> 76>
Potent Activity Some Activity No Activity
T. brucei brucei 
T. brucei rhodesiense 
T. brucei gambiense
P. falciparum 
P. berghei 
(exoerythrocytic only)
T. cruzi 
Leishmania 
P. gallinaceum 
(erythrocytic only)
Figure 7 Activity of DFMO on parasitic diseases
A series of tetraamines were prepared and examined for activity against P. 
falciparum 77
H , x H
H H
BnHN. ^  N
Compounds with benzyl groups on the terminal nitrogens were the 
most active followed by those with one benzyl and those with no alkylation 
were the least active. The central carbon chain was extended to twelve 
methylene units (68) and this had the optimum in vitro activity (IC50  0.2 pM).
NHBn
NHBn
n=3 67 
n= 8  6 8
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Alkylation on the terminal nitrogen was varied; however benzyl remained the 
best group with activity decreasing as substitution varied from benzyl > 
thienylmethyl > cyclohexylmethyl > n-butyl. The most active dibenzyl 
analogues were found to debenzylate when incubated with PAO although 
compounds such as (69) prepared to overcome this had no extra activity. 
The most active compound in vivo was (67) and when given in combination 
with DFMO was curative. Increasing the central chain past seven carbons 
led to an increase in toxicity. It was noted that such compounds 
accumulated to high concentrations in the cell due to greater accumulation of 
these bisbenzyl analogues compared to the free amine equivalents.7 8  
Although no evidence was obtained that showed (67) inhibited polyamine 
biosynthesis other studies showed (67) decreased ODC and AdoMetDC in 
cultured rat hepatoma cells.79  The debenzylation of the compound was 
though to be a contributing factor to its activity, as it is metabolised to the 
free amine which is then capable of repressing polyamine biosynthesis. 
Activity was less than chloroquine (IC50  0.014 p,M) but on a par with 
tetracycline (IC50  62 p,M) which has been used to treat multiply resistant 
malaria infections. It is worth noting that (67) also had activity against 
Leishmania donovani which is another parasitic infection.80
Trypanosoma cruzi is a protozoan parasite that causes Chagas 
disease, mainly affecting people in Central and South America. 
Trypanosomes contain a unique enzyme trypanothione reductase (TR) which 
has been targeted by the group of O'Sullivan.81 A number of spermidine and 
spermine analogues were prepared and (70) and (71) were found to be 
competitive inhibitors of TR. It is hoped that these compounds will be 
modified to produce irreversible inhibitors.
R
H2N N
70
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Bellevue and co-workers80  have prepared compounds and tested 
them for antitumour activity or antiparasitic activity. Two compounds (54) 
and (5 5 ), described earlier, had excellent antitumour activity and they
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extended the range of analogues by preparing symmetrical and 
unsymmetrical compounds. Analogues with a 3,3,3 carbon skeleton had 
excellent antitumour activity but little antitrypanosomal activity in vitro. In 
contrast the 3,7,3 skeleton was more effective against parasites than 
tumours. The most active analogue was (72) and it is also being evaluated 
against P. falciparum and Leishmania donovani.
H
N.
H
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The mechanism of action of (72) is as yet unknown; however the 
activity of bisbenzyl analogue (67) is thought to be related to its rapid 
metabolism by PAO. The metabolism of diethyl analogue (47) has been 
shown to proceed via A/-dealkylation followed by SSAT acetylation and 
oxidation by PAO (Scheme 4).82
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H
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diaminopropane
Scheme 4 Metabolism of diethylnorspermine analogue (47)
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De et al. had looked at diaminobutanes and alkanolamines for 
reversal of chloroquine resistance. Their most active compound was (73) 
although further studies were halted due to problems with photosensitivity of 
the active compound.83
2.7 DNA Binding Properties of Polyamine Analogues
Polyammonium salts bind to DNA through an electrostatic interaction 
which is non-sequence specific, with high affinities when the charge is + 3  or 
+4. Whilst remaining close to the DNA the polycation retains a high degree 
of freedom within the polyamine-DNA complex.30’ 34  Cullis and co-workers 
favour the "bind and slide" mechanism where the. polyamine slides up and 
down the phosphate backbone of DNA.71 In contrast, the group of Burrows 
and co-workers35  favour the minor groove with the polyamine hydrogen 
bonding to the edges of the base pairs. Studies have shown that three to 
four carbon spacing is nearly ideal to ensure full protonation of the nitrogens 
and hence maximum interaction. The exact position of the binding 
interaction is not known (e.g. major groove, minor groove or phosphate 
backbone); however there are some crystal structure of polyamines bound to 
oligomers.84’ 85> 86 In one case spermine was found to span the major 
groove.84
Edwards and co-workers have synthesized a number of polyamine 
analogues with both antitumour and antiprotozoal activity.69’ 77  The 
mechanism of action is not clearly understood, although one hypothesis is 
that they may act through displacement of the naturally occurring polyamines 
from DNA binding sites. If such an action is relevant to the antitumour 
activity of such compounds correlation might be expected between DNA 
binding ability and growth inhibition. A large range of compounds were 
prepared which enabled the researchers to look at the effects of: length of 
the central chain; terminal A/-alkyl substitution; branching of the carbon chain; 
and the distance between the nitrogen atoms on DNA binding. The 
polyamines showed a wide tolerance for functional groups in the aminopropyl 
moiety and although increased alkyl substitution lowered DNA binding the 
effect was minimal. The order of ability to interact with DNA follows the
73
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pattern diamines < triamines < tetraamines and those compounds with 
terminal benzyl groups showed a preference for AT base pairs in DNA 
compared to GC base pairs in DNA. Polyamines with a central aromatic 
core (74) were comparable or superior to spermine for DNA binding.87
This finding compares well with the work of Stewart and Gray88  who 
looked at a wide range of such compounds. Their most active analogue for 
DNA binding was (75). They studied polyamine-DNA interactions to try and 
establish a set of rules for binding that might be used for the design of 
complexation agents in the future.
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2.8 Summary
Polyamines have been used in the treatment of a wide range of 
diseases and therapeutic uses are being discovered for them all the time. It 
seems hard to draw on all the examples given, which are so wide ranging, 
and come up with definitive structure-activity relationships. In cancer cases 
a simple ethyl group on a 3,3,3 carbon skeleton seems the best, whereas in 
parasitic diseases benzyl groups on a 3,7,3 skeleton are active. Links have 
been drawn between the ability of compounds to superinduce SSAT activity 
and their antitumour activity, whereas the ability of a compound to be 
metabolised may be important in parasitic cases. These simple compounds 
also have a remarkable affinity for DNA and RNA which may lead to 
interrupting protein synthesis. No link for activity can be drawn between 
therapy of different diseases but one thing remains true; there is every 
reason to investigate these types of compounds. In the next chapter we will 
discuss a number of putrescine analogues that were the lead into this project 
on polyamines as prospective antimalarials.
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3
3 Synthesis and Evaluation of Putrescine 
Analogues
3.1 Introduction and Rationale
The widespread occurrence of polyamines led to a large amount of 
research in this area. Of special interest was the synthesis of inhibitors of 
the polyamine biosynthetic pathway which led to the development of DFMO
(2.3.1). A number of fungi only possess the ODC pathway to synthesise 
putrescine so if an inhibitor could block ODC the fungi would die. Plants 
have the alternative method of synthesising putrescine via the arginine 
pathway and would remain unaffected.38
A wide range of ornithine and putrescine analogues had been 
prepared in the search for inhibitors of ODC and AdoMetDC and also to 
evaluate their affect on polyamine pools.43- 48  In our group previous work 
had focused on the design and synthesis of putrescine analogues for anti- 
fungal testing. It was found from these studies that the 1 ,4-diaminobut-2-ene 
moiety was especially interesting and synthesis of compounds continued. 
Initially (76) was identified as having good fungicidal properties and a series 
of A/-alkylated analogues were prepared which led to the antifungal 
compound (77).89- 90  Alicyclic derivatives were also prepared utilising well 
known Diels-Alder chemistry to synthesise a number of structures such as
(78).91
+
78
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(77) was shown to control a wide range of fungi including powdery 
mildew on barley and (78) was even more effective. Tests were done to see 
the effect these compounds had on the enzymes ODC and AdoMetDC and 
also on the levels of putrescine, spermidine and spermine in plants.38’ 89  
These results are briefly summarised in Figure 8.
ODC AdoMet
DC
put spd spm powdery
mildew
control
76 - 87% - 82% + >100% - 32% + 61% 75%
77 + 81% - 62% - 49% - 19% -4% 80%
78 - 18% + >100% - 68% no effect - 12% 93%
Figure 8 Variation in polyamines and enzyme levels due to antifungal 
compounds
These analogues do not deplete intracellular polyamines in plants 
sufficiently to account for their activity. Both (76) and (77) deplete 
AdoMetDC and it has been speculated that this may be related to their 
activity.38
As shown in 2.6 polyamines have been evaluated against a range of 
parasitic diseases, including malaria. Our group branched into the malaria 
area when (77) was screened against an in vitro culture of P. falciparum and 
showed promising activity. So from the anti-fungal work had come our "lead" 
compound and we decided to examine a wider range of polyamine 
analogues and evaluate their activity against malaria. Many of the 
compounds discussed in this chapter have been prepared before, either 
within our group or by other researchers; however little work had been done 
on their antimalarial activity.
3.2 Evaluation of Antimalarial Activity
It seems sensible at this point to discuss briefly the testing processes 
carried out on our compounds to investigate their activity. This work was 
carried out by Professor Stephen Phillips and Fiona McMonagle in the 
Division of Infection and Immunity, University of Glasgow. Initial tests were 
carried out in vitro and if interesting activity was found in vivo tests were 
used.
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3.2.1 In vitro Testing against P. falciparum Asexual Erythrocytic Stages 
- S. R. Phillips and F. McMonagle, Division of Infection and Immunity
P. falciparum culture adapted strains FCR (Gambia) and JS 
(Zimbabwe) were used. Both these strains are chloroquine sensitive and 
were grown as stock cultures in vitro in petri dishes by a modification of the 
candle jar technique of Trager and Jensen.92 In culture the parasites were 
asychronous in their growth and therefore all stages in the 48 hour asexual 
erythrocytic cycle would be represented at any one time. The assay system 
for screening compounds for activity against P. falciparum was that 
described by Desjardins et a/ .93 Each test concentration was carried out as 
a minimum in triplicate. After 24 hours incubation in a candle jar 100 
millilitres were removed from each well and replaced with 1 0 0  ml fresh 
medium containing 1 jnCi ^H-hypoxanthine.94 The plate was incubated for a 
further 18 hours before the parasites were harvested and parasite growth 
was measured as the incorporation of the isotope, using conventional liquid 
scintillation counting. The mean and standard deviation of the counts per 
minute for each dilution of the test compounds or the control cultures were 
calculated and the results displayed using Cricket graph. The results were 
analysed using a standard t-test.
The activity of the compounds was shown as the lowest concentration 
in pig mM where the test compound showed any reasonable activity. For a 
further comparison this lowest activity was converted into a lowest effective 
concentration (LEC) which, in p,M, takes into account the molecular weight of 
the compounds. Although not an accurate IC5 0  value the LEC does 
represent a good guide to a compound's activity. We analysed the data 
using an activity scale (Figure 9) designed to assess whether certain 
analogues were worth pursuing with in vivo testing and/or further chemical 
modifications. Chloroquine is >9 on this scale and any compound with 
activity less than 4 was not pursued.
Activity
Scale
1 2 3 4 5 6 7 8 9
Lowest
Activity
(M-g m,_1)
1000 500 100 50 10 5 1 0.5 0.05
Figure 9 Activity Scale for in vitro test results
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3.2.2 In vivo Testing against P. chabaudi- - S. R. Phillips and F. 
McMonagle, Division of Infection and Immunity
P. chabaudi AS strain, in inbred NIH mice, was handled as described 
by McDonald and Phillips.95 In brief three months old male inbred NIH mice 
were infected intravenously with 1x10^ P. chabaudi parasitized erythrocytes 
and groups of five mice immediately afterwards were injected with either 
chloroquine at 50 mg/Kg body weight or the test compounds. The 
compounds were dissolved in physiological saline and injected 
intraperitoneally. A control group of mice received saline only.
3.3 Synthesis of Lead Compound (77)
The synthesis of (79) had been reported previously.5 6  An Sn2 
displacement of (E)-1,4-dibromobut-2-ene with diethylamine yielded the free 
base (79). Dissolving the free base in ether and carefully adding ethereal 
hydrogen chloride (see 7, procedure A1) precipitated the hydrochloride salt 
(74%) (77). The resulting salt could be purified, if needed, by re-dissolving 
the salt in ethanol and precipitating with ether. This is a reliable way of 
producing dihydrochloride salts for this compound (Scheme 5).
Significant in vitro activity of (77) was present at 18-38 jllM  which was 
promising (c.f. IC50 chloroquine 0.014 pM; IC50  tetracycline 62 pM) but how 
could we try and improve on this?
Et
B k  / v  NHEt2, MeCN. ,I\L ^  .Et
Br Et N
79 1Et
E\ H+/ Et20
+ 1 T
2 C r  E r N H ^ ^ N V B  
7 7  Et
Scheme 5 Synthesis of lead compound (77)
By looking at (77) we can establish a number of features that may be 
altered to see how they affect the activity. The development of further 
analogues by this route would contribute to the elucidation of structure- 
activity relationships (Figure 10).
N-alkyl substitution
Carbon chain
Figure 10 Structural considerations for variation of (77)
1. Carbon chain - prepare unsaturated and saturated analogues to establish 
the importance of the trans-double bond and chain length.
2. Af-Substitution - vary the alkyl group to see the affect of size and form 
both tetra-substituted, disubstituted, symmetrical or unsymmetrical. 
compounds.
3.4 Alkyl Analogues of (77)
3.4.1 Synthesis of Compounds (83), (84), (85), (89), (90) and (92)
The free bases (80) and (81) had been prepared previously in our 
group.38- 57 (82) was prepared by a similar route.96 The free bases were all 
prepared utilising the well known Sn2  displacement of an alkyl halide with an 
amine quickly producing the desired compounds in good yields (Scheme 6). 
In previous work many of these compounds had been prepared as the 
dihydrobromide salts and we prepared the dihydrochloride salts (83), (84), 
(85). The yield of (80) was lower than expected, maybe due to a lower 
boiling point of the product. It was important when isolating the free base by 
concentrating in vacuo to keep the water bath temperature to a minimum so 
less product is lost. The dihydrochloride salts were precipitated by the 
addition of ethereal hydrogen chloride as described for (77).
In order to extend the series the unsymmetrically substituted 
compound (89) was prepared following the procedure reported (Scheme 
7 ) . 5 7  One equiv. of potassium phthalimide was heated with (Ey  1,4- 
dibromobut-2 -ene to yield (8 6 ), although some di-phthalimide was formed as 
a by-product. The phthalimide (8 6 ) formed white needle-like crystals which 
were purified easily by recrystallisation from acetone. Sn2  displacement as
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above yielded the protected diamine (87) which was not purified but 
hydrolysed in acid conditions. This method of removal of the phthalimide 
group is one of many and is used because of the good yields obtained. A 
basic work up yielded the free base and the hydrochloride salt was isolated 
as usual.
NHF^Ra, MeCN ^ n i
R-(=Me, R2=Me,80 
R1=H, R2=Et, 81 
R1=H, R ^ P r, 82
^ n i
H+/ Et20
R.
R NH 
2C f R2
R-
R ^M e, R2=Me,83 30% 
R1=H, R2=Et, 84 60%
R1=H, R2='Pr, 85 71%
Scheme 6  Synthesis of A/-alkylated derivatives (83), (84) and (85)
Br potassium 
phthalimide, 
acetone
NHEt MeCN
EtoN
c. AcOH/ HCI 
NaOH, CHCI3
87
O
2 CI NEt
89
Scheme 7 Use of the phthalimide protecting group to produce unsymmetrical 
analogue (89)
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The 1,4-diaminobut-2-ene moiety had been shown to give good 
activity in the anti-fungal tests.34 This had also been true in the earlier work 
by the scientists at Merrell Dow on ornithine and putrescine analogues 
(2.3.1 ).43’ 48- 31 In the malaria work the importance of the trans carbon- 
carbon double bond was investigated. The unsaturated analogue (77) was 
hydrogenated over palladium on carbon to yield (90) (compound prepared by 
4th year project student). The three carbon analogue (92) had been 
prepared by Ingold and Rothstein and we also prepared it (Scheme 8 ) . 97
+
Et2HN
77
NHEto MeOH
H?, Pd/C, - Et,HN
Br HNEt2, MeCN Et2N
90
NEt
NHEt2 
2 C l
2 91
H+/Et20
2Cl Et2HNv^ ^ / NHEt292  
Scheme 8  Synthesis of saturated putrescine analogues (90) and (92)
3.4.2 Biological Evaluation
The activity of (83), (84), (85), (89), (90) and (92) against an in vitro 
culture of P. falciparum  was assessed and compared with (77) with 
chloroquine as a control (Figure 11).
activity (pg m l1) LEC (pM)
tetraethyl 77 5-10 18-36
tetramethyl 83 50 232
A/,A/'-diethyl 84 50-100 232-465
A/,A/'-diisopropyl 85 100 411
/V,/V-diethyl 89 50 232
tetraethyl (sat. 4C) 90 100 366
tetraethyl (sat. 3C) 92 10-50 38-190
chloroquine 2 <1 <1.9
Figure 11 In vitro activity of aliphatic putrescine analogues
The tetraethyl analogue (77) was the most active compopund of this 
group. Keeping the tetrasubstituted pattern but decreasing the size of the
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alkyl group to methyl decreased the activity dramatically. Going from 
tetraethyl to A/,A/-diethyl also decreased the activity. Within the group (84), 
(85) and (89) the compounds were fairly similar, despite the change in 
substitution patterns and alkyl group size. The trans-carbon carbon double 
bond seemed to aid activity as the saturated compounds were both less 
active than (77). Surprisingly (92) with three carbons linking the nitrogens 
was more active than the four carbon saturated analogue (90).
These results should be compared with other testing on polyamines. 
Investigating polyamine analogues as anti-tumour agents (2.3.1). Porter6 3  
showed that monoalkylation of the terminal nitrogens in spermidine 
derivatives produced compounds with the best activity. It was also shown by 
Bergeron that tetrasubstitution on spermine analogues decreased activity.62  
In our in vitro evaluation of putrescine analogues against P. falciparum we 
found the opposite to be true as our tetrasubstituted compound was the most 
active. Increasing the size of the alkyl group decreased the activity which 
corresponds to the work of Bergeron65  where the order of activity was ethyl 
> isopropyl. We observed the same results from (77) to (85); however the 
compounds (84) and (85) do not show such a dramatic difference in activity. 
Finally the unsaturated compounds gave the best activity. This corresponds 
well with the results on ornithine and putrescine analogues for ODC inhibition
(2.3.1).
We prepared a number of aliphatic compounds but none had 
improved on the activity of our initial lead compound. We decided to produce 
a number of aromatic compounds and see the effect the hydrophobic group 
had on activity. This is an attractive idea as the work of Edwards7 7  on 
polyamines with antimalarial activity showed that terminal monoalkylation 
with aromatic groups greatly improved the activity of their compounds (2 .6 ).
3.5 Aromatic Analogues of (77)
3.5.1 Synthesis of Compounds (94), (96) and (98)
(94) was prepared as shown in Scheme 9 using freshly distilled 
benzylamine and excess amine was removed by distillation. The free base
(93) was converted into the dihydrochloride salt as usual to yield (94) in good 
yield (70%). In our hands tetrasubstituted compounds gave the best in vitro 
activity so an analogue was prepared that was substituted with diethyl and 
the hydrophobic benzyl group. (81) was stirred in acetonitrile and
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triethylamine and benzyl bromide was added dropwise, in an attempt to 
minimise side reactions of the extremely reactive benzyl bromide. After work 
up the yield of the desired product was fairly poor and there was an intense 
UV active spot on the baseline of the TLC plate. This may be due to over- 
alkylation of the nitrogen by benzyl bromide to give the quaternary salt. If 
this compound was to be prepared again a few changes could be made to try 
and improve the yield. Benzyl chloride might be tried as an alternative 
alkylating source or Hunig's base could be used instead of triethylamine. 
Hunig's base is often used to help prevent formation of quaternary salts in 
such reactions.
BnNH2, MeCN BnHN.
0 2  ~ NHBn 
H+/Et20
2CI BnH2 N.
94 NHoBn
BnBr, NEt3, MeCN
H+/CHCI3
2 0 1  Bn'NH- ^ N H Bn
HNEtPh, benzene ^N.
Br -------------------------------   ph-
Yield 
94 70%
96 44%
98 67%
h +/c h c i3
2Ci Ph
98
Scheme 9 Synthesis of aromatic putrescine analogues (94), (96) and (98)
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The other compound of this aromatic series to be prepared was (96). 
Sn2 displacement of the dibromide by A/-ethylaniline gave the free base as a 
white solid. This had been previously prepared by Roberts and Ross98 using 
the (E)-dichloroalkene. We had the dibromoalkene handy and obtained a 
67% yield compared to the reported 57%. The analytical data were 
expanded to include NMR and MS. The dihydrochloride salt was formed by 
bubbling dry HCI through a solution of the free base in chloroform, due to the 
insolubility of (97) in ether (Scheme 9).
3.5.2 NMR Studies on (95) and (97) and their Dihydrochloride Salts
Nuclei in regions of high electron density experience a field 
proportionally weaker than those in a region of low electron density. They 
are said to be shielded by the electrons and it takes a higher field to bring 
them into resonance (i.e. low 6 ). If the nuclei are in a region of low electron 
density it takes less field to bring them into resonance (i.e. higher 6 ). These 
principles can be applied to most compounds when analysing and explaining 
their NMR data.99
Going from the free base of an amine to the hydrochloride salt (95)- 
(96) we tend to see an increase in 5 values. The explanation for this is 
covered in 3.9. The nitrogen atoms in polyamines exert strong effects due to 
their electronegative behaviour. They will pull electrons towards themselves 
and away from any neighbouring atoms, hence deshielding them (Figure 
12).
When comparing the chemical shifts of 6 -H3 and 5 -H2 the methylene 
protons come at higher 5 than the methyl protons. The methylene protons 
are a - to the nitrogen atom which exerts a strong effect, however this 
decreases with distance. Typical vicinal coupling constants for the ethyl 
groups are 7 Hz, 3Jhh usually in the range 6 - 8  Hz. Our values for all ethyl- 
substituted compounds fall within the range 6.5-7.5 Hz. The allylic protons 
appear downfield as do the methylene protons "sandwiched" between a 
nitrogen and the benzyl ring (7-H2). In (95) and (96) the aromatic protons all 
have similar chemical shifts forming a close multiplet (Figure 12).
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95 (base) 8 96 (salt) 8 97 (base] 8 98 (salt) 8
6 -H3 1.03 6 -H3 1.08 6 -H3 1 .1 2 6 -H3 0.84
5-H2 2.50 5-H2 2.93 5-H2 3.33 5H2 3.26
1,4-H2 3.06 1,4-H2 3.56 1,4-H2 3.85 1,4-H2 3.99
7-H2 3.54 7-H2 4.05
2,3-H 5.68 2,3-H 5.82 2,3-H 5.62 2,3-H 5.55
9,10,11-H 7.24 9,10,11-H 7.26 9,11-H 6.65 10-H 7.15
10-H 7.20 9,11-H 7.38
Figure 1 2  Comparison of NMR data for aromatic amines
The aromatic amines (97) and (98) show an extra affect. In (97) the 
nitrogen lone pair is delocalised into the aromatic ring to form a number of 
resonance structures as shown below.
i
F k + ^RN
The nitrogen is now even more electron withdrawing due to the partial 
positive charge. All the methyl and methylene protons in the rest of the 
structure are at higher 8  than in (95) due to this effect, with the vinylic protons 
least affected. Due to the resonance structures protons 9-H and 11-H are 
shielded compared to 10-H with 9-H and 11-H therefore appearing at lower 
8 . The integral ratio for the aromatic region is 3:2. As (98) is formed the lone 
pair is now a bonding pair of electrons, there are no resonance effects, and 
the chemical shift values are more comparable with (96). 9-H and 11-H 
increase in chemical shift by 8  0.78 whereas 10-H is virtually unaffected.
The 13C NMR spectra of these compounds does not show such large 
effects of aromaticity as the 1H NMR although carbons 9-H and 11-H are 
shielded in (97).
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3.5.3 Biological Evaluation
As expected the addition of the dibenzyl moiety to give (94) greatly 
improved on the in vitro results so far. Again the tetrasubstituted analogue 
was the most active with (96) having greater activity than (94). The aniline 
analogue (98) was comparatively inactive (Figure 13).
activity pg ml-1 LEC50 pM
tetraethyl 77 5-10 18-36
dibenzyl 94 1-5 3-15
dibenzyldiethyl 96 0.5-1.0 1.3-2.5
diphenyldiethyl 98 >100 >272
chloroquine 2 <1 <1.9
Figure 13 In vitro results for the aromatic compounds
These results correspond well with those of Edwards77 where the 
most active compounds reported were monoalkylated with benzyl groups on 
the terminal nitrogens. The result of the phenyl derivative was surprising as 
Edwards had found the benzyl and phenyl analogues to have very little 
variance in activities. It is tetrasubstituted but in our hands those analogues 
have always given the better activity. One consideration is how these 
compounds appear to the cell. Work on the importance of charge in cell 
recognition and its relation to antiproliferative activity proved that tetracationic 
species were transported better than dicationic species (2.5.2). With the 
nitrogen lone pair delocalised into the aromatic ring the nitrogen will not be 
as highly charged as aliphatic analogues and may not appear totally 
dicationic. This may result in lower uptake and therefore lower activity.60
3.6 Quinoline-Polyam ine Derivatives
3.6.1 Synthesis of Compound (100)
The final compound of this series was the quinoline derivative (100). 
This had been prepared in 1969 by the group of Singh100 however the 
analytical data were incomplete. Synthesis is easy although not in great 
yield (25%) taking 4,7-dichloroquinoline and heating in phenol with diamine 
(88). The reported yield was only 32% to (99) so our yield to (100) was
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reasonable (Scheme 10). This route is analogues to the preparation of 
chloroquine which may also be prepared by this route.101
H
NEt.
99phenol
NHEt
1 0 0
Cl
H
Scheme 10 Preparation of the quinoline derivative
3.6.2 Biological Evaluation
Unsurprisingly the quinoline analogue had the best activity out of this 
range of putrescine analogues as shown in Figure 14.
activity pg ml-1 LEC pM
tetraethyl 77 5-10 18-36
dibenzyl 96 0.5-1.0 1.3-2.5
quinoline 1 0 0 0.05-0.005 0.13-0.013
chloroquine 2 <0.005 <0.009
Figure 14 Comparison of in vitro activity
The group of Singh had tested (99) in vivo against P. berghei and 
found it to be active when administered at 40 and 80 mg kg-1 and curative at 
160 mg kg-1 and higher. Our initial tests were on the dihydrochloride salt 
(100) carried out in vitro on P. falciparum where it had activity comparable 
with chloroquine.100
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3.7 Attempted Preparation of Bisquinolines
3.7.1 Introduction
Quinolinemethanols such as quinine and mefloquine have some 
activity against chloroquine-resistant parasites; however there is a significant 
amount of cross resistance among quinoline-containing antimalarial drugs. A 
promising lead was reports of several bisquinolines that are active against 
chloroquine-resistant malaria. These include piperaquine (101), 
hydroxypiperaquine (102) and 1,4-bis(7-chloro-4-quinolylamino)piperazine 
(103).102
/  \  
H N -N  N-NH 
\  /
R=H 101 
R=OH 102
A systematic study of bisquinolines had not been reported and a 
range of simple bisquinolines was prepared by Vennerstrom (Scheme 11). 
In the straight chain series the carbon bridge with two methylene units was 
the most active; however the greatest in vivo activity was observed with a 
central chain of trans-1,2 -cyclohexyl. 102 The diamine was heated with 4,7- 
dichloroquinoline in /V-methylpyrrolidinone, a solvent which has been shown 
to improve the yields of these types of reactions.103
diamine, NEt3 NH
Cl
Scheme 11 Synthesis of bisquinolines
Raynes et al. have also looked at some bisquinolines; however these 
were joined by bisamide links from the quinoline ring leaving the 
diethylaminobutyl side chain of quinoline intact (Figure 15). Two series of 
compounds were produced linked through the 6 -or 8 -position of the quinoline 
ring with the most active compounds being those linked through the 8 - 
position. When n=4 and the substitution was in the 8 -position the compound 
had 2-3 times greater activity than chloroquine against chloroquine-resistant 
strains of the parasite.104
8 8
Figure 15 Bisquinolines linked from the 6 - or 8 -position
Our work was concerned with putrescine analogues so we decided to 
prepare two analogues (104) and (105).
saturated 104 
unsaturated 105
3.7.2 Attempted Preparation of (105)
4,7-Dichloroquinoline was heated in phenol with (81) and sodium 
iodide crystals at 150-160 °C for 24 hours; however no product formation 
was observed. The reaction was also tried in A/-methyl-2-pyrrolidinone which 
is reported as increasing the facility of these reactions; however only impure 
black product was obtained (Scheme 12).
59
A) 81, phenol, Nal
B) 81, A/-methylpyrrolidinone I
105
Scheme 12 Attempted preparation of (105)
3.7.3 Attempted Preparation of (104)
Due to the unsuccessful attempted preparation of (105) we decided to 
prepare bisquinoline (106) and then alkylate the nitrogen atoms. (106) was 
prepared according to the procedure of Vennerstrom in reasonable yield 
(55%) with spectroscopic data comparable with the literature values 
(Scheme 13).102 Alkylation of amines had been reported by two groups 
using sodium borohydride-carboxylic acid systems. 105 >10 6 » 107 Using acetic 
acid various aromatic amines had been alkylated in good yield (Scheme 14).
Cl
NH1,4-diaminobutane,
NEt3, A/-methylpyrrolidinone
HN
106
Cl or
N
Cl
Scheme 13 Attempted preparation of bisquinoline (104)
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O
R V . . .  J l  NaBH4 _ R ' \  .R1
\ \ \ S ^  i
R"/ N H  R '""^O H  , nR”
Scheme 14 Alkylation of amines with carboxylic acids
Using route A we attempted to alkylate (106) using the chemistry 
reported by Marchini et al. who used sodium borohydride-carboxylic acid 
systems to alkylate a wide range of aliphatic and aromatic amines. 105 They 
assigned Na[(RCOO)3 BH] as the /V-alkylating species. Sodium borohydride 
was added portionwise to glacial acetic acid at 0  °C and (106) was then 
added. The suspension was heated at 80 °C for two hours until a clear 
yellow solution was formed. After cooling to room temperature the 
precipitate was collected ; however 1H and 13C NMR spectra confirmed the 
isolation of starting material.
For route B followed the procedure of Gribble et al. who had also 
reported the same reaction, only adding the reagents in a different order and 
carrying out the reaction under nitrogen. 107  Gribble and co-workers had 
looked at the alkylation of indoles and aromatic amines; however using their 
chemistry only starting material was isolated.
Both groups had successfully alkylated diphenylamine with acetic acid; 
however we saw no evidence of alkylation with our quinoline using either set 
of reaction conditions. This may be due to the lack of nucleophilicity of the 
nitrogen we want to alkylate and their chemistry, in our hands, was not 
extendable to alkylation of quinolines. If these types of compounds were 
studied in the future possible alkylation methods for aromatic amines have 
been discussed by Barton and Mohri.108
3.8 Biological Evaluation - In vivo Studies
Five compounds were carried forward to in vivo testing, (77), (92),
(94), (96) and (100), with chloroquine as a control. The compounds were 
tested in mice against a rodent malaria, P. chabaudi. Chloroquine at a dose 
of 50 mg kg-1 was curative and no parasitaemia was detected in mice over 
14 days. Our "lead" compound (77) delayed parasitaemia for a day, as did 
(92) when given at 100 mg kg- 1 or 300 mg kg-1, but this did not show any 
significant antimalarial activity. Compound (94) was given at 150 mg kg- 1 in
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three doses over 48 hours and had no activity but was toxic. (96) was given 
at 175 mg kg-1 in two doses 24 hours apart and was inactive. The quinoline 
analogue (100) was given at 25 or 50 mg kg-1 and was curative at the higher 
dose which compares well with chloroquine. This should be compared with 
the work of Singh100 where (99) (free base of (100)) was curative at 
160 mg kg_1 on P. berghei.
These results were disappointing. None of our compounds had any 
activity in vivo and it was surprising that (94) was toxic. Edwards reported 
some toxicity with their spermine analogues but only when the central carbon 
chain had more than seven carbon atoms present. We have no explanation 
for the toxicity of (94). Again it was surprising that (96) had no activity in vivo 
after being so promising in vitro. The dibenzyl analogues prepared by 
Edwards are known to be debenzylated by polyamine oxidase and it has 
been speculated that this may be related to their activity as well as their 
ability to accumulate to high concentrations in the cell. If that was indeed 
important and our tetrasubstituted compounds could not be metabolised in 
such a way this may explain the lack of in vivo activity of (96).77  This work 
has been submitted for publication.109
3.9 Electron Density Studies on Compound (107)
As part of her physical chemistry PhD Dr Kirsty McCormack looked at 
the electron density over our "lead" compound (77).110 If the polyamine- 
biological anion interaction is important then it will depend on distribution of 
the 2 + charge on the cation. Hopefully results may allow us to design 
rationally future compounds that may be active. A recent paper by Cohen 
and co-workers described molecular modelling of the same sort of 
interactions on spermine phosphate hexahydrate. 111 To provide crystals 
suitable for the study was my responsibility. From the dihydrochloride salt 
growing crystals of the correct size proved difficult so we decided to try the 
bis(hexafluorophosphate) salt instead. This was known by a member of our 
group to produce a solid that was easily crystallized. The 
bis(hexafluorophospate) salt precipitated out of water and crystals were 
grown from a solution of methanol/ether and obtained as colourless plates 
(Scheme 15).
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ammonium hexafluorophosphate,
H20
2PF6 + NH
107
Scheme 15 Ligand transfer to produce the bis(hexafluorophosphate) 
compound (107)
Unfortunately the hexafluorophosphate group was shown to be 
disordered at room temperature; but at the lower temperatures of the studies 
there was no significant dynamic disorder. A crystal structure was obtained 
(Figure 16) and this shows the bis(hexafluorophosphate) compound (107) to 
be centrosymmetric. The PF6 " counter ion was disordered at room 
temperature with four of the F atoms spinning around the F2 -P-F4  axis.
iH41
131
Figure 16 The crystal log raphic centrosymmetric structure of (107)
63
The work of Dr McCormack, both theoretical and experimental, 
showed that the carbon and nitrogen atoms carried partial positive charges 
whilst all the hydrogen atoms were slightly positive. This agrees with our 
NMR data when comparing the chemical shifts of the protons in free base 
and salt form i.e. (79) and (107) (Figure 17). In (107) each nitrogen carries a 
formal positive charge which acts as a powerful electron withdrawing group. 
The 2 + charge of the dication is actually distributed over the hydrogen atoms 
which places them in a deshielded environment. This leads to a downfield 
shift in the NMR 8  values, i.e. higher values of 8 . The shift is largest for 
those hydrogen atoms on carbons a  to the nitrogen and the effect diminishes 
for those (3 to the nitrogens. These results are consistently seen in NMR 
data for the amine salts (mostly hydrochloride) prepared throughout this 
thesis.
proton
environment
79
(free base)
107
(ammonium salt)
A (ppm)
CH3 -CH2 1.04 1.32 +0.28
CH3 -CH2 -N 1.54 3.22 +0 .6 8
N-CH2 -CH 3.12 3.88 +0.76
CH 5.70 6.15 +0.45
Figure 17 NMR comparison for compounds (79) and (107)
On the basis of these results Dr McCormack showed that the negative 
charges on the carbons and nitrogens were diffuse and the overall electron 
density of (107) was positive shown by the solid lines (Figure 18). A model 
of the phosphate backbone of DNA was chosen (Figure 19) and data 
showed the electron density of the molecule to be negative (dotted lines). 
From this we may predict a strong interaction between the polyamine 
analogue (107) and the phosphate backbone of such molecules as DNA. 
This interaction is not site specific as all points on (107) have a large positive 
potential. Full details of this work have been published. 110
Figure 18 Map of the theoretical electrostatic potential of (107)
Figure 19 Map of the theoretical electrostatic potential of the model 
phosphate group
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3.10 Summary
We started the project with our "lead" compound (77) and hopes of 
improving on its activity. We prepared a range of compounds varying the 
carbon chain and the A/-alkylation patterns to give us an idea of the types of 
compounds that would be worth investigating further. It was not surprising 
that the dibenzyl analogues had the best in vitro activity; however the in vivo 
results were disappointing.
Looking again at previous work on therapeutic polyamines 
(spermidine or spermine), authors in the anti-cancer field had found di­
alkylated analogues to be more active than the related putrescine 
compounds. We were looking to have strong interactions between our 
molecules and DNA and the spermidine analogues would have a 3+ charge 
whilst the spermine analogues would have a 4+ charge. This would give 
them a stronger interaction with DNA which might lead to improved activity. 
We decided to expand into synthesis of spermidine/spermine analogues to 
widen our biological test data and this chemistry is covered in the next 
chapter.
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4 Investigation of Spermidine and Spermine 
Analogues
4.1 Introduction
In the last chapter we examined a range of putrescine analogues for 
antimalarial activity; however in vivo results were disappointing. We decided 
to extend our work to study some spermidine analogues. This idea was 
based on previous workers' observations in the cancer field that spermidine 
analogues were more active than corresponding putrescine analogues. The 
extra charge on the molecule is believed to enhance the activity due to 
improved binding properties.64
Before the 1960s synthetic routes to polyamines were limited with few 
methods available for the selective modification of putrescine, spermidine, 
spermine and other polyamines. In the last few decades more literature was 
published, stimulated by the increased interest in this area. There are two 
major problems with functionalising polyamines: 1 attaching the group or 
groups to the correct nitrogen or nitrogens; and 2  having reactions that give 
reasonable yield. For many years low yields were accepted as long as 
"some" of the right product was isolated. 112
Figure 20 Numbering of spermidine and its derivatives
For ease of discussion the nitrogen atoms in spermidine are labelled 
as found in most older literature (Figure 20). Secondary amines are usually 
more basic than primary amines; however in spermidine they are not 
independent entities. Research has showed the primary nitrogens N1 and N8
H
N
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protonate in preference to N4, with N8 protonating first.113 N1 and N4 are 
only three carbons apart and the electron withdrawing effects of each other 
cause a decrease in basicity and regioselectivity, of course, depends on 
these reactivity differences which are often difficult to exploit.30  Over the 
years synthetic approaches have built up the desired polyamine using a 
combination of protecting group chemistry and selective reactions to 
construct the desired polyamines. In this chapter a wide range of chemistry 
used to produce polyamines will be highlighted.
4.2 Preparation of /V-Alkyl Spermidine Analogues
Dr Carol McClintock in this group had prepared some N-alkyl 
spermidine analogues for anti-fungal testing. 114 Previously, we had seen 
good antimalarial activity in vitro from compounds with good anti-fungal 
activity; therefore we decided to prepare a selection of these analogues for 
testing. Because these compounds are similar to spermidine they should be 
taken up by the cells efficiently and may have improved activity.
4.2.1 Synthesis of Spermidine Analogues (125), (126) and (127)
The synthetic route devised by Dr McClintock can be used to produce 
a wide range of compounds and is shown in Scheme 16. A number of key 
reactions are used:
1. Protection of amino acids as their tautylcarbamates (BOC) and 
subsequent deprotection
2. Mixed anhydride formation of amides
3. Borane reduction of amides.115
We prepared three polyamines from this general reaction scheme which 
gave us (3,4) (125), (3,5) (126) and (4,4) (127) carbon skeletons. This would 
enable us to see the effect of altering the carbon backbone whilst holding the 
alkyl substituent constant. The ethyl group was chosen due to the success 
found with it in anticancer work and also our anti-fungal studies.
All steps went in yields comparable to those reported. One 
problematic stage was the BOC deprotections. The hydrochloride salts of 
the amides (122), (123) and (124) tended to be hygroscopic which led to 
problems with isolation. In many cases the salt was obtained as a sticky 
semi-solid which only on occasion would crystallise. The coupling reactions 
gave fairly low yields, although Dr McClintock had also reported problems
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with this step. Sufficient quantities of (125), (126) and (127) were obtained 
for testing. Spectroscopic data were obtained and were consistent with 
literature values.
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Scheme 16 Preparation of N-alkyl spermidine analogues (125), (126) and 
(127)
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4.2.2 Other Reported Syntheses of A/-alkyl Polyamines
A wide variety of chemistry is available to the synthetic chemist when 
building polyamines, especially an increasing number of protecting groups 
may be used.
Nordlander and co-workers studied the production of linear amines 
based on the formation of peptide bonds and subsequent reduction (Scheme 
17).116 Rather than our approach of using carbamate protecting group 
chemistry the amino acids were converted into A/-(trifluoroacetyl)amino acid 
chlorides by a combination of ethyl trifluoroacetate and then oxalyl chloride. 
The acid chlorides were coupled with amines to produce protected amides 
which were reduced using borane-dimethyl sulphide to give unsymmetrical 
putrescine analogues. The protecting group could also be removed and the 
free amine coupled with other A/-(trifluoroacetyl)amino acid chlorides to give, 
after reduction, polyamides. This route leads to a potentially wide range of 
analogues.
O
TFAHN Cl
DCM, NHRR'
21--------  TFAHN
i) CF3C 0 2Et, MeCN
ii) oxalyl tphloride 
O
+
HoN O
TFAHN
O
m o o * KpCOs, MeOH 
H20
,0
H2N NRR'
O py- O
NRR'
i) K2C 03, MeOH, H20
ii) R"COCI, K2C 0 3, H20
iii) BH3-DMS;H+
3CI R"H2N " ~ V0 T ' ' '  N NHRR'
Ho
Scheme 17 Synthesis of polyamines
A similar approach was adopted by the group of Mamos who used the 
bulky triphenylmethyl (trityl, TRT) protecting group to protect their amino 
acids (Scheme 18).1 17  This protecting group was very useful as its 
hydrophobic and bulky nature facilitated work up and purification. The 
protected amino acid118 was coupled with various amines, using DCC, and
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reduced by lithium aluminium hydride to form protected amines. These could 
be further coupled with protected amino acids to give amides which were 
again reduced to give a variety of spermidine analogues. Again this route 
may lead to a variety of products and is of a similar length to Scheme 16.
These approaches used similar ideas to our group as seen in 
Scheme 16, but with different choices of protecting group and a variety of 
reducing agents for the reduction of polyamides.
Scheme 18 Synthesis of polyamines
The group of Joao used carbamate protecting group chemistry similar to that 
shown in Scheme 16 although functionalising amino alcohols, rather than 
acids (Scheme 19).119
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Scheme 19 Preparation of polyamines
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The aminoalcohol was BOC protected and the alcohol converted into 
a protected amine using the TROC (2 ,2 ,2 -trichloroethyl carbamate) reagent 
under Mitsunobu conditions. 120 The protecting groups were removed to 
yield mono-protected diamines which were reacted with acrylonitrile. 
Protecting groups were added to produce compounds that could be further 
functionalised when desired.
The group of O'Sullivan had also been looking at alkylated spermidine 
derivatives for testing against parasitic diseases (Scheme 20 ) . 81  
Spermidine was selectively protected on the primary nitrogens using ethyl 
trifluoroacetate, the secondary nitrogen was alkylated and the protecting 
groups were subsequently removed. This led to both primary (b) and 
secondary (a) functionalised derivatives in a low number of steps; however 
this route is only suitable where the carbon backbone is constant and the 
alkylating group changed. In order to produce analogues where the carbon 
chain varies the starting polyamine must be available.
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Scheme 20 Selective protection of spermidine in synthesis of its derivatives
72
4.3 Preparation of A/,A/-Dialkyl Polyamines
In tandem with the production of our A/-alkyl spermidine analogues we 
decided to look at A/,A/-dialkyl polyamines. These would contain a free 3- 
aminopropyl unit and be disubstituted on N8.
4.3.1 Synthesis of Saturated and Unsaturated Spermidine Analogues
The synthetic consideration was how to distinguish between the three 
available nitrogens of spermidine to functionalise where required. The 
approach of McClintock was fairly long with a number of low yielding steps 
and were designed for specific analogues. Our new approach used four key 
reactions: Gabriel synthesis; Sn 2 displacement; Michael addition on 
acrylonitrile and lithium aluminium hydride reductions (Scheme 21, Scheme 
22).
O
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H
Scheme 21 Preparation of unsaturated A/,A/-dialkyl polyamines
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The Gabriel synthesis has been well reviewed81- 121> 122« 123 and is 
widely used for the formation of primary amines, due to the excellent yields 
obtained and the variety of methods that may be used for removal of the 
phthalimide group. 124 In brief, it is the alkylation of a phthalimide anion with 
an alkyl halide and subsequent removal of the phthalimide group to leave a 
primary amine. We had access to unsaturated alkene (8 6 ) and the saturated 
phthalimides (136) and (137) shown in Scheme 22 were commercially 
available. The use of the phthalimide group does limit the reaction to 
secondary amines as primary amines have a tendency to attack the 
protecting group; however we only wanted to use secondary amines so this 
was not a consideration.
O O
Br^ 0 P N
n=1 136
n=2137 O
NHR2, MeCN Ft.\
o
n=1 R=Me 138 
c.HCI, c. AcOH n= 2  R=Me 139
NaOH, CHCI3 n=1  R=Et 140
n=2 R=Et 141
NC R
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n=1 R=Me 146 
n=2 R=Me 147
n= 1  R=Et 148 UAIH4 , AICI3 , Et20;
n=2 R=Et 149 OH‘
R
n=1  R=Me 142 
n=2 R=Me 143 
n=1 R=Et 144 
n= 2  R=Et 145
H2N
R 3CI R
n=1  R=Me 150 
n= 2  R=Me 151 
n=1 R=Et 152 
n=2 R=Et 153
n=1 R=Me 154 
n= 2  R=Me 155 
n=1 R=Et 156 
n=2 R=Et 157
Scheme 22 Preparation of saturated A/,A/-dialkyl polyamines
The Sn2 reaction is widely reported in the literature, although there 
are problems associated with overalkylation of the halide when preparing 
primary and secondary amines. In general the order of reaction is I > Br > Cl
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> F; however iodide ions can be added to improve the reactivity of other 
halogens. 125 We used the modification of potassium fluoride on Celite in our 
reactions. 126 The use of alkali metals in such reactions has been shown to 
promote /V-alkylations in aprotic solvents by allowing the protic organic 
compound to form hydrogen bonds with fluoride ion. After acidic removal of 
the phthalimide group and basic work up the diamines, (129), (8 8 ), (142), 
(143), (144) and (145), were isolated in excellent yields.
The Michael addition involves the addition of amines to an activated 
carbon-carbon double bond using reagents such as acrylamide, 
vinylpyridines, acrylic acid and its esters and acrylonitrile. 125 The reaction 
on acrylonitrile is extremely useful in our work as after reduction it adds a 3- 
aminopropyl unit, one of the common substructures of polyamines. 127 The 
reaction can be controlled by using stoichiometric ratios of the reactants to 
give mono- and di-substituted 2 -cyanoethylamines. Such a reaction was 
used by Israel et al. in the 1960s when preparing spermidine and spermine 
analogues. 128 Using the procedure of Israel et al. the diamine was stirred at 
0  °C and acrylonitrile was added dropwise over 15 minutes. The reaction 
was gradually warmed until it was heated at 60-70 °C for 2  hours. This 
method was designed to prevent overalkylation of the nitrogen and provided 
excellent results with yields of (130), (131), (146), (147), (148) and (149) all 
over 60%. If necessary the amine could be purified by distillation; however 
temperatures lower than 120 °C were needed to prevent retro-Michael 
reactions and hence loss of product.
Reduction of the nitrile is not straightforward as hydrogenation leads 
to a mixture of products. The intermediate is an aldimine which can be 
reduced to give the primary amine or it can react further under reducing 
conditions to give secondary or tertiary amines.
In hydrogenation reactions the choice of catalyst is crucial with cobalt, 
nickel and ruthenium catalysts yielding primary amines; copper and 
ruthenium tend to give secondary amines; and platinum or palladium gives 
tertiary amine products. In the laboratory the most common reagent is 
lithium aluminium hydride or borane. 1 2 5  We chose lithium aluminium
R -C N  ------► R -C  =  NH
H
-  R - C - N H 2
h 2
r - c - n h 2 ,h2
h 2
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hydride-aluminium chloride, for its ease of use and lack of reactivity with the 
carbon-carbon double bonds of (130) and (131). The use of aluminium 
chloride for aiding nitrile reductions is well documented and has been shown 
to increase the yield of such reductions. 129 ’ 130 This method has also been 
used by Bergeron and co-workers for the reduction of nitriles. 131
The main problem with lithium aluminium hydride work up is the 
formation of a sticky precipitate which makes product extraction less efficient. 
This was overcome by the addition of strict quantities of water and 15% 
sodium hydroxide. For every n g of lithium aluminium hydride was added n 
ml of water, 3n ml 15% NaOH, and n ml water. This gave an excellent solid 
which was filtered and washed. In many cases the product of the reduction 
"stuck" to the aluminium and was hard to recover in good yields. A recent 
alternative that may be considered is the replacement of the aqueous work 
up with triethanolamine. This is reported to have improved yields. 132 Widom 
and co-workers have also reported mild methods for extracting amines under 
neutral conditions. 133
The yields for the Michael addition and reduction are shown in Figure 21, 
with all but (133) formed in reasonable yield. The yield is related to the 
aqueous work up where, due to the hydrophilic nature of these compounds, 
some material is lost.
nitrile yield (%) product reduction yield 
(%)
130 60 132 58
131 90 133 35
146 87 150 58
147 66 151 60
148 68 152 62
149 74 153 57
Figure 21 Comparison of yields for Michael addition and subsequent 
reduction
The increasing number of nitrogens in these compounds leads to 
problems in synthetic reactions. If the products are impure column 
chromatography is extremely difficult, due to amines "streaking" on silica and 
sometimes alumina, and distillation is sometimes problematic. Using the 
reactions shown in Scheme 21 and 22 we obtained products in excellent 
yields and with high purity. The trihydrochloride salts were all formed by the
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use of ethereal hydrochloric acid as discussed in chapter 3 and were stable 
enough to be handled for medium lengths of time in the air and were 
submitted for testing.
4.3.2 Other Reported Syntheses of Spermidine Analogues
Phthalimides had been utilised by Edwards and co-workers when 
preparing spermidine analogues for antitumour testing.69  An appropriate 
bromophthalimide reacted with an aminosulphide, with the amine protected 
as a phthalimide. Removal of the protecting group with hydrazine resulted in 
spermidine analogues with the central nitrogen replaced by sulphur (Scheme
P h t h N B r  ') nBuLi, THF
P h t h N ^ ^ S H  10 H2NNH2 H2°  „  H2N ^ ^ . S ^ - ^ N H 2 
Scheme 23 Sulphur-substituted spermidine analogues
The Michael addition was utilised by Israel and co-workers. 128 A 
variety of analogues was prepared using this chemistry (Scheme 24).
Scheme 24 The use of acrylonitrile for polyamine synthesis
4.3.3 Analytical Data on A/,/V-Polyamines
It was easy to confirm that a diamine, such as (8 8 ), had undergone 
Michael addition due to the nitrile absorption in the IR spectrum and its CN 
peak in the 13C NMR spectrum. This is exemplified by Figure 22 below, 
showing the IR spectrum of (131). The nitrile resonance is observed as a 
sharp peak at 2250 cm’1, which is common to all these adducts. In this case 
we also observed the C-H absorption characteristic of a trans-carbon-carbon 
double bond, seen at 976 cm'1.
23).
H2N NHp i) 1 equiv. acrylonitrile H2N
ii) H2/ Ni
NH2
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Figure 22 IR spectrum of compound (131), neat solution
The 1H NMR data of polyamines are often inconclusive as many 
signals overlap whereas the 13C NMR data are usually more useful as the 
types of carbons present are easily identified. The 1H NMR (Figure 23) and 
13C NMR spectra (Figure 24) of (148) show the features common to this 
group of compounds. The 1H NMR spectrum shows the expected quartet 
and triplet for the ethyl groups and various multiplets for the aminopropyl 
unit. The methylene protons a- and (3- to the nitrile appear as triplets, 
coupled to each other, and this is characteristic of the 2 -cyanoethyl subunit.
The 13C NMR spectrum shows the aliphatic region where DEPT 
analysis identified all peaks as CH2 apart from the highest field CH3 . The 
quaternary nitrile peak is easily identifiable, occurring at 8  118.6. After the 
reduction the nitrile peak disappears from both IR and 13C NMR spectra and 
the 13C NMR spectrum shows an extra methylene peak.
Figure 23 1H NMR spectrum of compound (148), 200 MHz, CDCI3
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,T"B0 T 170 T"60
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"T"
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Figure 24 13C NMR spectrum of compound (148), 200 MHz, CDCI3
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A comparison of 13C NMR nitrile resonances and IR absorptions can 
be seen in Figure 25 with all values extremely similar.
13C NMR (ppm) IR absorption (cm-1)
146 118.4 2250
147 117.7 2250
148 118.0 2250
149 118.6 2247
130 118.8 2250
131 118.6 2247
Figure 25 Comparison of nitrile peaks in IR and 13C NMR spectra
The mass spectra of amines are not always particularly useful 
especially with the hydrochloride salts where FAB or CI/NH3 must often be 
used to identify molecular ions. Primary fragmentation of the molecular ion is 
favoured and amines fragment as shown in Figure 26. An example of a 
typical fragmentation pattern is shown below in Figure 26 for compound 
(149). The lower molecular mass peaks seen in the spectrum are typical of 
most polyamines. 134
R2(CH2)n— Nx C : l R3 — ^ R 2(CH2)n— N=CH2:HMiU' HN = CH,
* Ho  ^ _
Ri R1 Ri
m /z30
N'  NM 83
r
m/z 143
—  NH2
86 (100%)
Figure 26 Typical mass spectrum fragmentation of a polyamine
Analytical data for polyamines are usually conclusive, although 
microanalysis is not often possible due to the hygroscopic nature of most of 
the salts prepared.
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4.3.4 Biological Evaluation
Antimalarial Activity
The A/-alkyl and A/,A/-dialkyl polyamines were tested in vitro against P. 
falciparum and the results are shown in Figure 27.
activity (pg m l1) LEC (pM)
3,4-A/-ethyl 125 >1000 3540
3,5-A/-ethyl 126 >1000 3370
4,4- A/-ethyl 127 500 1690
3,4-unsat-A/,A/-dimethyl 134 500 1780
3,4-unsat-A/,A/-diethyl 135 500 1620
3,3-sat-A/,/V-dimethyl 154 100 370
3,3-sat-A/,A/-diethyl 155 >1000 3540
3,4-sat-A/,A/-dimethyl 156 1000 3370
3,4-sat-A/,A/-diethyl 157 10 30
chloroquine 2 <1 <1.9
Figure 27 In vitro activity of spermidine polyamines
The biological data were disappointing. Polyamines (125), (126), 
(155) and (156) were essentially inactive. Within the A/-ethyl series the most 
active compound had a 4,4 carbon chain (127) although it showed no 
significant activity. The unsaturated analogues (134) and (135) had virtually 
no activity, which was in contrast to the putresine results where the (E)-1,4- 
diaminobut-2-ene moiety improved activity. Comparing the A/,A/-dialkyl 
saturated analogues there is no consistent structure-activity relationships: 
3,3 dimethyl > 3,3 diethyl; 3,4 diethyl > 3,4 dimethyl. The most active 
compound of this group is (157); diethyl substituted with a 3,4 carbon chain 
and with a LEC similar to that of our original lead compound (77) of 18-36 
|iM. We did not prepare any A/-alkyl unsaturated analogues due to 
disappointing data for (134) and (135).
Previous work by Porter had seen success when spermidine 
analogues were tested as antitumour agents. N1,N8- Spermidines had 
activity in vitro against L1210 cell lines.63 The N1,N8-derivatives decreased 
all polyamine pools; in contrast to DFMO which did not affect the spermine 
pool. We have no information on the ability of our N ,A/-dialkyl polyamine 
analogues to affect polyamine pools.
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We can draw no logical conclusions from our results, other than the 
fact that the compounds were disappointing in activity and no correlation can 
be drawn between the variation of the carbon chain or the /V-substitution 
patterns.
It was decided to take the most active analogue (157) and prepare 
some derivatives containing a benzyl group to see if this improved the 
activity.
Antifungal Activity
Spermidine is the predominant polyamine in fungi and perturbation of 
spermidine function may be effective at reducing fungal growth. 
Commercially available spermidine analogues have been shown to control 
powdery mildew on barley under experimental conditions. Two of our 
spermidine analogues (125) and (126) were tested for anti-fungal activity by 
Dr D. R. Walters, Scottish Agricultural College, Auchincruive, with the full 
results published. 135
Greatest control was achieved using 1.0 mM of (125) which reduced 
rust infection of broad bean plants by 77.6%. Analysis was done to 
determine the effects of (125) and (126) on fungal polyamine biosynthesis 
and to look at the incorporation of radiolabelled ornithine into polyamines in 
fungus grown in the presence of the analogues. Neither compound had any 
effect on the incorporation of radio-labelled ornithine into polyamines, which 
suggests that fungal biosynthesis was unaffected by (125) and (126). These 
results are in contrast to tests on norspermidine which was shown to perturb 
polyamine biosynthesis in potatoes. In view of the antifungal activity of these 
compounds more detailed studies on their effects on polyamine metabolism 
are needed.
If these analogues are unable to perturb polyamine biosynthesis this 
may explain the lack of activity observed in our in vitro tests on P. falciparum. 
Certainly in other work the ability to disturb polyamine biosynthesis has been 
crucial for activity against antiproliferative diseases. 1* 63
4.4 Benzyl Substituted Spermidine Derivatives
There are three possible places that the benzyl group could be placed 
in (157) and therefore we have three target polyamines (162), (165) and 
(167).
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4.4.1 Preparation of Compound (162)
Scheme 25 shows formation of (162) by the same reactions used to 
form the A/,A/-dialkyl spermidine analogues (Scheme 22).
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Scheme 25 Formation of spermidine derivative (162)
The diamine (158) was prepared from phthalimide (137) displacing 
with /V-ethylbenzylamine. The Michael addition did not go cleanly as before 
with the desired nitrile (159) formed in only 21% yield and the dialkylated 
product (160) was isolated in 27% yield. This may be due to the viscous 
nature of (158) and stirring in a dilute solution of methanol or ethanol may 
improve this step. The mixture was separated by silica column 
chromatography with ethanol as eluent. Reduction went in good yield and 
the trihydrochloride salt of (161) was formed; however it was extremely 
hygroscopic and formed only as an orange thick oil. At this point we decided 
to examine an alternative salt for those hydrochlorides that were 
troublesome. Formation of the benzoate salt of (161) was attempted by 
stirring the free amine with benzoic acid in benzene; however no precipitation 
occurred. The same problem was observed when attempting to prepare the 
succinate salt. The use of oxalic acid is well known and has been previously 
used for formation of polyamine salts. 11 9  The triamine was dissolved in 
methanol and a solution of oxalic acid in methanol was added. Precipitation 
occurred immediately and the solid could be recrystallised to yield (162).
i
iiiI
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4.4.2 Preparation of Compound (165)
It is extremely difficult to functionalise a secondary nitrogen in the 
presence of the sterically more available primary nitrogen, so alkylation of N4 
in the presence of N1 was not attempted. The nitrile (148) contains the 3- 
aminopropyl unit effectively "hidden" as a 2 -cyanoethyl moiety and was used 
to overcome this problem (Scheme 26). Alkylation of (148) was achieved 
with benzyl bromide in acetonitrile and triethylamine. The same problem of 
overalkylation occurred as in 3.4 and (163) was isolated in 20% yield. The 
reaction could be repeated in the presence of Hunig's base to try and 
prevent quaternary salts forming. Mohri et al. have also looked at this 
problem and have shown that tertiary amines can be prepared from 
secondary amines and the alkyl halide in the presence of potassium hydride 
and triethylamine in good yields. 135  Reduction of the nitrile in the usual 
manner afforded (164) and this was converted into the trihydrochloride salt. 
This was also hygroscopic; however the product was not obtained in 
sufficient yield to attempt further preparation of salts. It is interesting to note 
that the hydride reductions of (159) and (163) gave higher yields than those 
for the aliphatic triamines, the values being nearer 80% than 60%. This is 
probably due to the hydrophobic group present on these compounds which 
makes them more organic soluble and easier to extract during work up.
BnBrr MeCNr NEt3 rNH 148
UAIH4-AICI3 , Et20; 
NaOH, CHCI3
H+/ Et20
3CI H3N
Scheme 26 Preparation of spermidine derivative (165)
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4.4.3 Preparation of Compound (167)
Reductive alkylation has been used widely in the alkylation of amines 
and has been widely reviewed. 122 - 136 It is a popular and longstanding route 
to amines, due to the high yields usually obtained and the ease of reaction. 
In this case alkylation must occur only at the primary nitrogen and work by 
Martell and co-workers had shown this was possible to achieve without 
protecting the internal nitrogens. 137 We used the chemistry of Sclafani et al. 
who had looked at selective alkylation of the primary nitrogens in polyamines 
with aromatic aldehydes. 138  Heating (153) at reflux in chloroform (dilute 
conditions) with 1 equivalent of benzaldehyde gave the imine in 2  hours 
which was not isolated but reduced with sodium borohydride in methanol 
using standard conditions. (166) was formed in excellent yield (95%) with no 
evidence of alkylation on the secondary amine (Scheme 27); presumably the 
primary amine of (153) is sterically more available than the secondary amine 
and reacts in preference with benzaldehyde. The trihydrochloride salt (167) 
was isolated as a cream solid.
HoN PhCHO, CHCI3; 
NaBH4, MeOH; H+; 
NaOH, CHCI3
BnHN
H+/ CHCU
BnH2N
Scheme 27 Formation of spermidine derivative (167)
4.4.4 Synthesis of W-Benzyl Spermidine (173) and Homologue (175)
So far we had only considered one compound with the benzyl on the 
secondary nitrogen (165). Bergeron and his group were interested in the 
formation of polyamine catecholamide iron chelators, including parabactin 
and agrobactin. They had been looking at the formation of A/-benzylated 
triamines for use in the selective acylation of polyamines leading to the 
formation of these compounds (Scheme 28). This chemistry also led into 
other selectively /V4-acylated compounds.112
RR
R
F
O
O
R"=OH Agrobactin 
R"=H Parabactin
Scheme 28 Synthetic routes to parabactin and agrobactin
We were interested in the variety of A/-benzyl compounds the group 
had prepared. We could then investigate the importance of the various 
nitrogens and carbon chains on antimalarial activity. The 3,4 (173) and 4,4 
(175) analogues were prepared following the principles of Bergeron and co­
workers (Scheme 29).112« 131« 1 39> 140
Benzylamine was alkylated with 4-chlorobutyronitrile in acetonitrile 
and triethylamine. This differs from the approach of Bergeron et al. who 
alkylated in the presence of butanol and sodium carbonate. The alkylation is 
accompanied by formation of the mononitrile (170) as well as the desired 
diniitrile (169); however purification was achieved using silica gel 
chromatography with ethanol as eluent. This problem was also reported by 
Bergeron et al. who proposed that a number of equilibria were controlling the 
reaction. The mononitrile (170) however could be further alkylated with 
acrylonitrile and purified in the same manner to yield dinitrile (171). This 
gave us the two desired dinitriles which were reduced with lithium aluminium 
hydride to yield the 3,4 (172) and 4,4 (174) /V-benzyl polyamines. Bergeron 
et al. chose to reduce the nitriles using hydrogen over Raney nickel, in 
ethanol, in the presence of sodium hydroxide. In a previous communication 
Bergeron had used lithium aluminium hydride for the same reduction and we 
followed this method, but using our basic work up. 131 The mixed salt that 
precipitated from the reduction was, in our case, washed with methanol to 
ensure maximum recovery of the triamines. Occasionally, after
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concentrating in vacuo, some salts still remained. The triamine (172) or
(174) was then taken up in small amount of DCM and the unwanted salt 
removed by filtration. After production of the trihydrochloride salts (173) and
(175) these compounds were submitted for testing.
BnNHo 4-chlorobutyronitrile. „ NC
168
MeCN, NEt3
LiAIH/i-AICU. EtoQ:
NaOH, CHCI3
HV Et20
169 26%
+
BnHN
170 30%
acrylonitrile
75%
171
UAIH4-AICI3 , Et20;
NaOH, CHCI3
Product Reported Yield Our yield 
167 65% 72% H2N
85%
172
H+/ Et20
3CI H3N
Scheme 29 Preparation of A/-benzylspermidines (173) and (175)
HBn 'r
4.4.5 Biological Evaluation
The in vitro results for the benzyl polyamines are shown in Figure 28. 
No data are available on compound (165).
Compound (167) with the benzyl on the primary nitrogen did show 
slightly improved activity compared to (157). Neither of the compounds 
prepared following the work of Bergeron et al. had better activity than (167) 
and we found that the 3,4 carbon chain analogue was the most active. This 
may be related to the extra hydrophobic nature of the compound and this 
agrees with the work of Edwards et al. on spermine analogues where
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terminal benzyl groups improved activity. It is speculated that the benzyl 
group is quickly removed by metabolism and that this action is related to the 
compounds activity.77
activity (pg m l1) LEC (pM)
3,4-sat-/V,A/-diethyl 157 10 32
/V-ethyl-A/-benzyl 162 1 2.5
A/,/V-diethyl-2°/V-benzyl 165 - -
A/./V-diethyM °A/-benzyl 167 5-10 12-24
3,4-A/-benzyl 173 10 60
4,4-A/-benzyl 175 50 140
chloroquine 2 <0.1 <0.19
Figure 28 In vitro results for benzyl spermidine compounds
There is little in the literature on the biological activity of 
unsymmetrically substituted spermidine analogues; however the work of 
Porter64 showed symmetrical A/7,/Vs-analogues did have better activity 
against L1210 cell lines than A/4-alkylated derivatives of spermidine. The 
relatively lower activity of (173) and (175) may be related to the inability of 
these analogues to affect polyamine pools and (173) was evaluated by 
Porter against L1210 cell lines and had only negligible activity. The 3,4 
carbon chain analogue (173) is more active than (175) maybe due to the 
similarity to spermidine and therefore more efficient cellular uptake. Work by 
O'Sullivan et al. on spermidine analogues as possible antiparasitic agents 
had shown that (bis)napthylspermidine had excellent activity.81
In contrast to the cancer work where diethyl substituents seem 
sufficient for good activity, in the parasitic diseases some aromatic moiety 
seems necessary.
4.5 Preparation of Sperm idine-Quinoline Derivatives
As in the previous chapter it was decided to prepare some quinoline- 
based compounds. Prior to 1942 little attention had focused on quinolines 
with alkylamino side chains in the four position, but since the discovery of 
chloroquine an explosion of literature was witnessed. Variations in the 
quinoline ring and the side chain were investigated.141 Work tended to 
concentrate on the formation of C-4 carbon chains attached to the quinoline
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ring so we decided to investigate some spermidine derivatives; including 
attaching the quinoline ring to a primary or secondary nitrogen. Previous 
workers in this area had prepared a quinoline derivative with a 3,3 carbon 
backbone attached by condensation of triamine (152) with 4,7- 
dichloroquinoline. 142 Marquez and co-workers had looked at a number of 
quinolines with polyamine side chains varying from 3,3; 3,4 or 3,4,3 with one 
quinoline ring attached. They had also looked at some bisquinolines with the 
two quinoline rings joined by 3,3 or 3,4,3 carbon chains.147
4.5.1 Synthesis of Compound (179)
The reaction of the triamine (153) with 4,7-dichloroquinoline was not 
attempted due to the small amount of triamine available. Instead the alkyl 
halide (177) was prepared via the corresponding alcohol (176).
3-aminopropan-2-ol
HBr, H2S 0 4
145, MeCN, NEt3
NHEt
H+/ EtpQ
Scheme 30 Formation of a spermidine-quinoline conjugate (179)
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The alcohol and bromide were previously prepared by Bolte143 who heated 
4,7-dichloroquinoline with 3 -aminopropan-1 -ol for 1 2  hours at 130 °C We 
adapted this route by heating for a slightly longer 18 hours, and trituration in 
1 mol dm-3 NaOH yielded a cream solid in 85% yield. The previous authors 
had precipitated the solid from ether and recrystallised it from ethanol-water 
to yield the product in 75% yield. The bromination was carried out, in our 
hands, by 48% hydrobromic acid and concentrated sulphuric acid compared 
to the previous authors who used only 48% hydrobromic acid. The quinoline 
derivative (178) was then prepared by the usual Sn2 reaction with diamine 
(145). The excess diamine was removed by Kugelrohr distillation and the 
trihydrochloride salt (179) was isolated in the usual manner (Scheme 30).
4.5.2 Attempted Synthesis of Compounds (180) and (182)
So far no attempts had been made to prepare spermidine analogues 
with a quinoline ring on N4. We had successfully prepared (179) with the 
quinoline on N1 so it would be interesting to compare activities of these 
analogues. The first attempt is shown in Scheme 31. The diamine (99) was 
stirred in acrylonitrile; firstly with sodium hydroxide in methanol and then with 
ethanol at higher temperatures and for up to 1 week. In both cases no 
product (180) was formed.
NEt. NC NEtHN
 acrylonitrile
Cl
99 180
Scheme 31 Attempted preparation of compound (180)
This is perhaps not a surprising result as the nitrogen we were trying 
to alkylate has reduced nucleophilic character due to delocalisation. Vitale 
and Chiocconi recently discussed alkylation of aromatic amines, although not 
quinolines, and used nBuLi and an alkyl halide to achieve alkylation. 144
The second attempt involved diamine (149) with the nitrile group 
already attached (Scheme 32). Synthesis followed the usual method of 
heating in phenol for 6  hours at 160 °C. After work up a cream solid was 
isolated; however no nitrile absorbance was seen in the IR and no nitrile 
peak appeared in the 13C NMR spectrum.
H
149, phenol
NEtc
NC NEt
Cl
182
Cl
181
Scheme 32 Attempted preparation of spermidine-quinoline conjugates
The resulting product was identified as (181) presumably due to a retro- 
Michael reaction occurring (Scheme 33). Previous authors had also shown 
that condensation with a secondary nitrogen was unlikely under these 
conditions145 although Singh et al. have prepared bisquinolines using 
secondary amines under the same conditions. 146 Attempts to prepare these 
analogues were discontinued.
Marquez et al. had tried to prepare a quinoline derivative with the 
quinoline ring attached to the secondary nitrogen (183).147
NC
nJ ~ V CN ^ c n  n c
Cl ClH
184NC CNphenol,
NC
NHCl
CNNC
ClCl 183
185
Scheme 33 Loss of acrylonitrile to give (185)
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They had heated 4,7-dichloroquinoline with dinitrile (184) in phenol 
then intending to reduce the dinitrile to a diamine; however only the 
mononitrile (185) was recovered.
4.5.3 Analytical Data on Spermidine-Quinoline Derivatives
All singly charged ions in the mass spectrum which contain carbon 
atoms will give rise to another peak one mass unit higher due to the natural 
abundance of 1 3C. Chlorine atoms consist of 35CI and 37CI present in an 
isotopic ratio 3:1, and bromine atoms consist of 79Br and 81 Br in the ratio 
1:1. Molecular ions or fragments that contain these atoms give rise to 
patterns in the spectrum due to this isotope effect (Figure 29).135
Cl
 m/z -- m/zi
Br
37CI 35CI
Probability of finding the two 
isotopes is 3:1, with the peaks 
two mass units difference
81 Br 79Br
Probability of finding the two 
isotopes is 1 :1 , with the peaks 
two mass units difference
CIBr
--- m/z.
37CI 
81 Br
35CI
79Br
There are four possibilities that may be 
observed in the spectrum:
35CI+79Br probability 37.5%
35CI+81Br |----------------- ["probability 12.5%
37CI+79Br v [probability 12.5%
37CI+81Br probability 12.5%
This leads to three peaks in the spectrum, 
mass difference of two units between each, 
in the ratio3:4:1
37CI 
79Br 
and 
35CI 
81 Br
Figure 29 Isotope effects form chlorine and bromine in quinoline compounds
The quinoline derivatives prepared contain chlorine and sometimes 
bromine and show these expected effects. Compound (177) has three 
molecular ions at m /z 301, 299 and 297 in the ratio 1:4:3. The other
quinolines prepared in this work contain only chlorine and we observe the 
1:3 ratio expected in those mass spectra.
The aromatic region of the 1H NMR spectrum of quinoline compound
(176) is shown in Figure 30. Many of the features of this spectrum are seen 
in all our analogues and are described below.
in
8 , 0
Figure 30 Typical aromatic region of a quinoline derivative, 360 MHz, CDCI3
Protons 3' and 2' are coupled with a value of 5.7 Hz which is a little 
larger than the corresponding coupling in quinoline itself of 4.3 Hz. Proton 6 ' 
is easily identified as a doublet of doublets coupling to both H-5' (9.0 Hz) and 
H-8 ' (2.1 Hz). H-8 ' is seen only as a doublet coupling to 6 ' (2.1 Hz) with no 
longer range effects seen. H-5' is also a doublet with a coupling constant of 
9.0 Hz again a little larger than that seen in quinoline (8.2 Hz). In the 1H 
NMR spectra of quinoline derivatives protons at 3' are 6 ' are shielded by 
resonance effects, similar to those seen earlier (3.4.2) and this results in
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them resonating at a higher field, i.e. lower 8 . Proton 8 ' is shielded by 
resonance but deshielded by the nearby chlorine atom and appears at 8  
7.65. The proton at 2' is deshielded by the electron withdrawing effects and 
resonance of the nearby nitrogen and occurs at the lowest field (Figure 31).
NHR
176 (ppm) 176 J  (Hz) 178 (ppm) 179 (ppm)
2' 8 . 2 2 5.7 7.75 7.81
3' 6.35 5.7 5.95 6.34
5' 7.91 9.0 7.66 7.25
6' 7.23 9.0, 2.1 6.60 6.82
8' 7.65 2 .1 7.15 6.84
Figure 31 Comparison of 1H NMR data for quinoline derivatives, 200 MHz, 
CDCI3
A combination of coupling constants and chemical shift values make 
the protons in these compounds identifiable although the smaller coupling is 
not always observed. Similar effects are observed in the 13C NMR spectra of 
related compounds (Figure 32).
176 {ppm) 178 (ppm) 179 (ppm)
2' 151.9 151.3 142.8
3' 125.8 125.2 124.4
4' 149.1 148.3 139.9
5' 127.2 126.4 127.9
6' 99.4 98.9 99.3
7' 136.2 135.4 137.3
8' 124.1 124.1 118.7
9' 152.6 151.5 155.5
10' 118.5 117.7 114.6
Figure 32 Comparison of 13C NMR data for quinoline derivatives
The carbons in C-2' and C-9' positions come at lowest field. C-4' is 
deshielded by its neighbouring nitrogen atom, whilst C-7' is deshielded by a
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chlorine atom which produces a weaker effect. The chemical shift values for 
both 1H and 13C NMR spectra are extremely constant, with the only notable 
difference being evident after conversion of free base (178) into the 
trihydrochloride salt (179).
4.5.4 Biological Evaluation
The in vitro activity of (1 79 ) was, unsurprisingly, excellent and 
comparable with chloroquine. It would be interesting to compare (100) and 
(179) and see the effect of the side chain on activity (Figure 33).
activity (pg ml-1) LEC (pM)
179 <0.1 <0.21
chloroquine 2 <0.1 <0.19
Figure 33 In vitro activity of a spermidine-quinoline conjugate
4.6 Investigations of Spermine Analogues
Previous work in the anticancer area had looked at the relative 
abilities of putrescine, spermidine and spermine analogues to inhibit cell 
growth.64 Conclusions drawn stated that the relative order of activity was 
spermine > spermidine > putrescine. Edwards and co-workers working on 
polyamines as antimalarials had also looked at spermine analogues; varying 
the central carbon chain from 5-12 methylene units and they also found the 
compounds with benzyl groups on the terminal nitrogens to be active.77
We decided to prepare the spermine analogues with benzyl groups on 
the internal nitrogens as these had not been investigated for antimalarial 
activity.
4.6.1 Preparation of Compounds (189) and (192)
The saturated analogue (189) was prepared in excellent yield starting 
from putrescine.148- 149’ 60 Putrescine was reductively alkylated using 
benzaldehyde, (186) and was then stirred at 60-70 °C in an excess of 
acrylonitrile to yield (188) which was reduced in the normal manner to afford 
the tetraamine in good yield. 1,4-Diaminobut-2-ene is not readily available
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and so diamine (93) was used, prepared as in 3.4, and the same set of 
reactions were then followed. The two tetraamines were converted into the 
tetrahydrochloride salts (189) and (192) which were hygroscopic peach 
coloured solids (Scheme 34).
HoN.
16
PhCHO, MeOH^ BnHN 
'2 NaBH4, MeOH, H+ 
NaOH, CHCI3 
100%
HoN.
4CI HoN
186NHBn
acrylonitrile 81%
Bn 187
Bn
N
UAIH4-AICI3 , Et20; NaOH 78%
N ' ^  ' NH* 
Bn 188
H+/ Et20
HBn 189
BnHN.
93
acrylonitrile 
NHBn 83% NC
HoN.
LiAIH4-AICI3
Bn 
N
190
Et20; NaOH 79%
N 
Bn
H+/E t20  1 9 1
4CI HoN HBn
Scheme 34 Preparation of spermine analogues (189) and (192)
4.6.2 Biological Evaluation
In vitro activity of the two spermine analogues is shown in Figure 34. 
The spermine analogues had good activity, better than any putrescine or
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spermidine analogues prepared. Again (189) was more active than the 
unsaturated analogue (192) which was consistent with the spermidine 
analogue results.
activity (pg ml-1) LEC (pM)
sat-dibenzyl 189 0.5-1 1-2
unsat-dibenzyl 192 5-10 10-20
chloroquine 2 <1 <1.9
Figure 34 In vitro activity of compounds (189) and (192)
Edwards et al. had isolated a polyamine analogues with a 3,7,3 
backbone and benzyl substituents on the terminal nitrogens and it had an 
IC50 value of 3.0 pM against P. falciparum  and was curative when 
administered at 15 mg kg-1 with DFMO.77 Our saturated spermine analogue 
(189) compares favourably with this in vitro value.
In the search for active compounds against T. cruzi O'Sullivan and co­
workers had extended the synthesis of spermidine derivatives to spermine 
derivatives.81 Using the same protecting group chemistry spermine 
analogues were prepared with internally alkylated nitrogen atoms. Their 
most active spermine derivatives had internal nitrogens alkylated with 
hydrophobic groups (Scheme 35).
H2N N
H
H
N NH2
i) CF3C 02Et, MeCN, H20
ii) RX, NEt3, MeCN
iii) K2C 03 MeOH
Scheme 35 Preparation of spermine derivatives
Synthetic routes to spermine analogues for study of antiparasitic 
activity were also investigated by Bellevue and co-workers80 who found the 
most active compound had a 3,7,3 carbon chain with the terminal nitrogens 
alkylated with cycloheptylmethyl. The 3,7,3 analogues had little anticancer
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activity so the carbon backbone seems to be of importance for parasitic 
diseases. Edwards in his work on spermine analogues had also found the
3.7.3 carbon skeleton to be active with benzyl substituted on the terminal 
nitrogens.77
4.6.3 Other Reported Syntheses of Spermine Analogues
Nordlander et a/ . 116 also looked at extending their methodology to 
higher chain polyamines. The amide with a free amino group could react 
with succinic anhydride and open the anhydride to add on a four carbon 
chain with a free acid group. This free acid group was converted into an 
amide and the amide reduced to yield the polyamine. This chemistry could 
be easily adapted to produce a wide range of analogues (Scheme 36).
O
HoN
O O
NRR'
CHCI3  |_|Q
o
'R"RN
H
N
NRR'
i) diamine, DCC
ii) UAIH4 , Et20
N ^ 0 ^ NRR'
Scheme 36 Preparation of higher polyamines
A similar approach was also used by Mamos et al. to give spermine 
analogues alkylated at either terminal or internal nitrogens. 117 The choice of 
amines is easily altered to provide a number of closely related structures. 
Protection of terminal nitrogens as trifluoroacetates followed by reduction 
gives amines with reduced charge due to the electron withdrawing effects of 
the terminal groups.60
The Michael addition with a variety of Michael acceptors has been 
used including methyl vinyl ketone, as shown in Scheme 37.69
O
2  steps
BnHN NHBn H o N .
BU ^ Bn
2  steps 
Bn / \ Bn
Scheme 37 Preparation of higher polyamines
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4.7 Preparation of Guanidinylated Tetraamines
4.7.1 Introduction
The group of Kumar and co-workers were studying the formation of 
1,3-diaminopropanes and their role in the activity of polyamines against 
leishmania. 150 Leishmania is a parasitic disease, as is malaria, so it was 
relevant to read about their studies. They prepared a number of compounds 
with the 1,3-diaminopropane pharmacophore where one nitrogen was 
present in a heterocyclic ring and the other in a guanidine group (Figure 35).
C1 R= COOCH3 
or
C2 R= H
R'= piperidine
(4-phenyl)piperazine 
(4-phenyl)piperidine 
4-(2-pyridyl)piperidine 
(4-methyl)piperidine 
(4-methyl)piperazine 
morpholine
RH= H  
or
RM= Et
Figure 35 Structure-activity results on 1,3-diamines
They discovered that the 1,3-diaminopropane subunit was a good 
backbone for designing antileishmanial agents. If one nitrogen was 
incorporated in a cyclic system the compounds (A) had moderate activity. If 
the free amine was functionalised with a 2-cyanoethyl group (B) activity 
increased. If the free amine was converted into a b/scarbomethoxy moiety
(0 1 ) activity reached a maximum compared to the free guanidine derivatives
(02) which had little activity. If both nitrogen atoms were in heterocyclic rings 
(D) the compounds had little activity (Figure 35).
Badry et al. had also looked at (bis)carbomethoxy guanidines as 
histamine-H2 receptor antagonists151 and Rao etal. had studied the reaction
NHR
A 'R‘
B 'R‘ CN
R"I
Y
N,
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of a number of di- and polyamines with /V,AT-b/scarbomethoxy-S- 
methylisothiourea. 152
We decided to convert the primary amines of (188) into 
(bis)carbomethoxyguanidines to see the effect on activity.
4.7.2 Synthesis of Compound (196) and its Salts
To introduce the free guanidine into a compound and then 
functionalise is often difficult due to the basicity of the guanidine moiety. 
Thiourea (193) was to be converted into the b/scarbomethoxy intermediate
(195) which would react with our tetraamine to yield the desired product. 
First attempts to prepare (195) followed the route of Hazelton et a/ . 153 which 
did not isolate (194), but precipitated (195) from solution; however no product 
was isolated. The next attempt followed the procedure of Schildneck and 
thiourea was methylated with dimethyl sulphate in water to give (194) in good 
yield. 154 (194) was then dissolved in aqueous sodium hydroxide and 
reacted with methyl chloroformate to give (195) in reasonable yield. 155 The 
tetraamine was stirred with (195) in ethanol overnight and purification was 
achieved by silica chromatography-150 The yield was low due to the large 
amount of aromatic impurities formed in the reaction and chromatography 
was repeated to isolate a pure product (196) (Scheme 38).
4.7.3 Analytical Data for Compound (196)
The 1H NMR spectrum of (196) shows the expected multiplets for the 
methylene protons 2, 3 and 6  which are least affected by the p-nitrogen 
atoms. The protons a- to nitrogen atoms 1, 4 and 5 appear as a multiplet at 
5 2.37 with protons at the 7 position appearing at slightly lower field due to 
the deshielding effects of the guanidine group (6  3.35). The methylene 
protons at H-3 occur in the expected area for benzylic protons and are 
followed by two singlets for the carbamate methyl groups. We observe two 
different signals for these methyl groups (5 3.62, 6  3.74), with an integral of 
1 :1, suggesting only one configuration of the (bis)carbomethoxy moiety 
although we have left stereochemistry undefined. The aromatic protons 
appear as a multiplet and we see a broad triplet for an NH group indicating 
coupling which must be CH2 NFL (8  8.29). The next NH peak is further 
deshielded and corresponds to NHCC^Me (8  11.59). Work by other groups 
on biscarbomethoxy guanidine compounds also report the NHCC>2 Me at 
fairly high 8  values. 151 - 152
100
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Scheme 38 Preparation of a biscarbomethoxy guanidine compound (196) 
and its salts (197) and (198)
Two methyl peaks also appear in the 13C NMR spectrum (5 52.5, 5 
53.1). The aromatic carbons appear as three CHs and one C in the usual 
order. We have three peaks left which are assigned to the two quaternary 
carbonyls and the guanidine quaternary carbon.
The guanidine moiety exists as tautomers. We also have the 
possibility of rotameric forms. Considering the wide variety of possible 
influences a fairly simple spectrum was obtained.
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H H
MeO N N.
T Y
O N
OY
OMe
10MeO—^
O
N O
16
A lN 8 
H
N
H
11 OMe 
12
1H ppm 13C ppm
2,3 1.37 2,3 24.5
6 1.62 6 26.3
1,4,5 2.37 1,4 39.4
7 3.35 5 50.8
13 3.44 1 0  or 1 2 52.5
1 0  or 1 2 3.62 1 0  or 1 2 53.1
1 0  or 1 2 3.74 7 53.7
15,16,17 7.19 13 58.5
NHCH2 8.29 17 126.5
NHC02Me 11.59 15 128.1
16 129.8
14 139.5
9 or 8  or 11 154.2
9 or 8  or 11 155.8
9 or 8  or 11 164.3
Figure 36 1H and 13C NMR data for compound (196)
Attempts were made to prepare the oxalate and hydrochloride salts of
(196). The oxalate salt (198) was prepared by dissolving (196) in a small 
amount of methanol and adding one equivalent of oxalic acid, also in a small 
amount of methanol. Unfortunately (196) precipitated as a sticky gum, 
although 1H and 13C NMR spectra were obtained. The 1H and 13C NMR 
spectra were very similar to the free base with the two methyl signals 
appearing in a ratio of 1:1. Protonation of (196) will occur initially at the most 
basic position which are the nitrogens of the benzyl group in the centre of the 
molecule. Oxalic acid is only a weak acid and as one equivalent was used 
only these nitrogens appear to be protonated giving simple spectra for (198), 
as seen for (196).
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Figure 37 1H NMR spectrum of compound (196), 200 MHz, CDCI3
H
Figure 38 13C NMR spectrum of (bis)carbomethoxy guanidine derivative 
(196), 50 MHz, CDCI3
The hydrochloride salt was prepared by precipitating the salt from 
chloroform with HCI/CHCI3 . Again only a sticky gum was obtained and the 
1H and 13C NMR spectra of (197) were more complicated than those seen 
previously. The most noticeable difference was the appearance of three 
singlets in the 1H NMR spectrum corresponding to three environments for 
the methyl groups and the 13C NMR spectrum shows extra peaks in both the
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aliphatic and aromatic regions. Using a stronger acid that was not added in 
a specific number of molar equivalents may have led to protonation of the 
(bis)carbomethoxyguanidine moiety (Figure 39).
OMe
H H
.0
 L
HV CHCI3 MeO—^
NH O
FU Jo+.AN N OMe
H HA
/ /  "MeO—\
NH O
N N OMe
H H
Figure 39 Protonation of the (b/s)carbomethoxy moiety
If we assume complete protonation of the benzyl nitrogens we could 
have protonation of one (bis)carbomethoxyguanidine moiety or of both. For 
each of these possibilities we could also see rotamers, as discussed before. 
This leads to a very complicated spectrum, and no attempts were made to 
assign any peaks.
4.8 Future Work
The preparation of spermidine analogues was, at first, a promising 
lead; however after preparing a number of compounds we still did not see 
any great antimalarial activity. The antifungal results were more promising 
and. No future work is planned on the synthesis of such spermidine 
analogues.
Spermine analogues were more promising and there are a number of 
leads that would be worth following up in this area. The work of a number of 
research groups has shown that 3,7,3 carbon skeletons impart greater 
antimalarial activity on polyamine analogues and are possibly the best for 
parasitic disease chemotherapy. (189) was our most active spermine 
derivative to date and it may be worth preparing the 3,7,3 analogue of this 
(199) to see if the change in carbon skeleton improves activity. The 3,7,3-
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b/sbenzyl analogue (200) may also be worth preparing and is similar to (67) 
which was prepared by Edwards et al. and has the benzyl groups on the 
terminal nitrogens.
Strong guanidinium-carboxylate interactions have been observed in 
substrate-enzyme binding with MGBG, an anti-tumour agent, and its 
analogues are known to be taken up by polyamine transporters. 15 6 - 157 - 158  
We do not intend to prepare any free guanines but those functionalised as 
(bis)carbomethoxy are worth considering as Kumar and co-workers found 
that these were more active than the free guanidine. The preparation of 
(bis)carbomethoxyguanidine (196) and its salts should be pursued. 
Alternative salts, e.g. picrate, maleate and succinate should be prepared to 
produce crystalline salts that could be tested. Again, the 3,7,3 analogue
(2 0 1 ) would also be worth preparing.
HoN
HBn 
N
HBn 
N
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BnHN
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4.9 Summary
The preparation of spermidine analogues led to a number of 
compounds; however out of those tested we did not see any great 
antimalarial activity. The addition of a benzyl group did increase activity, 
especially in the spermine area where results have been more promising.
We were still interested in looking at DNA binding as it is often 
mentioned that this may be related to good activity of polyamine analogues 
as they displace the natural polyamines from DNA. In the next chapter a 
number of polyamines were prepared that may lead to greater activity 
against P. falciparum.
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5
5 DNA Binding and Chemotherapy
5.1 Introduction and Rationale
The recognition of one molecule by another is crucial to many 
biological reactions such as DNA replication, molecular transport and also 
drug action. Within DNA the two antiparallel strands of adenine(A), thymine 
(T), guanine (G) and cytosine (C) are supported on the phosphate-sugar 
backbone and form different conformational types of DNA called A, B, D or Z, 
with B-DNA being the most common. The DNA structure that forms provides 
a variety of places for interaction with other molecules by hydrogen bonding, 
Van der Waals forces and electrostatic interactions.159
A compound can bind in a number of ways to DNA and can also show 
selectivity for the major or minor groove, specific base sequences and sites 
of DNA base pairs. We can broadly categorise the modes of DNA binding as 
follows.
Intercalators are planar molecules, usually consisting of three or four fused 
rings that insert between stacked nucleic acid base pairs, e.g. adriamycin
(2 0 2 ) which is important in cancer therapy.
OH DNA-G-[N-7]COCHoOH
OH CICH2CH
n + c h 3
CHoCHoCI
N -C H
OMe O OH H
202 /r repeat
HO -7]-G-DNADNA-G-[N-7;
NH
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Covalent groove binders contain electrophilic groups such as aziridines or 
cyclopropanes and are found in many compounds that are capable of 
covalent interaction with DNA. Nitrogen mustards are one of the most 
common classes acting by crosslinking DNA through covalent bonding to the 
guanine N-7 atoms in the major groove, e.g. mechlorethamine (203). 
Non-covalent minor groove binders are held in position by hydrogen 
bonds, Van der Waals forces and electrostatic interactions, e.g. distamycin A 
(204) and netropsin (205). The interactions of netropsin with AT-rich DNA 
are shown in Figure 40.
O
H
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H
N
N
O
204
H
N
NH,
+ 
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5'
HoN
205
Van der Waals forces 
Hydrogen bonds
Figure 40 Interactions of netropsin with AT-rich DNA
Polyammonium salts bind to DNA through electrostatic interactions 
which are, in most cases, non-sequence specific. Whilst remaining close to 
the DNA the polycation retains a high degree of freedom within the 
polyamine-DNA complex. The exact position of the binding interaction is not 
known, e.g. minor groove, major groove or phosphate backbone, and this 
has caused some debate (2.7). Spermine has been shown by crystal
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structure to bind to a dodecamer of DNA (CGCGAATTCGCG) and spans the 
major groove of a GC base pair with its terminal nitrogens making 
electrostatic interactions with phosphates on opposite strands of the DNA 
duplex. The central nitrogens are close to guanine 0-6  and cytosine N-4 
substituents.160* 161,162 Larger molecular weight DNA binding compounds 
such as proteins make use of complementary side chain interactions with AT 
and GC base pairs to promote tight complexation. Lower molecular weight 
polyamines bind to DNA but lack the structural features necessary to give 
pronounced AT/GC selectivity. 163
The structure, dynamics and reactivity of DNA with biologically active 
molecules and non-intercalating ligands have been the subject of many 
studies recently. 164 Several ligands show DNA-binding specificity that leads 
to inhibition of DNA and RNA synthesis and a broad spectrum of antiviral, 
antibacterial, antitumour and antiprotozoal activity. 165
Distamycin A (204) has been shown to bind to the minor groove of 
DNA by Van der Waals forces between the CH protons of the pyrroles and 
C-2 hydrogens of adenine; and by electrostatic interactions between the 
terminal cationic groups and the phosphate DNA backbone. Distamycin A 
has a specific interaction with dA.dT rich areas of DNA, in contrast to other 
pyrrole-amidine antibiotics such as anthramycin which exert a preference for 
dG.dC base pairs. 16 5 - 166
Berenil (206) is another AT selective DNA groove binder. It acts 
irreversibly on T. brucei brucei AdoMetDC and is used as an effective 
trypanocidal agent.161
These AT-rich sequences may correspond to areas of maximum 
molecular electrostatic potential which may attract ligands with cationic 
functional groups. Hydrogen bonding is not essential for AT selectivity. This 
is shown by the bisquaternary ammonium heterocycle (207) which cannot 
hydrogen bond but still binds in the minor groove with AT selectivity. In 
general, good steric fit in the minor groove is a key requirement so that the 
adduct can be stabilised by electrostatic potentials; however hydrogen 
bonding, where possible, will also contribute significantly to stability. 159 - 167
207
108
Our rationale for this area of work comes from work showing that the 
genome of P. falciparum is extremely rich in A+T (over 80% in most species) 
whilst the human host consists of only 59% A+T. Ligands specific for AT-rich 
DNA could be more inhibitory to the parasite than the host, and hence be 
effective antimalarials. 1 65 - 168
Those compounds with AT selectivity may be effective against 
parasitic diseases and indeed this is already the case with berenil. 
Distamycin A is also a potent inhibitor of parasite growth and investigations 
showed that this compound is more toxic to the ring stage of P. falciparum 
growth than trophozoite or schizont stages. This corresponds with the life 
cycle stage when most of the nucleic acid synthesis takes place. Distamycin 
A has been shown to be more toxic to parasites than mammalian cells. In 
contrast GC specific agents were more toxic to the mammalian cells than the 
parasite cells, as predicted by the rationale above. The use of distamycin A 
for anticancer work was abandoned, due to toxicity to the host. The toxicity 
against malaria parasites is 2000-3000 fold higher than against the host 
cells. There is hope that the extra permeability pathways found in the 
infected erythrocyte can be exploited to increase toxicity to the parasite and 
yet restrict the access to host cells, hence overcoming this problem.
Distamycin has suffered problems with low water solubility and there 
is concerted work to improve on this. A phenyl analogue of distamycin A 
(208) recognises AT-rich sequences of DNA through the minor groove as 
shown by Dasgupta and co-workers. 169
O
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Lee et al. prepared (209) where the amide group was replaced by an 
amidine moiety, to improve water solubility. 170 The C-terminus in (209) 
contains the dimethylaminoethyl moiety which like the propioamidine group 
of (208) and distamycin A recognize an AT base pair. It is these functional 
groups we are interested in for our polyamine work.
The use of diamidinic compounds on diseases caused by parasitic 
protozoa has greatly increased and Calonge and co-workers tested a 
number of diamidines, such as (210) and (211). The target of aromatic 
diamidines is DNA and binding takes place in the minor groove regions of 
DNA. Several other authors have found cationic diamidines to have strong 
inhibitory effects on AdoMetDC and putrescine transport in parasitic protozoa 
and host cells. This is shown by a depletion in polyamine pools and a 
reduction in cell proliferation. 171
There is some dispute as to whether the antiproliferative effect of such 
compounds may be due to displacement of polyamines from their site of 
interaction with DNA thereby inhibiting replication/ transcription; however the 
formation of amidines is definitely worth pursuing.
The dimethylaminoethyl moiety and propioamidine group recognize an 
AT base pair and we wanted to incorporate these groups into some of our 
analogues to see if there was any antimalarial activity. We proposed two 
spermidine and two spermine analogues to synthesize and test for activity in 
vitro against P. falciparum.172
The spermidine analogues (212) and (213)  contain the 4 carbon 
backbone with an A/-benzyl substitutent on one end. On the other end is the 
functional group dimethylaminoethyl (212) or propioamidine (213). The 
spermine analogues also contain the four carbon backbone with dibenzyl 
substitution similar to our active spermine analogue (189) and the 
dimethylaminoethyl group on each end in (214) and propioamidine groups in 
(215).
5.2 Approaches Towards Spermidine Analogues
5.2.1 Initial Approaches to Compounds (212) and (213)
Considering the structure of our two target compounds we decided 
that an approach similar to that of Scheme 16 would provide a suitable 
starting point. This would use the BOC protected aminobutyric acid (108) to 
prepare amides (216) and (217) using mixed anhydride coupling conditions. 
BOC removal and reductive amination would provide intermediate amides 
which would be reduced to give the target products (including separate 
production of the amidine moiety) (Scheme 39).
Production of amide (216) went in reasonable yield (65%) and it was 
obtained as cream crystals. Removal of the BOC protecting group gave a 
hygroscopic semi-solid (218) which would not crystallise, so reductive 
amination to (220) was attempted on the crude material. Using 1 equivalent 
of benzaldehyde, 1 equivalent of triethylamine and 1 .2  equivalents of sodium 
borohydride in methanol (218) were heated at reflux for 2  hours and then left 
at room temperature overnight. A complex mixture of products was 
obtained, shown by TLC, and purification was not attempted.
The functional groups that may be problematic are the amide and 
nitrile. Amides are not normally reduced by sodium borohydride, but require 
other reagents. This is also true about nitriles so the mixture of products was 
a surprise. 1 7 3  This route was discontinued as further stages in the 
sequence, e.g. selective reduction of amide functionality over nitrile in (2 2 1 ) 
would cause problems. An alternative was sought.
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Scheme 39 Attempted synthesis of compounds (212) and (213)
Purification of (217) caused problems when no crystallisation 
occurred. Alumina column chromatography was successful, eluting with 
hexane-ethyl acetate (4:1) enabling us to isolate (217), albeit in low yield 
(14%). Unfortunately the same problems with BOC deprotection and 
reductive amination occurred as with (2 2 0 ).
One alternative would be the reduction of (219) to the polyamine (224) 
and then selective reductive amination on the primary nitrogen as described 
before. This synthetic route was investigated briefly; however only 
intractable mixtures were obtained. The other consideration is use of the
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BOC protecting group. It is acid labile and removed easily in 3 mol dm-3 
acid; however these acid conditions might affect the nitrile group. If partial 
protonation was occurring in the deprotection step of (216) it could lead to 
the unwanted side reactions.
5.2.2 Other Approaches to (213)
We decided to prepare intermediate (225) which did not have the 
amide functionality and would allow direct formation of the amidine moiety 
from nitrile (223). In route A the benzyl group is added first and then the 2- 
cyanoethyl; whereas in route B the 2-cyanoethyl is added first followed by 
the benzyl group (Scheme 40).
| A h
BnHN
16
formic acid, 
benzaldehvd% BnHN. 
2 6  mol dm 3 HCI;
OH- 82%
NH
213 H
BnHN
225 " 2
acrylonitrile
HoN.
16
NH,
acrylonitrile 
60% HoN
Scheme 40 Attempted synthesis of compound (213)
PhCHO, reductive 
amination
226 H
Putrescine is particularly difficult to monofunctionalise due to the two 
identical amino groups and its tendency to give bifunctionalised compounds 
even if the diamine is used in excess. Bergeron and co-workers had looked 
at this problem and developed an alternative route for the preparation of 
(225).174 Putrescine was dissolved in formic acid at 0 °C and 1 equiv. of 
benzaldehyde was added. The solution was warmed to room temperature 
and then refluxed until the benzaldehyde had disappeared by TLC. After 
cooling and the addition of 6  mol dm-3 hydrochloric acid the solution was 
heated at reflux for 18 hours to remove any formamide. Distillation afforded 
(225) in good yield. We wanted to alkylate the primary nitrogen with 1 
equivalent of acrylonitrile whilst not affecting the benzylic nitrogen. The first 
attempt involved stirring diamine (225) at 0  °C and slowly adding 1 equiv. of 
acrylonitrile, following the procedure of Israel et alJ28 On work up, NMR
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spectroscopy revealed a complex mixture of alkylated products, shown by 
the extra quaternary carbon peaks in the nitrile region. The second attempt 
used the same reaction conditions but on a solution of (225) in ethanol to 
provide a more dilute system. Overalkylation occurred here also.
Route B also started from putrescine, this time utilising the chemistry 
of Israel et al. to form (226).128 Putrescine and 1 equiv. of acrylonitrile were 
stirred at 0  °C and then gradually warmed to 60-70 °C for 2  hours, and the 
product was purified by distillation. The benzyl group was then to be added 
by reductive amination. We chose to use the chemistry of Sclafani et a / .138 
heating (226) at reflux in chloroform with 1 equivalent of benzaldehyde to 
form the imine selectively on the primary nitrogen. After concentration of the 
solution sodium borohydride in methanol was added to reduce the imine. 
Unfortunately this route resulted in a large number of products in the final 
mixture, shown by TLC. Purification was not attempted.
Reactant Desired Product Conditions Result
225 213 1 equiv. overalkylation
acrylonitrile
225 213 1 equiv. overalkylation
acrylonitrile in
ethanol
226 213 CHCI3, PhCHO; mixture of
NaBH4, MeOH products
226 213 CHCI3, PhCHO; mixture of
NaCNBH3, products
MeOH
Figure 41 Attempts to prepare (213)
Examining the intermediate (226) the problem of side reactions may 
be related to the introduction of the benzyl group using reductive amination. 
The milder reducing agent sodium cyanoborohydride was used; however this 
also resulted in a number of products. This may be due to the slightly acidic 
nature of chloroform leading to side reactions of the nitrile group.
Looking at route A we have a problem of a mixture of alkylation 
products so if we can protect the secondary nitrogen we only have to 
concentrate on adding one 2 -cyanoethyl unit to the primary nitrogen.
The quickest route to protect the secondary nitrogen would be directly 
(route C) rather than the more laborious route of protection of the primary
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nitrogen then the secondary nitrogen and deprotection etc. shown in route D 
(Scheme 41).
BnHN
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Scheme 41 Attempted preparation of (213)
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Few routes are available for the selective protection of a secondary 
amine in the presence of the more sterically favourable primary amine. 
Selective reaction of the secondary amine in the presence of a primary 
amine was investigated by Barrett and Lana using 18-crown-6.175>176 18-C- 
6  is able to complex primary ammonium salts by N-H— O hydrogen bonding 
and N+■■■■O interactions. This is a form of dynamic protection with the 
primary nitrogen held in a complex whilst the secondary nitrogen is acylated 
(Figure 42).
BnHN
OTs
Figure 42 Complexation of NH3+ by 18-C-6
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Ganem et ai. had also used this type of methodology in the selective 
acetylation of secondary amines. 177  Adapting this route of Barrett et at. 
diamine (225) was stirred in acetonitrile with p-toluenesulphonic acid. The 
solution was concentrated in vacuo to give a clear oil which was stirred in 
DCM at 0 °C. Triethylamine (1.1 equiv.) and then trifluoroacetic anhydride 
were added and the solution was stirred at room temperature overnight. 
Purification of the concentrated solution was attempted using a mild basic 
wash and also column chromatography; however the desired product (227) 
was not obtained as a pure sample.
The longer route D was then attempted. The diprotected putrescine 
(228) had been prepared by Bergeron and co-workers by stirring (225) in 
THF with BOC-ON . 174 Purification was carried out by column 
chromatography rather than their distillation techniques as the lower 
pressures needed for efficient distillation were not easily attained on our 
vacuum pumps. This may be the reason for the lower than reported yield. 
We then wanted to protect the secondary nitrogen. Obviously the protecting 
group should not be acid sensitive as we wanted to remove BOC and leave 
on this new group. Removing the protecting group at a later stage was also 
a consideration as we did not want any side reactions with the nitrile group 
i.e. no reducing conditions. The choice of group was trifluoroacetyl which is 
base labile under mild conditions. The protected putrescine (228) was stirred 
in methanol with ethyl trifluoroacetate for 48 hours before concentrating in 
vacuo to give a thick yellow oil. Purification was achieved by silica 
chromatography and (229) was isolated in 53% yield. The reaction had not 
gone to completion by TLC suggesting that the secondary nitrogen is not 
highly susceptible to the reaction with the ester. This is not surprising due to 
the steric hindrance around the nitrogen; however the use of a stronger 
acetylating agent was not investigated in case of lability of the BOC group 
under harsher conditions. Column chromatography resulted in isolation of 
both the desired product and starting material which could be recycled. The 
BOC group was removed in the usual way to yield (230) as a thick yellow oil; 
however upon trituration with ether a white powdery solid was obtained in 
good yield (65%). Attempted alkylation of (230) in ethanol with one 
equivalent of acrylonitrile was attempted; however initial indications were that 
overalkylation had again occurred. This route was only attempted once on a 
small scale and may be worth pursuing.
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In brief, the selective protection of (225) on the primary nitrogen with 
the TFA group to give (232) goes in excellent (80%) yield; and could be an 
alternative strategy.
5.2.3 Analytical Data for Compounds (228), (229) and (230)
The variations in the NMR spectra as we introduce different protecting 
groups onto the polyamines are highly noticeable.
Formation of (228) led to the introduction of a BOC group, which is 
easily recognisable in the 1H NMR (Figure 43) and 13C NMR spectra 
because of the tert-butyl group.
11
| 1 . , I , I  . 1 I I 1 I I I ■ I I I I I I I I I I - | ■ ■ ■ ■ I ■ ■' 1 '  i 1 ■' '  1 I ’  t " 1 ' '  ’! " r " ’  1 1 I ’ 1 I ^  •* 'I  '  1 1 '■ I • ■ ■ • ■ ‘ ■
s ’ j, 7 .0  7 .0  ft.O fi.O 5 .0  5 .8  4.0 4 .3  S'.O 3.B 2,0  2.3  J.O i . f l
Figure 43 1H NMR spectrum of (228), 200 MHz, CDCI3
Protons 2  and 3 form the expected multiplet followed by a multiplet for 
H-1 and then H-4. The benzylic protons occur as a singlet as does the
aromatic region. In the 13C NMR spectrum we have the usual four peaks for
the aromatic ring with C10=C14 and C11=C13. The IR spectrum of (228)
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shows a sharp stretch at 3335 cm' 1 corresponding to the NH of the 
carbamate, and a variety of peaks around 1500-1700 cm-1 due to the C=0  
stretch of the carbamate (expected value ROCON 1740-1690 cm-1) and the 
C=C stretching of the aromatic ring. The C-H deformation of the aromatic 
ring gives two peaks at 754 and 700 cm-1 characteristic of a mono­
substituted benzyl ring, and this is common to all these adducts.
Figure 44 shows the 1H NMR spectrum of compound (229) containing 
the BOC and TFA protecting groups. The singlet for the BOC group is still 
present; however it appears very finely split, suggesting two environments for 
those protons. The usual multiplets appear for H-2 and H-3 with H-1 and H-4 
appearing more complex than in the spectrum of (228). The benzyl protons 
no longer appear as a singlet, but as two singlets indicating magnetic non­
equivalence. The aromatic region is also split into two distinct areas, rather 
than the usual singlet. The carbamate NH is slightly hidden underneath the 
benzylic protons signal. The IR spectrum is very similar to (228) with the 
C=0 stretches of the amide and carbamate overlapping at 1688 cm-1.
Figure 45 shows the 13C NMR spectrum of compound (229). The 
tertiary butyl group is obvious as the large CH3  identified by the use of 
DEPT. There is a large number of aliphatic CH2 peaks in the spectrum and 
in the aromatic region of the spectrum there are 5 CH peaks corresponding 
to each separate carbon atom and two quaternary peaks appear for C-9. 
The carbamate quaternary carbon is found at 6  155.9 and the TFA 
quaternary carbon peak is not observed. This is due to the C signal being 
split into a quartet by the three neighbouring fluorine atoms, and hence the 
signal is too weak to be seen. All these factors suggest the presence of 
rotamers of (229) with the magnetic inequivalence this brings due to 
interconversion between rotamers being slow on the NMR time scale.
Figure 44 1H NMR spectrum of compound (229), 200 MHz, CDCI3
<33
PFK
Figure 45 13C NMR spectrum of compound (229), 50 MHz, CDCI3
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The 1H NMR spectrum of (230) contains broad multiplets 
corresponding to the methylene protons 2,3, and 4. H-1 appears as a triplet 
at lower field due to the electron withdrawing effects of the amide group. The 
benzylic protons H-8  are partially obscured by the DOH peak of the NMR 
solvent so we are unable to ascertain whether it appears as two singlets. 
The aromatic region is still split into two distinct areas. The 13C NMR 
spectrum is more defining and is seen in Figure 46. The large CH3 signal is 
no longer present confirming BOC deprotection. Protons 2  and 3 appear as 
four CH2 peaks around 8  25. At lower field appears another CH2 peak and 
then four more CH2 carbons at approximately 8  50. This corresponds to 1-C 
and 8 -C leaving the single peak at 8  40 due to C-4. This appearance of extra 
peaks in the 13C NMR spectrum is characteristic of the presence of 
rotameric forms of (230). The two rotameric forms are magnetically 
equivalent in some regions of the spectrum as at 8  40 where only one peak 
is seen. Elsewhere multiple peaks are seen.
Figure 46 13C NMR spectrum of (230), 50 MHz, D2O 
5.2.4 Approaches Towards Compound (233)
In order to produce a suitable compound for testing (233) was 
established as a new target, containing an amide linkage rather than the 
benzyl group. This compound was designed as the selective acylation of 
primary amines was reported in the literature and we would see if this type of
16
230
mm
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reaction occurred in reasonable yield compared to the failed attempts at 
selective reductive amination.
The nitrile (226) was available and we wanted to carry out selective 
acylation on the primary nitrogen. A number of synthetic routes exist for the 
selective acylation of primary nitrogens; however we wanted mild conditions 
so as not to effect the nitrile group. Acyl cyanides have been investigated by 
Murahashi in these types of reactions in solvents such as DCM and 
acetonitrile. 178 We decided to follow the procedure of Bergeron who had 
used /V,A/-carbonyldiimidazole (CDI) in the selective acylation of spermidine, 
spermine and other polyamines. 179
Acylimidazoles are generated easily from the carboxylic acid and CDI 
in DCM, at room temperature, in only one-two hours. The amine is then 
added and after stirring for 24-48 hours the acylated amine is formed. 
Imidazole as a side product is easily removed in an aqueous wash and any
remaining carboxylic acid is removed by a slightly basic wash (Scheme 42).
NH
O
V
h 2n NHR
O
H
Scheme 42 Mechanism of selective acylation of primary amines
(226) was added to a pre-stirred solution of benzoic acid and CDI and 
the reaction was monitored by TLC. After 24 hours the reaction was worked
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up as described above to yield a glassy solid. Purification by silica 
chromatography yielded (234) as a white solid. The yield (33%) was fairly 
low, maybe due to the polar nature of the product and therefore loss of 
product during the aqueous work up (Scheme 43). No side reactions were 
observed; maybe the reductive amination step would proceed in a non-acidic 
solvent such as DCM or tetrachloroethane although this was not pursued.
CN
N,N-CD\, DCM, PhC02H
PIk  .N
Me3AI, NH4CI; toluene NH
Prw .N
233 H
Scheme 43 Attempted synthesis of (233)
Conversion of a nitrile into an amidine is carried out by the Pinner 
reaction and has been used to form the amidine functionality in compounds 
such as Distamycin A (204). The reaction is a two step process: reaction 
with HCI/alcohol to give an intermediate imidate salt, followed by a reaction 
with NH3/alcohol to yield the desired imidinium salt. An alternative to this 
traditional method is the use of the Garigipatis modification of Weinreb's 
reagent, which is particularly useful for sterically congested nitriles.180- 181 
The aluminium reagent, originally developed by Weinreb, was prepared by 
the addition of ammonium chloride to commercially available 
trimethylaluminium and the amine complex was then hydrolysed by water 
adsorbed on silica gel (Scheme 44).
HCI, R'OH ||*~* NH3, R'OH Classical Pinner
R -C N  ------------- ^  As.------------ ► JJ+ reaction
R OR' R NH2
R'= Me or Et 
MeAI(CI)NH2,
toluene, 80 °C H20 , S i02 |jj*~* Garigipatis modification
I________ ^  r  \ As. to Weinreb's reagent
H2N Cl R NH2 *
Scheme 44 Preparation of an amidine from a nitrile
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One problem with the Pinner reaction is the need for extremely dry 
solvents to prevent hydrolysis of the intermediate. For ease of the reaction 
and availability of reagents we decided to utilise the Garigipatis method on 
compound (234) to prepare the amidine. After stirring the trimethyl 
aluminium solution with ammonium chloride the nitrile was added and stirred 
at 80 °C for 2 0  hours. The solution was poured onto a slurry of silica gel and 
water and after five minutes the silica was filtered and washed with 
methanol. The concentrated solution was redissolved in a small amount of 
methanol to remove any remaining ammonium chloride and HCI/Et2 0  was 
added. A yellow hygroscopic solid was isolated which by NMR spectra 
showed a mixture of products (Scheme 43).
Lack of positive results from antimalarial testing of our other 
spermidine analogues prompted us to pursue the spermine analogues we 
had designed rather than the spermidine analogues which were proving 
troublesome.
5.3 Synthesis of Spermine Analogue (215) and its 
Tetrahydrochloride salt (235)
The amidine moiety is based around a three carbon unit which 
immediately suggests the dinitrile (187) used previously in the synthesis of 
benzylated spermine analogue (189) as a starting point (Scheme 45). The 
Garigipatis method for production of an amidine was utilised and, following 
the conditions described for (233) we were able to isolate (235) in 40% yield, 
as the hydrochloride salt. The lower than expected yield may be due to the 
polar nature of this compound. The work up involves hydrolysis on silica and 
the polar product will bind to very strongly to it. Although it was washed well 
with methanol some product may be retained on the silica. The 
tetrahydrochloride salt was prepared immediately from the free base.
CN
NC
Bn
toluene
187
+ NH
H
NH
HBn235 4CI
Scheme 45 Synthesis of compound (235)
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Loss of the nitrile peaks from both IR and 13C NMR spectra were 
indications that the reaction had occurred. An IR spectrum of the product 
showed a new absorption at 1689 cm-1 corresponding to the C=N stretch. 
The 1H NMR spectrum was not useful due to the large number of multiplets 
for the methylene protons. The 13C NMR spectrum also confirmed loss of 
the nitrile peak and the appearance of a new quaternary nitrogen at 6  167.0, 
corresponding to the amidine group. We encountered problems trying to get 
a molecular ion for (235) due to extensive fragmentation, even when Cl or 
FAB were used.
5.4 Synthesis of Spermine Analogue (214) and its 
Tetrahydrochloride Salt (243)
5.4.1 Introduction
The synthesis of (214) can be considered in a number of ways and is 
shown in Scheme 45: in route 1 the carbon skeleton is prepared, with the 
A/,A/-dimethylaminoethyl moiety present, and the aromatic group added last; 
whereas in route 2 A/,A/'-dibenzylputrescine is utilised and a two carbon unit 
attached at each secondary nitrogen to form the A/,A/-dimethylaminoethyl 
moiety. We decided to pursue both routes.
BnHN
Me0N
Me0N
NHBn
Scheme 45 Analysis of routes to (214)
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5.4.2 Attempted Synthesis of (214) via Route 1
To form a symmetrical polyamine with a central four carbon unit 1,4- 
dibromobutane or succinic acid are obvious starting materials and both 
routes are shown in Scheme 46.
SOCIg, O 
A/,A/-dimethylethylenediamine, 
Et20 , 8 8 %
A/,A/-dimethylethylenediamine,
237 H
b h 3, t h f
236 H
MeCN, 55%
Scheme 46 Attempted routes to compound (214)
Succinyl dichloride was stirred in dry ether at 0 °C and N,N- 
dimethylethylenediamine (2.2 equiv.) was added slowly. The resulting 
precipitate was filtered and recrystallised from MeOH-EtOH to yield (237). 
The amide reduction was attempted using borane in THF, as used previously 
for our polyamide reductions; however an impure and hygroscopic product 
was isolated which was difficult to purify.
The route from 1,4-dibromobutane was more direct using the usual 
Sn 2 reaction to yield (236). Purification was slightly problematic due to co­
distillation of the product with the starting materials; however on a small 
scale using Kugelrohr distillation the tetraamine was isolated.
We then looked at methods of alkylating the secondary nitrogens and 
a summary of our attempts can be found in Figure 47. The most obvious 
starting point was reductive amination using the usual conditions of 
benzaldehyde in methanol, followed by treatment with sodium borohydride.
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After monitoring the reaction of the tetraamine with benzaldehyde by TLC no 
imine formation had occurred. Direct alkylation with benzyl bromide was 
attempted. Stirring (236) in acetonitrile with Hunig's base, benzyl bromide 
was added slowly; however a large number of UV active products were 
identified by TLC. We wanted alkylation only on the secondary nitrogen and 
had used Hunig's base to help prevent quaternisation; however a large 
number of side reactions had obviously occurred. Reactions with the 
tetraamine and benzoyl chloride in DCM failed to give any product.
Wright had looked at the alkylation of amines by esters and lithium 
aluminium hydride in a one step reaction. 182 He had demonstrated that this 
reaction was unsuitable for preparation of secondary amines from primary 
amines, but was often suitable for the formation of tertiary amines. Low 
yields were recorded if an aromatic amine was alkylated; however the yields 
were generally good when dialkylamines were alkylated. Ethyl benzoate was 
useful as an alkylating agent for the introduction of a benzyl group and this 
method was thought to be good when the formation of quaternary salts was 
to be avoided.
Lithium aluminium hydride was stirred in THF for 30 minutes with 
tetraamine (236). Ethyl benzoate was then added dropwise and the solution 
was heated at reflux overnight. Work up was carried out using basic 
conditions and excess THF was removed by distillation. The resulting 
residue was isolated as a hydrochloride salt, however NMR spectroscopy 
showed only starting tetraamine to be present.
Reactant Desired Product Conditions Outcome
236 214 PhCHO, MeOH, No imine
NaBH4 formation
236 214 BnBr, MeCN, Complex mixture
Hunig's base,
236 214 PhCOCI, DCM Starting material
236 214 PhC02 Et, LiAIH4 Starting material
Figure 47 Summary of attempted routes to (214)
5.4.3 Synthesis of (214) via Route 2
The dibenzylputrescine derivative (186) was available in excellent 
yield from putrescine and we needed a way of adding a 2-aminoethyl unit. A 
review by Bradshaw et al. covers many synthetic routes to polyamines,
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including extending the polyamines by the 2-aminoethyl unit. A large number 
of routes are available for this process and a few are summarised in Figure 
4 8 . 183,184
[ | ^ ^ / N H C H 2CHO , NaCNBH3; HBr, Ac02H 
O
Figure 48 Synthetic routes to the 2-aminoethyl unit
Work started on the opening of an epoxide to form a 2-hydroxyethyl 
unit as prepared by Lee. 148 (186) was stirred in methanol and cooled with a 
dry ice bath as ethylene oxide was added. The flask was stoppered and 
stirred at room temperature overnight. After concentrating in vacuo the 
aminoalcohol (238) was isolated in 60% yield, comparable with the literature 
value. Transformation of the primary alcohol into a leaving group through, 
for example, bromination183 or tosylation was not attempted due to possible 
side reactions from aziridine formation. Instead conversion into either a 
primary amine or the dimethylamino moeity was investigated.
Conversion of an alcohol into a primary amine may be achieved in a 
wide variety of ways.184, 185> 186> 187 Direct conversion form the primary 
alcohol into the dimethylamino group was considered however a suitable 
method was not found.188- 189 The chemistry of Mitsunobu was used 
allowing the transformation of a primary alcohol to a phthalimide followed by 
conversion into the NH2 group and finally the tertiary amine (Scheme 47).
Alcohol (238) was stirred in THF with triphenylphosphine and 
phthalimide. Diethyl azodicarboxylate (DEAD) was added to produce a 
yellow solution which was stirred at room temperature for 12 hours. After 
concentrating in vacuo and triturating in ether-hexane to remove any
R
Reagent
[ > H
O
X=CI, Br X "  CN  
O
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triphenylphosphineoxide the remaining solution was purified by column 
chromatography. Silica was used, eluting with hexane-ethyl acetate; 
however the product was still impure and chromatography was repeated to 
get a pure product. This resulted in a low yield of (239) of only 15%. Due to 
the troublesome nature of this reaction another route was investigated.
Scheme 47 Attempted preparation of (214) via Mitsunobu chemistry
Another reagent for the addition of a two carbon unit is 
bromoacetonitrile or chloroacetonitrile (Scheme 48).
(240) was stirred in chloroform with Hunig's base and 
bromoacetonitrile was added dropwise and the solution was stirred at room 
temperature for 18 hours. The dihydrochloride salt was easily prepared by 
the procedure of Lee et a/ .148 After an aqueous work up the resulting solid 
was recrystallised form ethyl acetate-hexane to yield (241) as fine white 
needles. Reduction of the nitrile used the usual method of lithium aluminium 
hydride and aluminium chloride to yield (242) in good yield (80%).
The remaining consideration was how to form the A/,A/-dimethyl group. 
Conversion of primary amines into tertiary dimethylated amines may be 
achieved using formaldehyde and formic acid (Eschweiler-Clarke reaction) 
which is discussed in a review. 190 Reductive amination with formaldehyde 
can also be used184 with a variety of reducing agents, the most efficient 
being sodium cyanoborohydride. 191 Problems still existed with the reaction 
as a mixture of starting material and only partially methylated products were 
produced. Kim had used zinc-modified sodium cyanoborohydride to 
complete this type of reaction in excellent yields. The zinc-modified reducing
BnHN
NHBn
186
ethylene oxide, MeOH, 
Bn T 60%
HO
N
n ^ o h
238 Bn
DEAD, Ph3P, pthalimide,
NPhth
PhthHN : v  N 
t 239 Bn
Bn t
N
N
214 Bn
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agent was formed by mixing sodium cyanoborohydride and anhydrous zinc 
chloride in a 2:1  molar ratio, in ether. 192
BnH2N.
2Cf 240
BrCH2CN, MeCN
+  ► NC.
NH2Bn 70%
Bn
N
H o N
Bn
N.
37%HCHO, 
61%
241
N ' 'CN 
Bn
LiAIH4, AICI3, Et20; OH’ 
80%
n h 2
NaCNBH3, ZnCI2, Et20
242 Bn
.  \  + 
4CI NH
Scheme 48 Preparation of (214) and its salt (243)
The tetraamine was stirred in 37% aqueous formaldehyde in methanol 
and sodium cyanoborohydride and anhydrous zinc chloride were added. 
After 4 hours at room temperature basic work up yielded (214) as the free 
base in 61% yield. The tetrahydrochloride salt (243) was isolated from 
HCI/CHCI3  to yield a white solid which was slightly hygroscopic, but stable 
enough to be handled.
5.4.4 Analytical Data on (241), (242) and (214)
Formation of nitrile (241) was established by the characteristic CN 
absorption in the IR spectrum at 2230 cm-1 and in the 13C NMR spectrum a 
quaternary carbon peak occurs at 6  114.8. The El mass spectrum gives a 
molecular ion at m/z 346; however the most abundant peak is at m/z 91 
indicating the presence of a benzyl group. Microanalysis also confirmed the 
formation of a pure compound.
Reduction of (241) to give (242) was also easily analysed due to the 
loss of the CN stretch from the IR and the 13C NMR spectra. An extra peak
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appears in the aliphatic region of the 13C NMR spectrum due to the extra 
methylene formed in the reduction reaction. The 1H NMR spectrum no longer 
shows a singlet for NCHpCN but two triplets for NCHpCHpNHp. Cl was 
needed in order to gain accurate mass information; however the El spectrum 
showed the most abundant peak to have m/z 91 again showing the benzyl 
group.
The formation of the tertiary A/,/V-dimethylaminoethyl group of (214) is 
accompanied by a large methyl peak in the 13C NMR and 1H NMR spectra. 
The methylene protons appear as groups of broad multiplets due to the 
similarity in chemical shifts and it is the 13C NMR spectrum which is the most 
useful.
5.5 DNA Binding of Polyamines with a Central Aromatic Core
5.5.1 Introduction
As discussed in section 2.7 Edwards and co-workers had studied a 
number of polyamines with antitumour activity and looked for any 
correlations between activity and DNA binding. If the polyamine analogues 
act by displacing natural polyamines from their DNA binding sites then such 
an action may be relevant. Those polyamines, such as (244), with a central 
aromatic core were comparable or superior to spermine for DNA binding. 
This work also compared well with that of Stewart and Gray (2.7) who looked 
at a wide range of compounds, such as (245), studying their DNA 
interactions to establish structural parameters that would help in the design 
of DNA binding agents in the future.
H2N
H
N
244
N ^ /3 N H
H '2
NH2 (CH2)3HN
NH(CH2)3 NH2
NH(CH2)3NH2
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Another colleague in our group was looking at aromatic compounds 
with a central phenyl core and we decided to expand this work into the 
biphenyl system.
5.5.2 Synthesis of Biphenyl Compound (248) and Attempted Synthesis 
of (249)
Preparation of amide (246) proceeded in fair yield from 4,4'- 
biphenyldicarboxylic acid using the mixed anhydride route. Alumina 
chromatography, eluting with ethyl acetate gave an orange oil which 
solidified on standing and recrystallisation produced (246) as cream crystals. 
Reduction of the amide went in good yield (65%) using borane in THF to 
produce the dihydrochloride salt (248). For the production of the dibenzyl 
analogue (247) the mixed anhydride route was not used due to the low yield 
obtained for (246). Instead the dicarboxylic acid was heated at reflux in 
thionyl chloride for one hour until it had all dissolved and then concentration 
in vauco gave the diacid chloride. The acid chloride was stirred in dry ether 
at 0 °C and benzylamine was added dropwise. A vigorous reaction led to the 
formation of a precipitate which was filtered to yield (247) as a white powder. 
This material was extremely insoluble and a solvent system for 
recrystallisation was not found. Due to this lack of solubility borane reduction 
to produce (249) was not successful (Scheme 49).
= \  OHyo<H
A iBuOCOCI, NEt3, NHEt2 
B SOCI2, Et20  R'
BH3, THF; H+ R.
A 246 R=Et, R'=Et; 35% 
B 247 R=Bn, R'=H; 88%
248 R=Et, R'=Et; 65% 
/ "  'R 249 R=Bn, R'=H; -
Scheme 49 Preparation of (248) and attempted preparation of (249)
Fisher and co-workers had investigated alternative reducing agents 
for tertiary amides including lithium diisopropylaminoborohydride and lithium
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pyrrolidinoborohydride. They were reported to yield the amine or alcohol, 
depending on the steric requirements of the amide, in excellent yield. We did 
not investigate the use of such reagents. 193
5.5.3 Synthesis of Biphenyl Compound (252)
Initial investigations were concerned with adding the 4-carbon unit 
followed by the A/,A/-diethyl group (Route A, Scheme 50).
o
‘BuOCOCI, NEt3, 5 1 %
4-aminobutyraldehyde diethyl acetal 
O.
O OEt
HN 
EtO ) 3
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(| ;3 
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254
OH', DCM
= \  OH
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Scheme 50 Preparation of (252)
132
The dicarboxylic acid was reacted with 4-aminobutyraldehyde 
diethylacetal using mixed anhydride conditions, due to the instability of the 
diacetal in acid. This yielded (250) as a white solid in reasonable yield 
(51%). Attempts to hydrolyse the diacetal to the aldehyde using TFA or the 
milder water on silica gel both failed to give any product.
Instead the diamine (145) was coupled to the diacid to add the N,N- 
diethylaminobutyl moiety directly. The diacid was converted into the diacid 
chloride following the thionyl chloride route, and the diamine (145) was 
added to the acid chloride in dry ether. Due to possible protonation by any 
excess thionyl chloride, aqueous acid kept the salt of (254) in the aqueous 
solution and then basic work up allowed isolation of the free base (254) in 
52% yield. Reduction in the usual manner went in 64% yield and the 
tetrahydrochloride salt (252) was isolated as a cream-green solid (Route B, 
Scheme 50).
5.5.4 Preparation of Compound (256)
Compound (256) was designed to have the central aromatic core and 
contain the dimethylaminoethyl group used in distamycin analogues. The 
amide (255) was prepared in reasonable yield (51%) following the thionyl 
chloride route and reduction went again in good yield (55%) to form the 
tetrahydrochloride salt (Scheme 51).
O
> / /  % = \  .OH
HO \ = \\ //
SOCI2, N,N-dimethylethylenediamine . ~NMe2
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+ /~  
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I))*
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/ /  W
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O
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* / = \ ^ N H 2
V  4Cl" 
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Scheme 51 Preparation of compound (256)
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5.5.5 Analytical Data for Biphenyl Compounds
The aromatic region of the 1H NMR spectra of these compounds 
appears as an AA'BB' system in all of the biphenyl systems prepared. Also 
common to most spectra is the coupling of the amide NH to the neighbouring 
CH2 group, hence it appears as a triplet.
The aliphatic region of the 1H NMR spectrum of (246) would be 
expected to consist of a triplet and quartet for the ethyl groups. Instead we 
observe a broad singlet and a broad doublet (Figure 49). The aliphatic 
region of the 13C spectrum (Figure 50) consists of two CH3  peaks and two 
CH2 peaks. These results are due to the magnetic non-equivalence of the 
CH2 and CH3 peaks and is similar to that observed for N , N- 
dimethylformamide where the two methyl groups are also non-equivalent. 
The line broadening of the 1H NMR spectrum is probably due to 
interconversion between rotameric forms.
Figure 49 1H NMR spectrum of compound (246), CDCI3, 200 MHz
Figure 50 13C NMR spectrum of compound (246), CDCI3, 50 MHz
In general the mass spectra of these biphenyl compounds show 
peaks at m/z 91 and m/z 152 corresponding to fragmentation of the biphenyl 
system. Other peaks usually correspond to loss of fragments from either the 
amide or typical fragmentation patterns of an amine. The IR spectra consist 
of the expected amide stretch at about 1600 cm-1 and a peak between 860 
and 800 cm-1 for the paradisubstituted biphenyl system.
5.5.6 Preparation of Compound (259)
The work of Gray had established that the most active compounds 
had polyamine units attached to the central aromatic ring usually with free 
aminogroups in the terminal positions. Edwards speculated that the activity 
of the benzyl polyamines may be related to fast metabolism of the benzyl 
groups, so we designed compound (259). It was to be prepared as the 
hexahydrochloride salt which could lead to good DNA binding and the 
spermidine side chain with benzyl groups on the terminal positions which 
would be quickly metabolised to leave the free amino groups.
We wanted to carry out alkylation of the secondary nitrogen of 
spermidine so the two primary nitrogens were acylated. Following the 
procedure of Mossi80  spermidine was acylated with benzoic acid using CDI 
to provide selective reactions at the primary positions (see 5.2.4). (257) was 
isolated in 50% yield and was heated at reflux in DMF with a,a-dibromo-p- 
xylene and sodium carbonate. After work up (258) was isolated as a cream 
solid, in low yield (21%). Borane reduction of the tetraamide went in 
reasonable yield (57%) to yield the hexahydrochloride salt (259) (Scheme
52).
The 1H NMR spectrum of (258) consists of a large number of 
multiplets due to the similarity in chemical shift of a number of the protons. 
Two amide NH peaks appear at 6  6.93 and 7.56 and the aromatic region
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contains many multiplets for the protons of the three different phenyl rings. 
The protons for the central symmetrical ring appear as a singlet. 
Microanalysis of (258) confirms the purity of the sample. After the borane 
reduction to give (259) the 1H NMR spectrum simplifies and the aromatic 
region consists of two singlets corresponding to the central phenyl ring and 
the terminal benzyl moieties. There are three benzylic proton environments 
shown by the three singlets at 5 4.03, 4.04 and 4.24. The rest of the 
spectrum consists of multiplets for the aliphatic protons. It was necessary to 
use FAB MS to obtain a molecular ion and therefore accurate mass details 
for (259).
HoN A/.A/-CDI.
Ph. .N
N Ph
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Scheme 52 Preparation of (259)
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5.6 Future Work
Unfortunately a number of compounds are currently being tested so a 
lack of test data makes it hard to determine where this area will lead.
One promising area are those compounds with a central benzene 
ring. Possible future compounds include those shown below, (260), (261), 
(262) and variations of (263). The compounds with amidines are particularly 
interesting due to the high affinity such compounds have been shown to 
have for DNA. A comparison of DNA binding affinities for the polyamines we 
have prepared has not been made, but assays are available for such 
calculations if required.
NHMe-
260 H2N 261
NHMe.
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5.7 Additional Biological Data
In the week leading up to the PhD viva for this thesis additional 
biological data for compounds prepared in chapter 5 were received and are 
shown in the table on p137.
activity (pg ml-1) LEC (pmol)
sat-dibenzyl 189 1-0.5 2-1
amidine spermine 235 0.05-0.001 0.1-0.002
dimethylaminoethyl 0.05-0.01 0.1-0.02
spermine 243
tetraethyl-biphenyl 248 10-5 25-12
dimethylaminoethyl- 50 195
biphenyl 256
benzylspermidine- 0.05-0.001 0.05-0.001
biphenyl 295
chloroquine <0.01 <0.02
Results for compounds 235 and 243 were extremely good with activity 
close to that of chloroquine. It is not, however, correct to say whether this is 
due to increased DNA binding and/or greater selectivity of the compounds for 
AT base pairs although this could be studied in the future. The effect of 
these compounds on polyamine pools and/or polyamine biosynthetic 
enzymes would also be interesting.
The biphenyl compounds were generally not very active, apart from 
the benzyl spermidine analogue 295 which had excellent activity. This 
compound would also be worthy of further study.
5.8 Summary
Yet again the spermidine analogues have proven challenging to 
prepare. Synthetically the spermine analogues are easier due to the 
symmetry of the compounds and our two target compounds were prepared in 
good yield. The next chapter covers two areas where this project might lead 
in the future and gives a brief idea of the types of chemistry it may involve.
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6 Iron Chelation and Macrocyclic Polyamines
6.1 Introduction
This chapter does not seek to cover the wide area of iron chelation 
and macrocyclic polyamines as both are wide ranging and diverse topics. 
Instead a few ideas that were explored in the final stages of this PhD project 
will be discussed and also where it may lead in the future.
6.2 Iron Chelation
6.2.1 Introduction
A wide range of iron chelators, including some natural products, 
have been shown to possess antimalarial activity in vitro and in vivo. This 
includes desferrioxamine (264), although it is not orally active which is an 
essential requirement for treatment of the disease in the tropics. 194
Most clinical impetus for the development of iron chelators has been 
to find treatment for iron overload and this has met with some success. 
Desferrioxamine B has been used to treat iron overload and is one of a 
family of fungal siderophores. Coordination of Fe(lll) occurs via the 
hydroxamate moieties; however hydroxamates are sensitive to the acidic 
environment in the stomach. 195
The malaria parasite spends an essential part of its life cycle in the 
human red blood cell. Many metabolic processes of the erythrocytic 
(human red blood cell) malarial parasite are dependent on iron and 
withholding iron from the parasite, by iron chelators, could conceivably 
disrupt the metabolism of the trophozoite. This may work by preventing
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DNA synthesis, disrupting proteolysis of the host haemoglobin as well as 
other essential functions.194- 196> 197
HoN
OH
I
N
NH
264
OH
N
O
What is needed is an orally active compound with high affinity for 
Fe(lll); which does not redistribute iron supplies in the body and is 
metabolically degraded. 198
6.2.2 Synthesis of Compound (267)
Following the procedure of McKendrick we prepared a tetrazole 
(267) to see if compounds of this type had any activity against the malaria 
parasite. 199
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Scheme 53 Preparation of (267)
90% NC N CN 
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Starting from pyridine-2 ,6 -dicarboxylic acid the diamide (265) was 
prepared and then dehydrated to give dinitrile (266). This was reacted 
with sodium azide to form the tetrazole (267) in excellent yield (Scheme
53). Unfortunately (267) was only active down to 50 p,g ml-1 (246 pmol) 
when tested in vitro against P. falciparum.
6.3 Macrocyclic Polyamines
6.3.1 Introduction
Saturated polyamine macrocycles have been known and studied for 
a long time and have been used mostly as chelating agents for transition 
metal ions. The literature covering this area is prolific and this brief 
introduction will not attempt to provide a comprehensive review of the area. 
Macrocyclic polyamines were discovered to have properties similar to 
biomolecules such as porphyrins (268), peptides (269) and naturally 
occurring polyamines such as spermidine and spermine. One of the major 
properties of macrocyclic polyamines is their strong basicity which leads to 
new properties not shown by the linear polyamines.20 0
Mixed donor macrocycles have been studied because they do not 
normally yield the extreme thermodynamic and kinetic stabilities of the 
tetraaza macrocycles. Recent work by Lindoy has looked into preparing 
"pendant arm" macrocycles with donor groups incorporated in the arms. It 
has been shown by Kaden that such compounds exhibit properties that 
often resemble their parent unsubstituted macrocycles as well as their open 
chain analogues, i.e. a substituted polyamine.201 We decided to make 
initial investigations in this area to see if any antimalarial activity was 
observed.
269 H
O O
268
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6.3.2 Approaches Towards Compound (273)
Following the chemistry of Armstrong and Lindoy, Williamson 
condensation between 1,2-dibromoethane and salicylaldehyde gave 
(270) in good yield (Scheme 54).202> 203
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Scheme 54 Preparation of (272) and attempted preparation of (273)
The macrocycle (271) was prepared according to Grimsley et al. by 
warming the aldehyde and 1,2-ethanediamine in methanol with sodium 
borohydride and borax. Low yields (32%) of the macrocycle were obtained; 
however this was also reported in the literature. Formation of the bisamide 
by stirring (271) and acrylamide in methanol at reflux for two days was 
achieved following the procedure of Chia201 isolating (272) in 37% yield. 
Reduction of the diamide to give (273) had previously not been reported 
and in our hands initial experiments led to only black intractable products.
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No biological data are available of these macrocycles; however the area is 
worth studying in further detail.
6.4 Future Work
6.4.1 Macrocycles That Chelate Iron (III)
Macrocyclic structure is extremely favourable for metal complexation 
so it might be possible to find macrocyclic polyamines that could chelate 
iron and hence disrupt the parasites' growth in the red blood cell and hence 
be used as an antimalarial.
Only limited information is available on macrocycles that will chelate 
iron (III) ; however Kimura had looked at macrocyclic polyamines with side 
arms on a ring carbon.204- 205 a,p-Unsaturated carboxylic acid esters and 
a linear polyamine react via a Michael addition and intramolecular lactam 
formation in a one step annulation reaction to yield (274). Borane 
reduction would then lead to the saturated macrocyclic polyamine with a 
side arm (275) (Scheme 55).
a n  n  NH2 NH2r  f
NH HN"
u
MeOH
NH HN
NH HN
BH3, t h f
275
NH HN
NH HN
Scheme 55 Formation of a macrocycle with a pendant phenol moiety.
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Starting from coumarin, polyamines with pendant phenols were 
prepared and Kimura speculated that such compounds would have 
interesting biological activities.206 Initial studies in this project prepared 
(274) successfully and this synthesis may be worth pursuing. Further work 
also led to the formation of macrocycles (276, 277) with pendant pyridyl 
moieties (Scheme 56).207 Initial work in this area led to formation of 
(276), however the borane reduction gave a mixture of products.
MeOH
NH HN
NH HN
276
NH HN
NH HN
277
NH HN
Scheme 56 Macrocycles with pendant pyridines
These phenol and pyridyl pendant arms project into the cavity and 
are able to co-ordinate metal ions such as iron and nickel axially in contrast 
to a large number of the basic macrocycles that co-ordinate copper and 
zinc, among others (Figure 51 ).200
Fe 'i11
N r r > H
\F e  h i
Figure 51 Chelation of Fe(lll) by polyamine macrocycles 200
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This area would be worth investigating by preparing some 
compounds for in vitro antimalarial testing varying the carbon chain to 
produce a variety of analogues. Both amide and amine are thought to have 
activity so a combination of both might lead to some useful structure-activity 
relationships.
i
6.4.2 2,3-Dihydroxyterephthalimides
The naturally occurring siderophores are low molecular weight Fe(lll) 
sequestering agents produced by microbes and they are able to 
accommodate the preferred octahedral geometry of Fe(lll). Garrett et al. 
studied the coordination chemistry of the bidentate 2,3- 
dihydroxyterephthalimides (278) and found them to be excellent chelators 
of Fe(lll) considering that they were such simple compounds.208 Our group 
had been looking at compounds similar to this, but as amines rather than 
amides; however it might be worth investigating a number of these 
compounds. We could envisage a variety of substituents on the amide from 
benzyl to extended polyamines.
OH
278
6.4.3 2,6-Dioxopiperazines
An excellent review by Hider197 discusses a range of iron chelating 
agents with clinical potential. Herman et al. also cover the activity of such 
compounds.209 One compound discussed is "Zinecard" (279) one of a 
family of bisdioxopiperazines first synthesized by Ciba Geigy chemists in 
the late 1950s. It is uncharged and can therefore enter cells where the 
cyclic imide links are cleaved by intracellular enzymes to generate a 
chelator capable of binding Fe(lll) (Scheme 57). In general this range of 
compounds were developed as potential anti-tumour agents.210’ 211
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Scheme 57 Activation of (279) by enzymes to yield an Fe(lll) chelator
This bisdioxopiperazine moiety may provide a group that we could 
add to our polyamines to produce a variety of compounds that could be 
tested for activity against P. falciparum, for example (280).
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6.5 Summary
A few ideas for future areas our group may expand into have been 
briefly described. The chemistry of macrocyclic polyamines is new and 
interesting and little work has been done to ascertain if any of these 
compounds have antimalarial activity. Iron chelation has been studied in 
depth and there is evidence in the literature that it may prove a useful 
therapeutic tool against malaria. If we can combine both areas then we 
have a broad range of future work to cover!
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7
7 Experimental
Reagents were purchased from Aldrich Chemical Company 
(Gillingham, UK) or Lancaster Synthesis (UK) and were used without 
further purification. Organic solvents were obtained from Rhone-Poulenc- 
Rorer and were dried, as necessary, using the procedures described by 
Perrin and Armarego. Melting points (m.p.) were determined in open 
capillaries using a Gallenkamp apparatus and are uncorrected. 1H and 
13C NMR spectra were obtained on a Bruker AM200-SY spectrometer 
operating at 200 MHz and 50 MHz respectively, or where stated, at 360 
MHz and 90 MHz respectively on a Bruker AM 360 spectrometer. J Values 
are given in Hz. 13C NMR spectra were assigned with the aid of 
Distortionless Enhancement by Polarisation Transfer (DEPT)-edited 
spectra. The numbering schemes shown are used for ease of assigning 
the NMR spectra and do not refer to the system of nomenclature. Mass 
spectra (MS) were recorded on an updated AEI M S 1 2  or MS902 
spectrometers; percentile figures refer to relative intensity as a percentage 
of the base peak. MS were obtained using electron-impact ionisation (El) 
mode or, if stated, chemical ionisation (Cl) mode or fast atom bombardment 
(FAB). Infra-red (IR) spectra were obtained on a Perkin Elmer PU 9800 FT- 
IR spectrophotometer. Retention factors (Rf) were obtained by analytical 
Thin Layer Chromatography (TLC) on Merck aluminium-backed silica 
plates of 0.25 mm thickness or Merck aluminium-backed alumina plates 
thickness 0.2 mm; chromatograms were visualised using UV conditions at 
154 nm or by staining with iodine. All column chromatography was carried 
out on silica gel (particle size 70-230 mesh) or alumina gel (particle size 
150 mesh).
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In vitro against P. falciparum  asexual erythrocytic stages - S. R. 
Phillips and F. McMonagle, Division of Infection and Immunity.
P. falciparum culture adapted strains FCR (Gambia) and JS 
(Zimbabwe) were used. Both these strains are chloroquine sensitive and 
were grown as stock cultures in vitro in petri dishes by a modification of the 
candle jar technique of Trager and Jensen.92 In culture the parasites were 
asychronous in their growth and therefore all stages in the 48 hour asexual 
erythrocytic cycle would be represented at any one time. The RPMI 1640 
culture medium was supplemented with 10% group AB (from the West of 
Scotland Blood Transfusion Service [WSBTS]) or occasionally A serum 
(from RSP) and the parasites grown in outdated group O (from WSTBS) or 
occasionally with fresh group A red blood cells (from RSP). The outdated 
red blood cells were obtained one month after donation into citrate dextrose 
and fresh erythrocytes were collected into heparin at 1 0  iu/ml final 
concentration. Comparisons were made between fresh and outdated red 
blood cells to demonstrate that compounds with antimalarial activity had 
comparable activity in both fresh and outdated red blood cells (data not 
shown) and that both sources of the serum were equally effective in 
supporting parasite growth. The AB and A serum was heated at 60 °C  for 
30 min before use (for reasons of safety). The assay system for screening 
compounds for activity against P. falciparum was that described by 
Desjardins et al.93 In brief the parasites were grown in the presence or 
absence of the test compounds or control substances in 96 well flat- 
bottomed tissue culture plates, each well containing a total volume of 2 0 0  
ml with erythrocytes at a 3% haematocrit and a starting parasitaemia of 
0.5%. Each test concentration was carried out as a minimum in triplicate. 
After 24 h incubation in a candle jar 100 ml were removed from each well 
and replaced with 1 0 0  ml fresh medium containing 1 mCi 3 h -  
hypoxanthine. 94  The plate was incubated for a further 18 h before the 
parasites were harvested and parasite growth measured as the 
incorporation of the isotope, using conventional liquid scintillation counting. 
The mean and standard deviation of the counts per minute for each dilution 
of the test compounds or the control cultures were calculated and the 
results displayed using Cricket graph. The results were analysed using a 
standard t-test.
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In vivo against P. chabaudi - S. R. Phillips and F. McMonagle, 
Division of Infection and Immunity.
P. chabaudi AS strain, in inbred NIH mice, was handled as 
described by McLean and Phillips.95 In brief three months old male inbred 
NIH mice were infected intravenously with 1x1 0 $ P. chabaudi parasitized 
erythrocytes and groups of five mice immediately afterwards injected with 
either chloroquine at 50 mg/Kg body weight or the test compounds, as 
follows: 3 and 10 at 100 or 300mg/Kg body weight, 7 at 150 mg/Kg, 11 at 
175 mg/Kg and 12 at 25 or 50 mg/Kg. Compound 7 was given as three 
equal doses over 48 hours and 11 as two equal doses 24 hours apart. The 
compounds were dissolved in physiological saline and injected 
intraperitoneally. A control group of mice received saline only. The 
parasitaemia was followed in the mice by daily thin blood smears which 
were stained with Giemsa's stain and recorded as the numbers of 
parasitized erythrocytes in 105  erythrocytes. The mean parasitaemia for 
each group was calculated and the time to reach 2 % parasitaemia was 
determined and compared for each group using a student’s t test. 
Differences were considered significant when p< 0.05.
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7.1 Experimental to Chapter 3
General Procedure A1-Formation of Hydrochloride Salts.
Ethereal hydrogen chloride was prepared by carefully bubbling dry HCI gas 
through a solution of dry ether until saturated. The free base was dissolved 
in an appropriate amount of ether and was then treated with an excess of 
dry HCI/Et2 0 . The precipitate was removed by filtration and recrystallized 
using Et0 H/Et2 0 .
General Procedure A2-Formation of Hydrochloride Salts.
The free base was dissolved in an appropriate amount of CHCI3 and then 
treated with an excess of dry HCI/CHCI3 (prepared by bubbling dry HCI gas 
through chlorofom until saturated). The solution was concentrated in vacuo 
and recrystallized using EtOH/Et2 0 .
(E )-N ,N ,N ‘,N '-T e tra e th y \^  ,4-diam inobut-2-ene Dihydrochloride  
7 7 5 6
("Ej-A/,A/,A/',A/'-Tetraethyl-1,4-diaminobut-2-ene 79 was prepared as 
reported and the dihydrochloride salt was prepared by general procedure 
A1 to yield 77 as white crystals (74%), mp 239.1-240.1 °C; vmax(KBr)/crrr1 
2677 (-CH2-), 1625 (C=C), 956 ((E)-C=C, C-H bend); 5h (2 0 0 MHz, D2 0 )
1.07 (1 2 H, t, J 7.0, 6 -H3 ), 2 . 8 6  (8 H, q, J 7.0, 5-H2), 3.50 (4H, m, 1,4-H2),
5.86 (2 H, m, 2,3-H); 5c (50MHz, D2 0 ) 8  9.3 (CH3 -6 ), 48.2 (CH2 -5), 53.2 
(CH2-1 and -4), 129.6 (CH - 2  and -3); m/z (El) 198 (M+-2 H, 1 .2 %), 126 
(100), 8 6  (91), 56 (72), 42 (70), (Found: M+-2H, 198.2051. C 1 2 H2 6 N2 
requires 198.2043).
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(E )-N ,N ,N ',N  -Tetraethyl-1 ,4-d iam inobut-2-ene  
Bis(hexafluorophosphate) 107110
107 was prepared by this group as decribed by McCormack and co­
workers and crystals grown from a solution of Me0 H/Et2 0  (100%). mp 189-
189.5 °C.
(Ej-A/jA^A/'jAT-TetramethyM ,4-d iam inobut-2-ene  
Dihydrochloride 8338* 57
2Cf
Synthesis of (EJ-A/^A/^/V'-tetramethyl-l ,4-diaminobut-2-ene 80 was 
carried out as described by Cook.38 The dihydrochloride salt was prepared 
by general procedure A1 to yield 83 as white crystals (30%), mp >250 °C; 
Vmax(KBr)/cm- 1 2662 (-CH2-), 1620 (C=C), 961 ((E)-C=C, C-H bend); 8 h 
(200MHz, D2 0 ) 2.70 (12H, s, 5-H3), 3.69 (4H, m, 1,4-H2), 5.99 (2H, m, 2,3- 
H); 8 c  (50MHz, D20 ) 43.2 (CH3 -5), 58.9 (CH2 -1 and -4), 130.2 (CH- 2  and 
-3); m/z (El) 142 (M+-2H, 1.1%), 97 (32), 82 (45), 58 (100), 42 (62), (Found: 
M+-2H, 142.1471; C, 44.42; H, 13.19; N, 9.16. C8 H i8 N2 requires 142.1467; 
C, 44.65; H, 13.02; N, 9.37.).
(E^-A^A/'-DiethyM^-diaminobut^-ene Dihydrochloride 8438> 57
^ 2  2 4 5
2 CI
1 3 H 2
The free base (E>A/,/V'-diethyl-1 ,4-diaminobut-2-ene 81 was prepared as 
reported by Cook38 and the dihydrochloride salt was prepared by general 
procedure A 1 to yield 84 as white crystals (60%), mp >250 °C;
Vmax(KBr)/cm-i 2760 (N-H), 2548 (-CH2-), 1591 (C=C), 976 ((E)-C=C, C-H 
bend); 5h (200MHz, D20 ) 0.87 (6 H, t, J 6.9, 6 -H3), 2.69 (4H, q, J 6 .8 , 5 -H2),
3.32 (4H, m, 1,4-H2), 5.64 (2 H, m, 2,3-H2); §c (50MHz, D2 0 ) 13.0 (CH3 -6 ),
44.8 (CH2 -5), 49.9 (CH2 -1 and -4), 130.7 (CH-2 and -3); m/z (El) 142 (M+ 
-2H, 1.1%), 97 (49), 82 (90), 6 8  (67), 56 (100), 41 (56), (Found: M+-2H, 
142.1451; C, 44.66; H, 9.37; N, 13.02. C8 H i8 N2 requires 142.1465; C, 
44.58; H, 9.33; N, 12.91).
(E )-N ,N '-D i isop ro py l-1 ,4 -d iam ino bu t-2 -en e  D ihydrochloride
8596
6
The free base ('E)-A/,A/'-diisopropyl-1,4-diaminobut-2-ene 82 was prepared 
as described. The dihydrochloride salt was prepared by general procedure 
A1 to yield 85 as white crystals (71%), mp 238.0-240.1 °C; vmax(KBr)/cnr1 
2870 (N-H), 2531 (-CH2-), 1585 (C=C), 970 ((E)-C=C, C-H bend); Sh 
(200MHz, D20 ) 0.99 (12H, d, 6 -H3 , J 6 .8 ), 3.10 (2H, sept, 5 -H, J 6 .8 ), 3.41 
(4H, m, 1,4-H2), 5.71 (2H, m, 2,3-H); 8 c  (50MHz, D2 0 ) 19.1 (CH3 -6 ), 46.2 
(CH-5), 51.2 (CH2-1 and -4), 129.1 (CH-2 and -3); m/z (El) 170 (M+ -2H,
1.2%), 155 (12), 112 (64), 96 (50), 70 (100), 58 (22), (Found: M+-2H, 
170.1794; C, 49.05; H, 9.58; N, 11.19. C i0 H2 2 N2 requires 170.1790; C, 
49.38; H, 9.95; N, 11.52).
(EJ-/V,/V'-Dibenzyl-1,4-diaminobut-2-ene Dihydrochloride 94
To a predistilled sample of benzylamine (4.99 g, 10 equiv.) was added ('£)-
1,4-diaminobut-2-ene (1.02 g, 4.67 mmol) in toluene (100 ml) over a period 
of one h at 40°C. A white precipitate appeared almost immediately and the
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mixture was stirred at room temperature until no more starting material was 
present by TLC. CHCI3 (100 ml) was added and the solution was washed 
well with water (3x50 ml). The organic extracts was dried (Na2 S0 4 ), filtered 
and concentrated in vacuo. The residual oil was distilled to remove any 
excess benzylamine (36-40 °C, 1 mm) and the residue, (E)-N,N'-d\benzy\-
1 ,4-diaminobut-2-ene 93 was isolated as a clear oil. The dihydrochloride 
salt was prepared by general procedure A1 to yield 94 as white crystals 
(1.10 g, 3.27 mmol, 70%), mp >250 °C; v max(KBr)/cnr1 3032 (Ar C-H), 
2610 (-CH2 -), 1585 (C=C), 1500 (Ar C=C), 978 ((E)-C=C, C-H bend), 745 
(Ar C-H bend), 696 (Ar C-H bend); 8 h (200MHz, D20 ) 3.61 (4H, m, 1,4-H2),
4.64 (4H, s, 5-H2), 5.88 (2 H, m, 2,3-H), 7.31 (10H, s, 7,8,9-H); 8 c  (50MHz, 
D20 ) 48.4 (CH2-1 and -4), 51.4 (CH2 -5), 129.4 (CH- 2  and -3), 130.2 (CH-9),
130.6 (C-6 ), 130.7 (CH-7), 131.3 (CH-8 ); m/z (El) 266 (M+-2H), (Found: M+- 
2 H, 266.1762. C i8 H2 2 N2 requires 266.1758).
(E^-tyA/jA/^A/'-DiethyM^-diaminobutane Dihydrochloride 90
77 (0.765 g, 2.82 mmol), 10% Pd on charcoal (0.30 g) and MeOH were 
placed in a flask under hydrogen. The solvent was degassed 3 times and 
left under vacuum for a further 15 min. The hydrogen was released and the 
mixture was stirred for 72 h. The mixture was filtered through Celite which 
was washed with MeOH (3 x 20 ml) and the filtrate was concentrated in 
vacuo. The resulting solid was recrystallized from ethanol/diethyl ether to 
yield 90 as a fawn solid (50%), mp >250 °C; vmax(KBr)/ci7r 1 2970 (NH), 
2667 (-CH2-), 8 h (2 0 0 MHz, D2 0) 0.90 (1 2 H, t, J7.1, 6 -H2), 1.41 (4H, m, 2,3- 
H2), 2.85 (8 H, q„ J7.1, 5-H2), 2.80 (4H, m, 1,4-H2); 6 c  (50MHz, D2 0) 9.1 
(CH3 -6 ), 2 1 . 6  (CH2 -5), 48.2 (CH2 - 2  and -3), 51.6 (CH2-1 and -4); m/z (El) 
200 (M+-2 H, 2.8%), 98 (39), 8 6  (100), 70 (12), 58 (46), 42 (40), (Found: M+- 
2H, 200.2261. C1 2 H2 8 N2 requires 200.2270). (Grateful thanks to RAC for 
preparation of this compound).
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(E>A/,A/-Diethyl-1,4-diaminobut-2-ene Dihydrochloride 8957
This was prepared as described and gave 1H, 13C NMR and IR spectra and 
yield were comparable to those already reported (65%). (Found: M+-2H, 
142.1492. C8 H1 8N2 requires 142.1512)
A/jA/jA/'jA/'-TetraethyM.S-diaminopropane Dihydrochloride 9297
The free base A/,A/,A/',A/'-tetraethyl-1,3-diaminopropane 91 was prepared 
as reported. The dihydrochloride salt was prepared by general procedure 
A1 to give 92 as a white powdery solid (17%), mp >250 °C; vmax(KBr)/cnrr1 
3427 (N-H), 2926 (-CH2-), 2663 (-CH3 ); 5h (2 0 0 MHz, D20 ) 1.02 (12H, t, J
7.0, 5 -H3 ), 1.90 (2H, m, 2-H2), 2.80 (4H, m, 1,3-H2), 3.00 (8 H, q, J 7 .0, 4- 
H2 ); §C (50MHz, D2 0 ) 9.3 (CH3 -5), 19.7 (CH2 -2 ), 48.5 (CH2 -1 and -3), 49.3 
(CH2 -4); m/z (El) 186 (M+-2H, 2 .8 %), 113 (34), 98 (6 8 ), 8 6  (1 0 0 ), 72 (17), 
58 (30), (Found: M+-2H, 186.2100. C n H 26 N2 requires 186.2096).
(Ej-A/jA/'-Dibenzyl-A/jA/'-diethyM ,4-d iam inobut-2-ene  
Dihydrochloride 96
8
NH
// \W
V  J
NH 1
3
2 CI
\  10 
11
The free base 81 (0.5 g, 3.52 mmol) was diluted with MeCN at rt and NEt3 
(4 ml, 28.2 mmol) was added with stirring. Benzyl bromide (1.67 ml, 14.1
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mmol) was added dropwise and the solution was stirred for 1 h. The 
solution was filtered and the filtrate was concentrated in vacuo to give a 
white residue. The residue was dissolved in water (10 ml), made basic with 
NaOH and extracted with EtOAc (2x10 ml). The organic extracts were dried 
(Na2 S0 4 ), filtered and concentrated in vacuo to give ('E)-A/,A/'-dibenzyl- 
A/,A/-diethyl-1,4-diaminobut-2-ene 95 as an oil, 8 h (200MHz, D2 O) 1.03
11.7 (CH3 -H ), 47.0 (CH2 -IO), 55.0 (CH2-1 and -4), 57.5 (CH2 -5), 126.7 
(CH- 2  and -3), 128.1 (CH-7), 128.9 (CH-9), 130.6 (CH-8 ), 139.6 (C-6 ). The 
dihydrochloride salt 96 was prepared by general procedure A1 as a 
creamy powder (0.608g ,1.54 mmol, 44%), mp 214.1-216 °C; 
Vmax(KBr)/crrr1 3425 (N-H), 3084 (C-H), 2966 (-CH2-), 2796 (N-CH2), 2577 
(NH), 1494 (C=C), 1452 (C=C), 974 ((E)-C=C, C-H bend), 739 (Ar C-H 
bend), 697 (Ar C-H bend), 8 h (2 0 0 MHz, D2 0 ) 1.08 (6 H, t, J 7.2, 1 1-H3), 
2.93 (4H, q, J7.2, 10-H2), 3.56 (4H, m, 1,4-H2), 4.05 (4H, s, 5-H2), 5.82 (2H, 
m, 2,3-H), 7.26 (10H, m, 7,8,9-H); 8 c  (50MHz, D2 0 ) 9.1 (CH3 -H ), 48.6 
(CH2 -IO), 53.3 (CH2-1,4), 57.4 (CH2 -5), 129.6 (CH- 2  and -3), 130.1 (CH-7),
130.3 (C-6 ), 130.8 (CH-9), 131.6 (CH-8 ); m/z (El) 322 (M+-2H, 0.3%), 202 
(0.2), 174 (8.3), 148 (19) and 91 (100), (Found: M+-2H, 322.2437. 
C2 2 H3 0 N2 requires 322.2419).
(E )-N ,N '-D iethyI-N,N  -d iphenyl-1,4-d iam inobut-2-ene  
Dihydrochloride 9898
The free base 97 was prepared by a slight modification of the procedure of 
Roberts and Ross. (Ej-1,4-dibromobut-2-ene (1 g, 4.7 mmol) and N- 
ethylaniline (2.5 ml, 18.8 mmol) were heated at 1 0 0  °C for 4 h with stirring 
after which time the solution turned deep red. Water (10 ml) was added 
and the mixture was extracted with ether (2 x1 0  ml) and the organic extracts
(6 H, t, J 7.1, 11 -H3 ), 2.50 (4H, q, J7 .1 , 10-H2), 3.06 (4H, m, 1,4-H2), 3.54 
(4H, s, 5-H2), 5.68 (2H, m, 2,3-H), 7.24 (10H, m, 7,8,9-H); 8c  (50MHz, D20)
10
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were dried (K2 CO 3 ), filtered and concentrated in vacuo to give a yellow 
residue. MeOH was added and a creamy precipitate appeared which was 
recrystallised from MeOH to give a white solid (0.93g, 3.14 mmol, 67%), 
vmax(KBr)/crn- 1 2931 (C-H), 1598 (Ar C=C), 1506 (Ar C=C), 967 ((E)-C=C, 
C-H bend), 756 (ArC-H bend), 694 (ArC-H bend); §h (200MHz, D20 ) 1.12 
(6 H, t, J 7.05, 6 -H3 ), 3.33 (4H, q, J 7.05, 5-H2), 3.85 (4H, m, 1,4-H2), 5.62 
(2 H, m, 2,3-H), 6.65 (6 H, m, 9,10-H), 7.20 (4H, m, 8 -H); Sq (50MHz, D2 0 )
12.3 (CH3 -6 ), 44.6 (CH2 -5), 51.6 (CH2-1 and -4), 112.2 (CH-2 and -3),
115.8 (CH-8 ), 127.8 (CH-10), 129.2 (CH-9), 148.1 (C-7); m/z (El) 294 (M+,
15.9 %), 174 (84), 144 (9), 120 (24), 104 (43), 91 (83), 83 (100), 77 (57), 
(Found: M+> 294.2077. C2oH2 6 N2 requires 266.2058). The dihydrochloride 
salt 98 was prepared following general procedure A2 in 80% yield, mp 
189.1-190.2 °C decomp; vmax(KBr)/cm-1 3424 (N-H), 3047 (Ar C-H), 2900 (- 
CH2-), 1621 (C=C), 1596 (Ar C=C), 1480 (Ar C=C), 977 ((E)-C=C, C-H 
bend), 785 (Ar C-H bend), 701 (Ar C-H bend); 8 h (200MHz, D20 ) 0.84 (6 H, 
t J 7.2, 6 -H3 ), 3.26 (4H, q, J 7.2, 5-H2), 3.99 (4H, m, 1,4-H2), 5.55 (2H, m,
2,3-H), 7.15 (4H, m, 8 -H), 7.38 (6 H, m, 9,10-H); 5c  (50MHz, D2 0 ) 10.3 
(CH 3 -6 ), 54.2 (CH2 -5), 59.2 (CH2-1 and -4), 115.1 (CH-2 and -3), 122.8 
(CH-8 ), 129.9 (CH-1 0 ), 131.5 (CH-9 ), 137.2 (C-7); m/z (El) 294 (M+-2H, 
80%), 174 (100), 158 (58), 134 (52), 104 (38), 77 (35), (Found: M+-2H, 
294.2092. C2 oH2 0 N2 requires 294.2088).
('E,)-/V-(7-Chloroquinolin-4-yl)-W',W'-Diethy 1-1-1,4-d iam inobut-2- 
ene Dihydrochloride 100100
The free base was prepared as described and the solid was recrystallised 
from ether (25%), mp 113.0-115.1 °C [lif°o  121-122 °C]; 8 h (2 0 0 MHz, 
CDCI3 ) 1.02 (6 H, t, J7.2, 6 -H3 ), 2.52 (4H, q, J7.2, 5-H2), 3.10 (2 H, d, J 5 .2 ,
4 -H2), 3.90 (2H, d, J5.1, 1-H2), 5.48 (1H, bs, NH), 5.80 (2H, m, 2,3-H), 6.40 
(1 H, d, J 5.4, 3'-H), 7.33 (1H, dd, J 8.9, 2.0, 6 '-H), 7.72 (1H, d, J 8.9, 5'-H),
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7.95 (1H, d, J 2.1, 8 '-H), 8.50 (1H, d, J5.3, 2'-H). The bulk of the free base 
was converted into the dihydrochloride salt following general procedure A1 
to yield 100 as a hygroscopic brown solid (20%), vmax(KBr)/cnr1 3060 (Ar 
C-H), 2932 (C-H), 2866 (C-H), 1582 (Ar C=C), 1544 (Ar C=C), 978 ((E)-C=C 
C-H bend), 898 (Ar C-H bend), 804 (Ar C-H bend); 5h (200MHz, D2 0 ) 0.97 
(6 H, t, J 7.2, 6 -H3), 2.86 (4H, q, J7.2, 5-H2), 3.51 (2 H, d, J 5.2, 4-H2), 4.04 
(2 H, d, J 5.1, 1-H2), 5.52 (2H, m, 2  or3-H), 5.90 (2H, m, 2 or3-H), 6.43 (1H, 
d, J 5.3, 3'-H), 7.26 (1H, d, J 8.9, 2.0, 6 '-H), 7.46 (1H, d, J8.9, 5'-H), 7.76 
(1H, d, J 2 .1 , 8 '-H), 8.01 (1H, d, J 5.3, 2 '-H); 6 c  (50MHz, D2 0 ) 9.9 (CH3 -6 ),
43.1 (CH2 -5), 44.9 (CH2 -4), 53.1 (CH2 -1), 97.9 (CH-6 1), 116.0 (C-10‘),
119.5 (CH-2 ' or -3’), 123.7 (CH-2 ' or -31), 125.9 (CH-8 1), 127.1 (CH-31),
129.6 (CH-5'), 133.5 (C-71), 147.2 (C-4‘), 148.2 (C-91), 150.3 (CH-2 '); m/z 
(El) 305 (M+-2H, 0.3%), 303 (M+-2H, 1.0%), 288 (55), 232 (100), 178 (46), 
162 (16), 144 (15), 110 (31) and 8 6  (57), (Found: M+-2H, 305.1496. 
C i 7 H 22N 3 37CI requires 305.1473; Found: M+-2H, 303.1486 . 
C i7 H2 2 N335CI requires 303.1502).
A/,A/'-Bis(7-chloroquinolin-4-yl)-1,4-diaminobutane 106102
N Cl
This was prepared according to the procedure of Vennerstrom on a 10 
mmol scale and 106 was isolated in 55 % yield, mp 340.1-342 °C [lit. 339- 
341 °C]. IR, 1H NMR and 13C NMR spectra were identical to published data.
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Attempted prepartion of Af,Af,-B is (7 -c h lo ro q u in o lin -4 -y l)-A /,A /'- 
diethyl-1 ,4-d iam inobutane 104
Attempt 1: Following the procedure of Marchini105  NaBhU (0.4630 g, 10 
equiv) was added portionwise to glacial AcOH (1 1  ml) at 0 °C. The diamine 
106 (0.5020 g, 1.22 mmol) was then added and the suspension heated at 
80 °C for 2 h after which time the solution was clear yellow. After cooling to 
rt ppt occured and the solid was collected by fitration. The cream solid was 
identical by 1H and 13C NMR spectra to starting material.
Attempt 2: Following the procedure of Gribblei0 7  1 06 (0.50 g, 1.27 mmol) 
was stirred in glacial AcOH (2  ml) at 50-55 °C under N2 and NaBH4  added 
portionwise over 30 min. The solution was heated for 20 h and the 
resulting solid triturated in 6  mol dm-3 NaOH. The cream solid was 
collected by fitration and was identical by 1H and 13C NMR spectra to 
starting material.
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Attempted preparation of (E>)-A/,A^-(7-Chloroquinolin-4-yl)-/V,yV,- 
diethyl-1,4-diam inobut-2-ene 105
81 (0.10 g, 0.71 mmol) was heated in phenol (0.3 g) with 4,7- 
dichloroquinoline (0.28 g, 2  equiv) and Nal ( 2  crystals) at 150-160 °C for 24 
h. The residue was partitioned between 3 mol dm"3 HCI (10 ml) and EtOAc 
( 1 0  ml) and the aqueous layer was washed with more EtOAc (3x10 ml). 
The aqueous was then made basic NaOH (s) and extracted with CHCI3 . 
The organic extracts were dried (K2 C O 3 ), filtered and concentrated in 
vacuo, however no product was observed.
7.2 Experimental to Chapter 4
General Procedure B1- Alkylation of Bromophthalimides with 
Diamines.
The phthalimide (12 mmol) was finely ground with 50% KF on Celite (12 
mmol) and stirred in MeCN (60 ml). The diamine (10 equiv.) was added 
and the solution stirred at 40-60 °C for 24 h. The resulting solution was 
filtered and concentrated in vacuo to give the crude phthalimide which was 
taken up in c.HCI and c.AcOH (60 ml:60 ml) and heated at reflux for 72 h. 
Water (100 ml) and activated charcoal were added and the solution was 
heated for a further 1 h before filtering through a pad of Celite. The filtrate 
was concentrated in vacuo to 25 ml and the residue made basic (pH 12) 
with NaOH(s). The solution was extracted with CHCI3 (3 x 50 ml) and the 
combined organic extracts were dried (K2 CO3 ), filtered and concentrated in 
vacuo to yield the diamine as the free base.
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General Procedure B2- Michael Addition on Acrylonitrile.
Acrylonitrile (1 equiv.) was added dropwise over 15 min to the stirred amine 
(10 mmol) at 0 °C (ice-water bath). The solution was allowed to warm to rt 
then 45 °C for 30 min and heated at 60-70 °C for 2  h before being 
concentrated in vacuo, with care, to yield the desired nitrile. Purification, 
when necessary, was achieved by reduced pressure distillation (T<120 °C).
General Procedure B3- Reduction of Nitrile.
Solid UAIH4  ( 2  equiv.) was stirred in dry ether (80 ml) under N2 . AICI3 ( 2  
equiv.) was added carefully and the suspension was stirred for 1 0  min. The 
amine ( 8  mmol) in dry ether ( 1 0  ml) was added dropwise and the solution 
was stirred at rt for 18 h. The stirred solution was cooled with an ice bath 
and excess UAIH4  was decomposed via careful addition of water (1 ml/ g 
UAIH 4 ), 15% NaOH (3 ml/ g UAIH4 ) and water (1 ml/ g UAIH4 ). The 
resulting solid was filtered off and washed well with ether and ethanol and 
the combined filtrates were concentrated in vacuo. The residue was 
partitioned between CHCI3  (20 ml) and 15% NaOH (20 ml) and the 
aqueous layer was washed with further amounts of CHCI3 (2 x1 0  ml). The 
combined extracts were dried and concentrated in vacuo to give the 
triamine as the free base.
(E )-1 -Phthalimido-4-bromobut-2-ene 8657
Following the procedure of Cook, 8 6  was prepared in 65% yield. 1H, 13C 
NMR and IR spectra were identical to those of the literature compound, mp 
99.5-100.7 °C (acetone) [lit. 95-96 °C (EtOH)].
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8 6  (4.07 g, 14.3 mmol) and 50 % KF on Celite ( 8  g) were stirred in MeCN 
(60 ml) as in procedure B1 to yield the free base as a clear yellow oil (1.07 
g, 9.4 mmol, 64%), v'max(CHCI3 )/cm-i 3384 (N-H), 1670 (C=C), 974 ((E)- 
C=C, C-H bend); 5h (2 0 0 MHz, CDCI3) 0.55 (2 H, s, NH2), 1.17 (6 H, s, 5- 
H3), 1.84 (2H, d, J 5.8, 1-H2), 2.24 (2H, d, J 5.1, 4-H2), 4.63 (2 H, m, J
5.0,15.5, 2,3-H); 5 c  (50MHz, CDCI3) 42.8 (CH2 -1), 44.1 (CH3 -5), 60.6 
(CH2 -4), 125.9 (CH-2 o r -3), 133.9 (CH-2 o r -3); m/z(EI) 114 (M+, 3.2%), 97
(38.7), 84 (21.8), 6 8  (13.2) and 58 (100), (Found: M+, 114.1159. C6 H1 4N2 
requires 114.1157).
A/,/V-DiethyM,4-diaminobutane 145
A/-(4-Bromobutyl)phthalimide (4.03 g, 14.2 mmol) and 50% KF on Celite (8  
g) were stirred in MeCN (70 ml) as in procedure B1 to yield the free base as 
a clear oil (1.72 g, 11.9 mmol, 84%), vmax(CHCI3 )/cnrr1 3362 (N-H), 1466 (- 
CH2-); 8 h (200MHz, CDCI3) 1.07 (6 H, t, J7.1, 6 -H3), 1.53 (4H, m, 2,3-H2),
2.44 (2H, t, J 6.9, 1-H2), 2.55 (4H, q, J 7.2, 5-H2), 2.75 (2H, t, J 6.7, 4-H2), 
3.04 (2H, s, NH2); 5c (50MHz, CDCI3) 11.1 (CH3 -6 ), 23.9 (CH2-2 or -3),
31.3 (CH2-2 or -3), 41.6 (CH2-1 or -5), 46.2 (CH2-1 or -5), 52.2 (CH2 -4); 
m/z (El) 144 (M+, 1.1%), 112 (12.6), 96 (71.2), 8 6  (51.5), 77 (92.3), 72 (51.8) 
and 58 (100), (Found: M+, 144.1636. C3 H2oN2 requires 144.1645).
A/,A/-Diethyl-1,3-diaminopropane 144
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A/,A/-Diethyl-1,3-diaminopropane 144
A/-(3-Bromopropyl)phthalimide (4.06 g, 14.9 mmol) and 50% KF on Celite 
(8  g) were stirred in MeCN (70 ml) as in procedure B1 to yield the free base 
as a clear oil (2.04 g, 15.7 mmol, 94%), Vmax(CHCl3 )/cnrr1 3378(N-H), 1468 
(-CH2-); 5h (2 0 0 MHz, CDCI3) 0.15 (6 H, t, J7 .1 , 5-H3), 0.57 (2 H, s, NH2), 
0.71 (2 H, tt, 6.9Hz, J7.1, 2-H2), 1.61 (2 H, t, 1-H2), 1.61 (4H, q, J7.1, 4-H2),
1 . 8 6  (2 H, t, J 6.7, 3-H2); 5c (50MHz, CDCI3 ) 11.9 (CH3 -5), 31.1 (CH2 -2 ),
40.9 (CH2-1 or -4), 46.9 (CH2-1 or -4), 50.9 (CH2 -3); m/z (El) 130 (M+, 
4.4%), 113 (2.6), 100 (4.2), 96 (13.6), 8 6  (56.7), 74 (6 8 .6 ) and 45 (100), 
(Found: M+, 130.1473. C7 H18N2 requires 130.1476).
A/,/V-Dimethyl-1,4-diaminobutane 143
A/-(4-Bromobutyl)phthalimide (4.02 g, 14.2 mmol) and 50% KF on Celite (8  
g) were stirred in MeCN (70 ml) as in procedure B1 to yield the free base as 
a clear oil (1.61 g, 13.9 mmol, 98%), vmax(CHCl3 )/cnrr1 3380 (N-H), 1466 (- 
CH2-); 5h (200MHz, CDCI3 ) 0.53 (2H, bs, NH2), 0.53 (4H, m, 2,3-H2), 1.26 
(6 H, s, 5 -H3 ), 1.30 (2H, t, J 6 .8 , 1 -H2), 1.74 (2 H, t, J 6 .6 , 4-H2); 5c (50MHz, 
CDCI3 ) 23.4 (CH2-2 or -3), 29.9 (CH2 - 2  or -3), 40.4 (CH2 -1), 43.7 (CH3 -5),
52.9 (CH2 -4); m/z (El) 116 (M+, 5.7%), 96 (11.1), 85 (3.3), 77 (10.1), 74
(15.4), 58 (100), 56 (7.7) and 45 (18.1), (Found: M+, 116.1317. C6 H1 6 N2 
requires 116.1320).
/V,A/-Dimethyl-1,3-diaminopropane 142
HoN. ^N
3 1 4
A/-(3-Bromopropyl)phthalimide (4.10 g, 14.9 mmol) and 50% KF on Celite 
(8  g) were stirred in MeCN (70 ml) as in procedure B1 to yield the free base
162
as a clear oil (1.38 g, 13.3 mmol, 89%), vmax(CHCl3 )/cnrr1 3380 (N-H), 
1464 (-CH2-); 6 h (2 0 0 MHz, CDCI3) 0.87 (2H, tt, J7A , 7.1, 2-H2), 0.99 (2H, 
s, NH2), 1.47 (6H, s, 4 -H3 ), 1.58 (2H, t, J7.1, 1-H2), 2.01 (2H, t, J 6.8, 3-H2); 
6c (50MHz, CDCI3 ) 29.7 (CH2-2), 38.9 (CH2-1), 43.9 (CH3-4), 55.9 (CH2- 
3); m/z (El) 102 (M+, 3.7%), 96 (1.6), 85 (18.4), 77 (5.0), 74 (2.3), 58 (100) 
and 44 (14.9), (Found: M+, 102.1147. CsHi4 N2 requires 102.1137).
/V-Benzyl-A/-ethyl-1,4-diaminobutane 158
A/-(4-Bromobutyl)phthalimide (5.09 g, 17.7 mmol) and 50% KF on Celite (8  
g) were stirred in MeCN (40 ml) with A/-ethylbenzylamine (26 ml, 10 equiv.) 
as in procedure B1 . Excess A/-ethylbenzylamine was removed by reduced 
pressure distillation and purification of the resulting oil achieved by alumina 
column chromatography, eluent Hex:EtOAc (1 :1 ) and then flushed with 
MeOH to remove the product isolated as a red oil (2.2756 g, 11.1 mmol, 
63%), vmax(CHCI3 )/cm-i 3380 (NH), 2975 (-CH2-), 2940 (-CH2-), 2800 (N- 
CH2), 1600 (Ar C=C), 1580 (Ar C=C), 1490 (Ar C=C), 730 (Ar C-H), 700 (Ar 
C-H); 8 h (200MHz, CDCI3 ) 1.01 (3H, t, J7.1, 6 -H3 ), 1.54 (4H, m, 2,3-H2),
2.44 (4H, m, 1-H2, NH), 2.50 (2H, q, J7 .1, 5-H2), 2.77 (2H, t, J 6.3, 4-H2), 
3.56 (2H, s, 7-H2), 7.27 (5H, s, 9,10,11-H); 5c (50MHz, CDCI3 ) 11.0 (CH3-
6 ), 24.4 (CH2 - 2  or -3), 28.0 (CH2-2 or -3), 40.4 (CH2-1 or -5), 46.7 (CH2-1 or 
-5), 52.6 (CH2 -4), 57.5 (CH2 -7), 127.0 (CH-1 1 ), 128.2 (CH-9), 129.2 (CH- 
10), 138.3 (C-8 ); m/z (El) 206 (M+, 0.4%), 160 (4.5), 148 (27.6), 115 (16.7), 
91 (100) and 70 (25.1), (Found: M+, 206.0059. C-|3 H 2 2 N 2 requires 
206.0062).
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Af-('2-Cyanoethyl)-A/',A/,'dim ethyl-1,3-diam inopropane 146
142 (0.90 g, 8.85 mmol) was treated with acrylonitrile (0.6 ml, 1 equiv.) 
according to general procedure B2 to yield the free base as a clear pale 
yellow oil (1.20 g, 7.74 mmol, 87%), vmax(CHCI3 )/cm -1 3262 (N-H), 2250 
(CN), 1464 (-CH2-); 5h (2 0 0 MHz, CDCI3) 1.64 (2 H, m, J 7.0, 2-H2), 1.87 
(1 H, bs, NH), 2.19 (6 H, s, 4-H3), 2.30 (2 H, t, J7.1, 3 -H2), 2.50 (2 H, t, J6.5, 1- 
H2), 2.66 (2H, t, J 6.9, 6 -H2), 2.90 (2H, t, J 6 .6 , 5-H2); 8 C (50MHz, CDCI3)
18.5 (CH2 -2 ), 27.7 (CH2 -6 ), 45.1 (CH2 -3), 45.5 (CH3 -4), 47.5 (CH2 -1 ), 57.7 
(CH2 -5), 118.4 (C-7); m/z (El) 155 (M+, 2.6%), 141 (4.1), 115 (2.9), 96 (6 .6 ), 
85 (6 .2 ), 77 (5.7), 72 (8.4), 70 (11.3), 58 (100) and 53 (28.7), (Found: M+, 
155.1436. C8 H i7 N3 requires 155.1446).
Af-(2-Cyanoethyl)-Af,,A/'-dimethyl-1,4-diaminobutane 147
143 (1.05 g, 9.10 mmol) was treated with acrylonitrile (0.65 ml, 1 equiv.) 
according to general procedure B2 to yield the free base as a colourless oil 
(1.05 g, 6.19 mmol, 6 8 %), bp 94-98 °C (0 .1  mmHg); Vmax(CHCI3 )/cnv1 
3318 (N-H), 2250 (CN), 1466 (-CH2-); 8 h (2 0 0 MHz, CDCI3) 1.11 (4H, m,
2,3-H2), 1.47 (1H, bs, NH), 1.82 (6 H, s, 5-H3), 1.89 (2H, t, 4-H2), 2.13 (2H, t, 
J 6 .6 , 1 -H2), 2.25 (2H, t, 7-H2), 2.51 (2 H, t, J 6 .6 , 6 -H2); 8 c  (50MHz, CDCI3)
17.7 (CH2 - 2  or -3), 24.4 (CH2 - 2  or -3), 26.9 (CH2 -7), 44.2 (CH2 -4), 44.5 
(CH3 -5), 48.1 (CH2 -1), 58.6 (CH2 -6 ), 118.0 (C-8 ); m/z (El) 169 (M+, 2 .2 %), 
129 (2.4), 115 (2.3), 96 (4.4), 84 (6.1), 77 (3.0), 70 (3.9), 58 (100), 53 (5.6) 
and 45 (10.7), (Found: M+, 169.1586. CgHi9 N3  requires 169.1594).
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A/-(2-Cyanoethyl)-yV',A/'-diethyl-1,3-diaminopropane 148
144 (1.48 g, 11.40 mmol) was treated with acrylonitrile (0.75 ml, 1 equiv.) 
according to general procedure B2 to yield the free base as a colourless oil 
(0.98 g, 7.54 mmol, 6 6 %), bp 6 6 - 6 8  °C (0.03 mmHg); vmax(CHCl3 )/cnr1 
3232 (N-H), 2250 (CN), 1468 (-CH2-); SH (200MHz, CDCI3) 0.75 (6 H, t, J
7.1, 5 -H3 ), 1.37 (2H, m, 2-H2), 1.58 (1H, bs, NH), 2.20 (4H, q, J 6.9, 4-H2),
2.20 (4H, m, 1,3-H2), 2.41 (2H, t, J 6.7, 7-H2), 2.64 (2H, t, J 6 .6 , 6 -H2); 6 c  
(50MHz, CDCI3 ) 1 0 . 6  (CH3 -5 ), 17.3 (CH2 -2 ), 26.0 (CH2 -7), 44.0 (CH2-3 or 
-4), 45.6 (CH2-3 or -4), 46.8 (CH2 -1 ), 50.1 (CH2 -6 ), 117.7 (C-8 ); m/z (El) 
183 (M+, 5.3%), 116 (15.3), 100 (4.0), 96 (7.2), 8 6  (100), 77 (25.4), 72
(39.8), 64 (2.8), 58 (31.2) and 53 (19.8), (Found: M+, 183.1748. C i0 H2 1 N3 
requires 183.1758).
Af-(2-Cyanoethyl)-A /,,A /'-d iethyl-1y4-d iam inobutane 149
9 8 M 2 4 5
7 1 3
145 (1.81 g, 12.60 mmol) was treated with acrylonitrile (0.85 ml, 1 equiv.) 
according to general procedure B2 to yield the free base as a colourless oil 
(1.85 g, 9.37 mmol, 74%), bp 1 1 0 - 1 1 2  °C (0.7 mm); vmax(CHCl3 )/cm ' 1  
3316 (N-H), 2247 (CN), 1469 (-CH2-); 8 h (2 0 0 MHz, CDCI3) 0.71 (6 H, t, J
6 .8 , 6 -H3), 1.18 (4H, m, 2,3-H2), 1.44 (1H, bs, NH), 2.21 (4H, q, J 6 .8 , 5-H2),
2.21 (4H, m, 1,4-H2), 2.34 (2H, t, J 6 .6 , 8 -H2), 2.60 (2H, t, J 6 .6 , 7-H2); 8 c  
(50MHz, CDCI3 ) 11.4 (CH3 -6 ), 18.3 (CH2 - 2  o r -3), 24.4 (CH2 - 2  o r -3), 27.7 
(CH2 -8 ), 44.7 (CH2-4 or -5), 46.4 (CH2-4 or -5), 48.7 (CH2 -1), 52.4 (CH2 -7),
18.6 (C-9); m/z (El) 197 (3.6%), 143 (1.4), 123 (8.5), 112 (2.7), 98 (5.2), 8 6  
(100), 72 (7.3) and 58 (18.6), (Found: M+, 197.1911. C n H 2 3 N3 requires 
197.1921).
165
(E>yV-(2-Cyanoethyl)-A/',A/'-dimethyl-1,4-diaminobut-2-ene 130
129 (0.92g, 8.10 mmol) was treated with acrylonitrile (0.55 ml, 1 equiv.) 
according to general procedure B2 to yield the free base as a colourless oil 
(0.79 g, 4.88 mmol, 60%), bp 76°C (0.07 mmHg); vmax(CHCI3 )/cm-i 3318 
(N-H), 2250 (CN), 1458 (-CH2-), 976 ((E) C=C, C-H bend); 5h (200MHz, 
CDCI3) 1.23 (1H, bs, NH), 1.87 (6 H, s, 5-H3), 2.18 (2 H, t, J 6 .6 , 7-H2), 2.54 
(2 H, d, 4-H2), 2.54 (2 H, t, J 6 .6 , 6 -H2), 2.94 (2 H, d, 1 -H2), 5.31 (2 H, m, 2,3- 
H); Sc (50MHz, CDCI3) 18.6 (CH2 -7), 44.2 (CH3 -5), 45.1 (CH2 -6 ), 50.4 
(CH2 -4), 61.4 (CH2 -1), 118.8 (C-8 ), 129.6 (CH-2 o r -3), 131.1 (CH- 2  o r -3); 
m/z (El) 167 (M+, 8.5%), 122(5.2), 97(30.2), 84(35.4), 68(5.3), 58(100)
| and 55 (8.5), (Found: M+, 167.1428. C9 H17 N3 requires 167.1434).
(,EJ)-A/-(2-Cyanoethyl)-A/,,A/'-diethyl-1,4-diaminobut-2-ene 131
5
8 8  (0.99g, 6.95 mmol) was treated with acrylonitrile (0.46 ml, 1 equiv.) 
according to general procedure B2 to yield the free base as a pale yellow 
oil (1.22 g, 6.26 mmol, 90%), vmax(CHCI3 )/cm - 1 3321 (N-H), 2247 (CN), 
1460 (-CH2-), 978 ((E) C=C, C-H bend); 5h (2 0 0 MHz, CDCI3) 0.95 (6 H, t, J
7.1, 6 -H3), 1.52 (1H, bs, NH), 2.44 (4H, q, J 7.1, 5-H2), 2.44 (2H, t, J 6 .6 , 8 - 
H2), 2.82 (2H, t, J 6 .6 , 7-H2), 2.99 (2H, d, J5.0, 4-H2), 3.19 (2H, d, J 5.0, 1- 
H2), 5.58 (2H, m, 2,3-H); Sc (50MHz, CDCI3) 11.4 (CH3 -6 ), 38.4 (CH2 -8 ),
44.0 (CH2 -5), 46.3 (CH2 -7), 50.3 (CH2 -4), 54.5 (CH2 -1 ), 118.6 (C-9), 129.6 
(CH-2 o r -3), 131.9 (CH-2 o r -3); m/z (El) 195 (M+, 12.3%), 180(61.4), 123 
(100), 112 (18), 8 6  (69.4), 70 (23.7), 58 (100) and 55 (46.8), (Found: M+, 
195.1740. C-|iH2 -|N3  requires 195.1744).
A/-Benzyl-A/-ethyl-A/'-(2-cyanoethyl)-1,4-diaminobutane 159
13
158 (2.2756 g, 11.1 mmol) was treated with acrylonitrile (0.80 ml, 1 equiv.) 
according to general procedure B2. Purification was cheived using silica 
column chromatography, eluent EtOH to yield the free base as a colourless 
oil (0.5900 g, 2.33 mmol, 21%), vmax(CHCl3 ) /c n r1 3020 (Ar-H), 2940 (- 
CH2-), 2810 (N-CH2), 2240 (CN), 1595 (Ar C=C), 1490 (Ar C=C), 745 (Ar C- 
H), 695 (ArC-H); 8 h (200MHz, CDCI3) 1.03 (3H, t, J7.1, 9-H3), 1.48 (4H, m,
2,3-H2), 1.71 (1H, bs, NH), 2.43 (6 H, m, 1,4,6-H2), 2.54 (2H, q, J 7.3, 8 -H2), 
2.80 (2H, t, J  6.7, 5-H2), 3.56 (2H, s, 10-H2), 7.32 (5H, m, 12,13,14-H); 8c 
(50MHz, CDCI3) 11.7 (CH3 -9), 16.5 (CH2 - 2  or -3), 24.5 (CH2-2 or -3), 27.6 
(CH2 -6 ), 44.9 (CH2 -1 or -4 or -8 ), 47.1 (CH2-1 or -4 or -8 ), 48.9 (CH2-1 or -4 
o r -8 ), 52.6 (CH2 -5), 57.9 (CH2 -10), 116.7 (C-7), 126.7 (CH-14), 128.1 (CH- 
12), 128.8 (CH-13), 139.6 (C-11); m/z (El) 168 (M+-Bn, 16.4%), 205 (M+- 
C3 H4 N, 0.3%), 190 (0 .2 ), 148 (44.1), 134 (1 2 .2 ), 120 (7.3), 106 (1 .2 ) and 91 
(100), (Found: M+, 168.1509. C9 H 1 8 N3 requires 168.1517; Found: M+, 
205.1725. C-13H2 1 N2 requires 205.1745).
Also isolated from the column as a clear oil was Af-Benzyl-W-ethyl-A/W'- 
(2-cyanoethyl)-1,4-diaminobutane 160 (0.9254 g, 2.997 mmol, 27%),
CN
13
vmax(CHCI3 )/cm - 1 3020 (Ar-H), 2945 (-CH2-), 2820 (N-CH2), 2245 (CN), 
1600 (Ar C=C), 1480 (Ar C=C), 740 (Ar C-H), 695 (Ar C-H); 8 h (2 0 0 MHz, 
CDCI3) 1.04 (3H, t, J7.1, 9-H3), 1.44 (4H, m, 2,3-H2), 2.38 (8 H, m, 1,4,6- 
H2), 2.51 (2 H, q, J 7.1, 8 -H2), 2.77 (4H, t, J 6 .8 , 5-H2), 3.54 (2H, s, 1 0 -H2),
167
7.32 (5H, m, 12,13,14-H); 5c (50MHz, CDCI3) 11.6 (CH3 -9), 16.7 (CH2 -2  or 
-3 ), 24.3 (CH2 - 2  or -3), 24.8 (CH2 -6 ), 47.2 (CH2-1 or -4 or -8 ), 49.4 (CH2-1 
o r-4 o r -8 ), 52.4 (CH2 -1 o r -4 o r -8 ), 52.9 (CH2 -5), 57.9 (CH2 -1 0 ), 116.7 (C-
7 ), 126.7 (CH-14), 128.1 (CH-1 2 ), 128.9 (CH-13), 139.6 (C-11); m/z (El) 
312 (M+, 1.7%), 258 (8 ), 221 (4.1), 176 (4.8), 148 (72.7) and 91 (100), 
(Found: M+, 312.3128. C i9 H2 8 N4  requires 312.3132).
(E )-N -(3 -A m \n o p ro p y \)-N ,fN '-d \e th y \^  ,4-diam inobut-2-ene  
Trihydrochloride 135
131 (0.91 g, 4.64 mmol), UAIH4  (0 . 0 2  g, 2 equiv.) and AICI3 (0.17 g, 2  
equiv.) in dry ether were treated according to general procedure B3 to yield 
the free base 133. This was converted into the trihydrochloride salt 135 
via procedure A1 and isolated as a pink powder (0.42 g, 1.37 mmol, 35%), 
mp 192.1-193.4 °C; vmax(KBr)/crn- 1 3424 (N-H), 1462 (-CH2-), 966 ((E)- 
C=C, C-H bend); 5h (200MHz, D20 ) 1.14 (6 H, t, J7.3, 6 -H2), 1.95 (2 H, m,
8 -H2), 3.01 (4H, m, 7,9-H2), 3.11 (4H, q, J 7.3, 5-H2), 3.65 (2 H, d, J5.1, 1- 
H2), 3.71 (2H, d, J 5.6, 4-H2), 5.97 (2H, m, 2,3-H); 5c (50MHz, D2 0 ) 9.2 
(CH3 -6 ), 24.6 (CH2 -8 ), 37.4 (CH2 -9), 44.9 (CH2-5 or -7), 48.1 (CH2-5 or -7),
49.1 (CH2-1 or -4), 53.1 (CH2-1 or -4), 127.8 (CH-2 or -3), 131.08 (CH- 2  or 
-3); m/z (El) 198 (M+-4H, 0.3%), 125 (70.6), 110 (6 6 .8 ), 98 (34.5), 84 (100), 
72 (32.3) and 58 (70), (Found: M+-4H, 198.1995. C -nH 2 4 N 3 requires 
198.2018).
A/-(3-Am i nopropy I)-N',N'-&\ m ethyl-1,4-diam inobutane  
Trihydrochloride 155
147 (0.51 g, 3 mmol), LiAIH4  (0.23 g, 2 equiv.) and AICI3 (0.82 g, 2  equiv.) 
in dry ether were treated according to general procedure B3 to yield the 
free base 151. This was converted into the trihydrochloride salt 155 via 
procedure B1 and isolated as a white powder (0.28 g, 1.80 mmol, 60%),
168
mp 204.5-206.5 °C; vmax(KBr)/cm-i 3424 (N-H), 1476 (-CH2-); 8 h 
(200MHz, D2 0 ) 1.61 (4H, m, 2,3-H2), 1.91 (2H, m, 7-H2), 2.71 (6 H, s, J 7.1, 
5-H3), 2.97 (8 H, m, 1,4,6,8-H2); 5c (50MHz, D2 0 ) 22.1 (CH2-2 or -3), 23.5 
(CH2 - 2  or -3), 24.6 (CH2 -7), 37.4 (CH2 -8 ), 43.5 (CH3 -5), 45.36 (CH2 -1 or -4 
or -6 ), 47.8 (CH2-1 or -4 or -6 ), 57.6 (CH2-1 or -4 or -6 ); m/z (El) 173 (M+- 
3H, 3 .2 %), 129 (6 .8 ), 115 (4.2), 98 (8.5), 84 (22.3), 71 (10) and 58 (100), 
(Found: M+-3H, 173.1887. C9 H2 3N3  requires 173.1882).
W-(3-Aminopropyl)-Ar,A/'-dimethyl-1,4-diaminopropane  
Trihydrochloride 154
6 H 2 2 I 4
3CI
7 5 1 3
146 (1 . 2 1  g, 7.77 mmol), UAIH4  (0.66 g, 2  equiv.) and AICI3  (2.40 g, 2  
equiv.) in dry ether were treated to general procedure B3 to yield the free 
base 150. This was converted into the trihydrochloride salt 154 via 
procedure B1 and isolated as a white hygroscopic solid (1.21 g, 4.51 mmol, 
58%), Vmax(KBr)/cm- 1 3423 (N-H), 1466 (-CH2-); 8 h (200MHz, D2 0 ) 1.97 
(4H, m, 2,6-H2), 2.75 (6 H, s, 4-H3), 3.01 (8 H, m, 1,3,5,7-H2); 5c (50MHz, 
D2 0 ) 2 2 . 1  (CH2 -2), 24.6 (CH2 -6 ), 37.4 (CH2 -7), 43.7 (CH3 -4), 45.3 (CH2 - 1  
or -3 or -5), 45.6 (CH2-1 or -3 or -5), 55.1 (CH2-1 or -3 or -5); m/z (El) 160 
(M+-3H, 0.3%), 159 (M+-3H, 1.3%), 132 (3), 114 (5.2), 98 (4.5), 85 (50.3), 72
(14.5), 70 (18) and 58 (100), (Found: M+-3H, 159.1741. CsH2iN 3 requires 
159.1746).
(rE>)-/\/-(3-Aminopropyl)-/V,,Ar-dim ethyl-1,4-diam inobut-2-ene  
Trihydrochloride 134
130 (0.68 g, 4.10 mmol), UAIH4  (0.31 g, 2 equiv.) and AICI3 (1.09 g, 2 
equiv.) in dry ether were treated according to general procedure B3 to yield 
the free base 132. This was converted into the trihydrochloride salt 134 
via procedure B1 and isolated as a white powder (0.67 g, 2.40 mmol, 58%), 
mp 244.5-246.0 °C; vmax(KBr)/cm-i 3424 (N-H), 1470 (-CH2-), 982 {(E)- 
C=C, C-H bend); 5h (200MHz, D2 0 ) 1.98 (2H, m, 7-H2), 2.75 (6 H, s, 5-H3),
169
3.02 (4H, m, 6 ,8 -H2), 3.70 (4H, m, 1,4-H2), 5.99 (2 H, m, 2,3-H); 5c (50MHz, 
D2 0 ) 24.6 (CH2 -7), 37.5 (CH2 -8 ), 43.1 (CH3 -5), 44.9 (CH2 -6 ), 49.0 (CH2 -1 
or -4), 58.9 (CH2-1 or -4), 127.9 (CH-2 or -3), 131.6 (CH- 2  or -3); m /z 
(CI/NH3) 173 (M+-1, 13%), 172 (M+-2, 1 0 0 %), 141 (0 .2 ), 129 (1.1), 115 (0.5) 
and 98 (0.3), (Found: M+-1, 173.1845. CgH2 3 N3  requires 173.1798; 
Found: M+-2, 172.1811. C9 H2 2 N3 requires 172.1809).
^-(S-AminopropylJ-A/^A/'-diethyl-IjS-diaminopropane  
Trihydrochloride 156
3CI
148 (0.99 g, 5.40 mmol), UAIH4 (0.41 g, 2  equiv.) and AICI3 (1.44 g, 2 
equiv.) in dry ether were treated according to general procedure B3 to yield 
the free base 152. This was converted into the trihydrochloride salt 156 
via procedure B1 and isolated as a cream powder (0.98 g, 3.35 mmol, 
62%), mp 171.2-173.6 °C; vmax(KBr)/cm-i 3424 (N-H), 1470 (-CH2-); §H 
(200MHz, D2 0 ) 1.11 (6 H, t, J 7.3, 5-H2), 1.79 (4H, m, 2,7-H2), 2.71 (4H, t, J 
7.6, 6 ,8 -H2), 2.88 (2H, t, J 7.7, 1-H2), 2.99 (2H, t, 3-H2), 3.08 (4H, q, J7.3, 4- 
H2 ); 5c (50MHz, D2 0 ) 9.8 (CH3 -5), 23.1 (CH2 -2 ), 26.4 (CH2 -7), 38.2 (CH2-
8 ), 46.1 (CH2 -1 , -3 or -4), 48.2 (CH2 -1 , -3 or -4), 50.3 (CH2 -1, -3 or -4); m/z 
(El) 187 (M+-3H, 1.3%), 113 (2 0 .6 ), 98 (21.5), 8 6  (100), 72 (28.5) and 58 
(41.1), (Found: M+-3H, 187.2039. CioH2sN3 requires 187.2030).
yV'lS-AminopropyO-A/^JV'-diethyM^-diaminobutane 
Trihydrochloride 157
3CI
149 (0.63 g, 3.73 mmol), UAIH4  (0.28 g, 2 equiv.) and AICI3  (0.99 g, 2 
equiv.) in dry ether were treated according to general procedure B3 to yield 
the free base 153. This was converted into the hydrochloride salt 157 via 
procedure B1 and isolated as a cream hygroscopic powder (0.61 g, 2.15 
mmol, 57%), vmax(KBr)/cnrr1 3420 (N-H), 1466 (-CH2-); 8 h (200MHz, D2 0)
1.08 (6 H, t, J 7.3, 6 -H3 ), 1.49 (4H, m, 2,3-H2), 1.69 (2H, m, 8 -H2), 2.64 (2H, t,
170
J 6.9, 9-H2), 2 . 6 8  (2 H, t, J 7.0, 7-H2), 2.77 (2 H, t, J 6.9, 1-H2), 2.95 (4H, q, J 
7.3, 5-H2), 3.01 (2 H, t, J 7.0, 4-H2); 8 c  (50MHz, D2 0 ) 9.2 (CH3 -6 ), 22.1 
(CH2 - 2  or -3,) 25.3 (CH2 - 2  or -3), 27.4 (CH2 -8 ), 38.4 (CH2 -9), 46.2 (CH2 -1, 
-4, -5 or -7), 48.0 (CH2 -1, -4, -5 or -7), 48.3 (CH2 -1, -4, -5 or -7), 52.1 (CH2- 
1, -4, -5 or -7); m/z (El) 187 (M+-3H, 1.3%), 113 (20.6), 98 (21.5), 8 6  (100), 
72 (28.5) and 58 (41.1), (Found: M+-3H, 201.2194. C n H 2 7 N3 requires 
201.2184).
(V-Benzyl-A/-ethyl-A/'-(3-aminopropyl)-1,4-diaminobutane  
Oxalate 162
13
159 (0.50 g, 1.93 mmol) was stirred in Et20  (30 ml) with UAIH4  (0.29 g, 4 
equiv.) and AICI3 (1.03 g, 4 equiv.) according to general procedure B3 to 
yield A/-Benzyl-A/-ethyl-A/'-(3-aminopropyl)-1,4-diaminobutane (0.4332 g,
I.65 mmol, 87%) as a clear oil, 5h (200MHz, CDCI3 ) 0.92 (3H, t, J7.1, 9- 
H3), 1.38 (4H, m, 2,3-H2), 1.51 (2H, m, 6 -H2), 2.29-2.65 (10H, m, 1,4,5,7,9- 
H2), 3.45 (2 H, s, 1 0 -H2), 7.16 (5 H, m, 12,13,14-H); §C (50MHz, CDCI3 )
I I . 7  (CH3 -9 ), 24.8 (CH2 - 2  or -3), 27.9 (CH2 - 2  or -3), 33.7 (CH2 -6 ), 40.3 
(CH2 -1 or -4 or -8 ), 47.1 (CH2-1 or -4 or -8 ), 47.7 (CH2 -1 or -4 or -8 ), 49.9 
(CH2 -5), 52.9 (CH2 -7), 57.9 (CH2 -10), 116.7 (C-7), 126.7 (CH-14), 128.1 
(CH-1 2 ), 128.8 (CH-13), 139.6 (C-11). The free base 161 (0.0621 g) was 
dissolved in MeOH (1 ml) and oxalic acid (0.032 g, 1.5 equiv.) in MeOH (1 
ml) added. Precipitation appeared immediately and the product was 
recrystallised from H2 0-EtOH to yield a white solid in quantitative yield, 
Vmax(KBr)/crn-i 3426 (NH3+), 2953 (-CH2-), 1608 (C 0 2-), 1496 (Ar C=C), 
1310 (C 02‘), 744 (Ar-H), 701 (Ar-H); §H (200MHz, D2 0 ) 1.09 (3H, t, J1.2,
9 -H 3 ), 1.52 (4H, m, 2,3-H2), 1.85 (2H, dt, 6 -H2), 2.83-3.04 (10H, m, 
1,4,5,6,8-H2), 4.11 (2H, s, 10-H2), 7.28 (5H, m, 12,13,14-H); 8 c  (50MHz, 
CDCI3 ) 8.79 (CH3 -9 ), 21.3 (CH2 - 2  or -3), 23.6 (CH2-2 or -3), 24.5 (CH2 -6 ),
37.3 (CH2-1 or -4 or -8 ), 45.3 (CH2-1 or -4 or -8 ), 47.7 (CH2-1 or -4 or -8 ),
48.3 (CH2 -5), 51.5 (CH2 -7), 57.3 (CH2 -10), 129.8 (CH-11), 130.1 (CH-13),
130.9 (CH-14), 131.6 (C-1 2 ), 171.0 (C=0); m/z (CI/NH3 ) 264 (M+-1 , 57%),
171
245 (5), 219 (4), 207 (10) and 136 (19), (Found: M+-1, 264.2445. 
C1 8 H3 1 N3 requires 264.2450).
/V-Benzyl-W-(2-cyanoethy I)-AT, N', -diethyl-1,4-diam inobutane  
163
148 (0.2049 g, 1.04 mmol) was stirred in MeCN (5 ml) and NEt3 (0.3 ml, 2 
equiv.). BnBr (0.12 ml, 1 equiv.) was added dropwise and the solution was 
stirred for 2 h after which time it was concentrated in vacuo. The residue 
was partitioned between Et2 0  (5 ml) and H2 O (5 ml) and the organic 
extracts washed with water (2x5 ml), dried (K2 C O 3 ), filtered and 
concentrated in vacuo to yield 163 as a clear oil (0.0558 g, 0.21 mmol, 
20%) vmax(CHCI3 )/cm-i 2955 (C-H), 2254 (CN), 1524 (Ar C=C), 720 (Ar C- 
H bend) 724 (Ar C-H bend); Sh (200MHz, CDCI3 ) 0.97 (6 H, t, J 7.1, 6 -H3 ),
1.45 (4H, m, 2,3-H2), 2.39 (2 H, t, J 6.9, 4-H2), 2.48 (2 H, t, J 7.0, 1-H2), 2.50 
(4H, q, J7.1, 5-H2), 2.52 (2 H, t, J 7.0, 8 -H2), 2.78 (2 H, t, J 7.0, 7-H2), 3.61 
(2 H, s, 10-H2), 7.28 (5H, m, 12,13,14-H); 8 c  (50MHz, CDCI3 ) 11.6 (CH3-6 ),
16.3 (CH2 - 2  or -3), 24.7 (CH2 - 2  or -3), 25.2 (CH2 -8 ), 46.8 (CH2-4 or -5),
49.2 (CH2-4 or -5), 52.7 (CH2 -1 ), 53.7 (CH2 -7), 58.4 (CH2 -10), 118.9 (C-9),
127.2 (CH-14), 128.4 (CH-1 2 ), 128.6 (CH-13), 138.9 (C-11); m/z (El) 287 
(M+, 1 .2 %), 233 (1.6), 196 (23.4), 176 (2.7), 160 (10), 123 (20.7), 98 (7.5), 
91 (47.3) and 8 6  (100), (Found: M+, 287.2378. C 1 8 H 2 9 N 3 requires 
287.2361).
13
172
A/-(3-Aminopropyl)-A/-benzyl-A/',A/,,-d iethyl-1,4-diam i nobutane
Trihydrochloride 165
H 3 N  9
163 (0.0440 g, 0.15 mmol) was reduced following general procedure B3 
using UAIH4  (0.035 g, 6  equiv.) and AICI3 (0.1220 g, 6  equiv.). The free 
base was taken up in DCM, filtered and concentrated in vacuo to yield 164 
as a clear oil (0.0348 g, 0.12 mmol, 80%), 8h  (200MHz , CDCI3 ) 1.03 (6 H, t, 
J 7.2, 6 -H3 ), 1.46 (4H, m, 2,3-H2), 1.62 (2 H, m, 8 -H2), 2.45 (6 H, m, 1,4,7- 
| H2), 2.53 (4H, q, J 7.2, 5-H2), 2.72 (2H, t, J 6 .6 , 9-H2), 3.12 (2H, bs, NH2),
3.53 (2 H, s, 10-H2), 7.29 (5H, m, 12,13,14-H); 8 c  (50MHz, CDCI3 ) 11.5 
! (CH3 -6 ), 24.6 (CH2-2 or -3), 25.1 (CH2-2 or -3), 30.7 (CH2 -8 ), 40.5 (CH2 -1,
-4, -5 or -7), 46.8 (CH2 -1, -4, -5 or -7), 51.3 (CH2 -1 , -4, -5 or -7), 52.8 (CH2- 
1 , -4, -5 or -7), 53.7 (CH2 -9), 58.7 (CH2 -10), 126.7 (CH-14), 128.1 (CH-1 2 ),
128.8 (CH-13), 140.7 (C-11). The trihydrochloride salt 165 was prepared 
by general procedure B1 and was isolated as a hygroscopic yellow semi­
solid in essentially quantitative yield, vmax(KBr)/cnrr1 2940 (-CH2-), 2791 (- 
NH+), 1610 (Ar C=C), 1580 (Ar C=C), 1499 (Ar C=C), 742 (Ar C-H bend), 
695 (Ar C-H bend); 8h (200MHz , D2 0 ) 1.20 (6 H, t, J 7.3, 6 -H3 ), 1.70 (4H, 
m, 2,3-H2), 2.10 (2H, m, 8 -H2), 3.11 (12H, m, 1,4,7,9-H2), 4.37 (2H, s, 10- 
H2), 7.47 (5H, m, 12,13,14-H); 5c (50MHz, D2 0 ) 9.1 (CH3 -6 ), 21.4 (CH2-2 
or -3), 22.5 (CH2-2 or -3), 37.3 (CH2 -8 ), 48.1 (CH2 -9), 48.2 (CH2 -1 , -4, -5 or 
-7), 50.4 (CH2 -1, -4, -5 or -7), 51.5 (CH2 -1, -4, -5 or -7), 52.6 (CH2 -1, -4, -5 
or -7), 58.3 (CH2 -10), 129.6 (C-11), 130.4 (CH), 131.2 (CH), 131.6 (CH); 
m/z (CI/NH3 ) 292 (M+-2H7.2%), 234 (0.09), 219 (0.03), 2 0 0  (0.3), 163 
(0.06), 91 (0.36) and 8 6  (0.34), (Found: M+-2H 292.2757. C 1 8 H3 4 N3  
requires 292.2762).
173
A/-(A/-benzyl-3-aminopropyl)-A/',A/'-diethyl-1,4-diaminobutane
Trihydrochloride 167
13
Following the procedure of Sclafani et al. 138 to a solution of 153 (0.1676 g, 
0.84 mmol) in CHCI3 was added benzaldehyde (0.08 ml, 1 equiv.). The 
solution was heated at reflux for 2  h and then concentrated in vacuo to yield 
the crude imine which was taken up in MeOH (15 ml). NaBH4  (0.13 g, 4 
equiv.) in MeOH (5 ml) was added and the solution was heated at reflux for 
2 h before leaving at rt overnight. It was concentrated in vacuo and the 
residue was partitioned between CHCI3  (15 ml) and 1 mol dm-3 NaOH (5 
ml) and the organic layer was washed with 1 mol dm-3 NaOH (2 x 5  ml). 6  
mol dm-3 HCI was added to the CHCI3 extract and the aqueous layer was 
separated. The aqueous layer was rebasified to pH14 (NaOH), extracted 
with CHCI3 , dried (K2 CO3 ), filtered and concentrated in vacuo to yield the 
free base 166 as a clear oil (0.2328 g, 0.80 mmol, 95 %), 8 h (200MHz, 
CDCI3 ) 1.01 (6 H, t, J7.1, 6 -H3 ), 1.47 (4H, m, 2,3-H2), 1.62 (2 H, m, 8 -H2 ), 
1.70 (2H, m, NH), 2.41 (2H, t, 4-H2), 2.50 (4H, q, J7A , 5-H2), 2.63 (2H, t, J
6.9, 1-H2), 2.67 (2 H, t, J 6.9, 7-H2), 2.68 (2H, t, J6.9, 9-H2), 3.77 (2H, s, 10- 
H2), 7.31 (5 H, m, 12,13,14-H); 5c (50MHz, CDCI3 ) 11.6 (CH3 -6 ), 24.8 
(CH2 - 2  or -3), 28.1 (CH2-2 or -3), 30.3 (CH2-8 ), 46.7 (CH2 -1, -4, -5, -7 or -9),
47.9 (CH2 -1, -4, -5, -7 or -9 ), 48.5 (CH2 -1 , -4, -5, -7 or -9 ), 50.0 (CH2 -1 , -4, 
-5, -7 or -9), 52.8 (CH2 -1 ,  -4, -5, -7 or -9), 54.1 (CH2 -10), 126.8 (CH-14),
128.0 (CH-1 2 ), 128.3 (CH-13), 140.5 (C-11); The trihydrochloride salt 167 
was isolated following general procedure B1 as a cream powder in 82 % 
yield, mp 220-222.2 °C; vmax(KBr)/cnrH 3423 (O-H), 2943 (-CH2-), 2787 (- 
NH+), 1637 (Ar C=C), 1581 (Ar C=C), 1497 (Ar C=C), 748 (Ar C-H bend), 
697 (ArC-H bend); 5h (2 0 0 MHz, D2 0 ) 1.10 (6 H, t, J 7.3, 6 -H3 ), 1.61 (4H, 
m, 2 ,3 -H2), 1.98 (2 H, m, 8 -H2), 2.96 (8 H, m, 1,4,7,9-H2), 3.04 (4H, q, J 7.3,
5 -H2), 4.10 (2 H, s, 1 0 -H2), 7.35 (5H, m, 12,13,14-ArH); 8 c  (50MHz, D20 )
9 . 0 1  (CH3 -6 ), 21.5 (CH2 - 2  or -3), 23.5 (CH2 - 2  or -3), 23.7 (CH2 -8 ), 44.7 
(CH2 - 1 , -4, -5, -7 or -9), 45.3 (CH2 -1, -4, -5, -7 or -9), 47.9 (CH2 -1 , -4, -5, -7 
or -9), 48.2 (CH2 -1 , -4, -5, -7 or -9), 51.7 (CH2 -1 , -4, -5, -7 or -9), 52.1 (CH2- 
10), 130.2 (CH-14), 130.6 (CH-1 2 ), 130.7 (CH-13), 131.2 (C-11); m /z
174
(CI/NH3) 292 (M+-2 H, 1 0 0 %), 263 (0 .1 ), 217 (0.4), 2 0 2  (0 .1 ), 145 (0 .2 ) and 
106 (0.2), (Found: M+-2H 292.2750, C 1 8H3 4 N3 requires 292.2747).
/V,A/-Bis-(3-cyanopropyl)benzylamine 169112> 131> 139> 140
Benzylamine (0.50 g, 4.66 mmol) and 4-bromobutyronitrile (1.02 ml, 2.2 
equiv.) were stirred in MeCN (15 ml) and NEt3 (0.65 ml, 2.2 equiv.) for 48 h 
at 40 °C. The solution was concentrated in vacuo and the residue was 
partitioned between 3 mol dm*3 HCI (15 ml)and CHCI3 (15 ml). The 
aqueous layer was washed with CHCI3 (2x10 ml) and then made basic to 
pH 14 using NaOH(s). The aqueous was extracted with CHCI3  (3x15 ml) 
and the organic extracts dried (K2 CO3 ), filtered and concentrated in vacuo 
to give a clear yellow oil. Purification was achieved via silica gel column 
chromatography with EtOH as eluent to yield the desired product as a clear 
oil (0.2945 g, 1.22 mmol, 26 %), 1H NMR data were identical with 
published data211; Rf 0.76. (EtOH); vmax(CHCI3 )/cm - 1 3608 (N-H), 3022 
(Ar-H), 2962 (-CH2-), 2821 (N-CH2 ), 2249 (CN), 1602 (Ar C=C), 1494 (Ar 
C=C), 727 (Ar C-H bend), 698 (Ar C-H bend); 8 c  (50MHz, CDCI3 ) 14.4 
(CH2 -2 ), 2 2 . 8  (CH2), 51.8 (CH2), 58.0 (CH2), 119.4 (C-4), 126.8 (CH-9),
128.0 (CH-7), 128.4 (CH-8 ), 138.2 (C-6 ); m/z (El) 241 (M+, 1.5%), 187
(26.3), 164 (1.1), 118 (0.9), 104 (0.8), 91 (100), 77 (1.6) and 65 (11.3), 
(Found: M+, 241.1591. C 1 5H1 9 N3 requires 241.1579).
Isolated from the same column chromatography as a clear oil was Af-(3- 
cyanopropyl)benzylamine 170 (0.2536 g, 1.39 mmol, 30 %),
8
MS was identical with published data. Rf 0.41 (EtOH); vmax(CHCI3 )/crrr1 
3583 (N-H), 3022 (Ar-H), 3010 (-CH2-), 2250 (CN), 1602 (Ar C=C), 1495 (Ar
C=C), 768 (Ar C-H bend), 699 (Ar C-H bend); Sh (200MHz, CDCI3) 1.37 
(1 H, s, NH), 1.79 (2H, m, 2-H2), 2.43 (2H, t, J 6 .6 , 3-H2), 2.73 (2H, t, J6.6, 1- 
H2), 3.76 (2 H, s, 5-H2), 7.27 (5H, s, 7,8,9-ArH); 8 c  (50MHz, CDCI3 ) 14.9 
(CH2 -2 ), 25.8 (CH2), 47.4 (CH2), 53.8 (CH2), 119.8 (C-4), 127.1 (CH-9),
128.0 (CH-7), 128.4 (CH-8 ), 140.1 (C-6 ); m/z (El) 174 (M+, 1 1 %), (Found: 
M+, 174.1143. C n H i4 N2 requires 174.1157).
A/,/V-Bis-(4-aminobutyl)benzylamine Trihydrochloride 175112> 131.
139, 140
The dinitrile 169 (0.30 g, 1.20 mmol) was reduced using general procedure 
B3 and converted into the trihydrochloride salt via procedure A1 to give 
cream crystals (0.3081 g, 0.86 mmol, 72%), Vmax(KBr)/cnr1 3423 (N-H), 
2962 (C-H), 1998 (C-H), 1599 (Ar C=C), 1498 (Ar C=C), 746 (Ar C-H bend), 
696 (Ar C-H bend); 5h (200MHz, D2 0 ) 1.57 (4H, m, 3-H2), 1.70 (4H, m, 2- 
H2), 2.87 (4H, t, J7.3, 4-H2), 3.06 (4H, t, J 8.0, 1-H2), 4.24 (2H, s, 5-H2), 
7.37 (5H, s, 7,8,9-H); 8 c  (50MHz, D20 ) 21.5 (CH2-2 or -3), 24.8 (CH2-2 or 
-3), 39.8 (CH2 -4), 52.6 (CH2 -1 ), 58.1 (CH2 -5), 129.8 (C-6 ), 130.4 (CH-9),
131.2 (CH-7), 132.0 (CH-8 );
/V-(2-Cyanoethyl)-A/-(3-cyanopropyl)benzylamine 171112- 131> 139> 
140
n 8
NC
4' CN
3' 3
170 (0.2536 g, 1.46 mmol) was stirred in acrylonitrile (0.41 ml, 4 equiv.) at 
70-80 °C for 24 h. The solution was concentrated in vacuo and purified by 
silica chromatography, with EtOH as eluent, to yield 171 as a clear oil 
(0.2481 g, 1.09 mmol, 75 %) 1H NMR and IR were identical with published 
data210, Rf 0.81 (EtOH); 8 c  (50MHz, CDCI3) 14.4 (CH2 -2'), 16.3 (CH2 -3 '),
23.1 (CH2 -2 ), 48.9 (CH2 -1') 51.5 (CH2 -1), 58.1 (CH2 -5), 118.9 (C-3 or -4'),
119.5 (C-3 or -4'), 127.2 (CH-9), 128.2 (CH-7), 128.4 (CH-8 ), 137.8 (C-6 ); 
m/z (El) 227 (M+, 0 .6 %), 187 (20.4), 173 (4.7), 150 (0.6), 118 (0.9), 91 (100) 
and 65 (11.3), (Found: M+, 227.1433. C1 4H1 7N3 requires 227.1422).
/V-(4-Aminobutyl)-JV-(3-aminopropyl)benzylamine 
Trihydrochloride 173112> 131> 139> 140
172 was prepared using general procedure B3 stirring dintrile 171 (0.2481 
g, 1.10 mmol), UAIH4  (0.38 g, 4 equiv.) and AICI3 (1.33 g, 4 equiv.) in dry 
ether (20 ml) to yield a clear oil (0.2026 g, 1.05 mmol, 95 %), 1H NMR data 
were identical with published material.2 10  New data: 8 c  (50MHz, CDCI3 )
24.4 (CH2 - 2  or -3), 30.9 (CH2 - 2  or -3), 31.6 (CH2 -2 '), 40.5 (CH2-1 or -1 '),
42.1 (CH2 -I or -1 '), 51.3 (CH2 -3‘ or -4), 53.6 (CH2 -3‘ or -4), 58.7 (CH2 -5),
126.7 (CH-9), 128.1 (CH-7), 128.7 (CH-8 ), 134.0 (C-7); The 
trihydrochloride salt 173 was isolated as cream crystals in 89% yield, 
Vmax(KBr)/cm- 1 3433 (N-H), 2966 (C-H), 1989 (C-H), 1601 (Ar C=C), 1499 
(Ar C=C), 748 (Ar C-H bend), 699 (Ar C-H bend); 8 h (200MHz, D2 0 ) 1.49
8
H3N
+
177
(2H, m), 1.63 (2H,m), 1.96 (2H,m), 2.82 (4H, m), 3.04 (4H, m), 4.19 (2H, 
s, 5-H2), 7.33 (5H, s, 7,8,9-H); 8q (50MHz, D20 )  21.4 (CH2-2 or -3), 22.5 
(CH2-2 or -3), 24.7 (CH2-2'), 37.4 (CH2-3' or -4), 39.6 (CH2-3‘ or -4), 50.2 
(CH2-1 or -1'), 52.7 (CH2-1 or -1'), 58.2 (CH2-5), 129.9 (C-6), 130.3 (CH-9), 
! 131.0 (CH-7), 131.7 (CH-8); m/z (CI/NH3) 236 (M+-2H, 100%), 217 (0.1),
179 (0.45), 165 (0.4), 134 (0.3), 108 (0.5) and 91 (0.2), (Found: M+-2H, 
236.2124. C-|4.H26 N3 requires 236.2121).
I
The following compounds were prepared following the procedure of 
McClintock.114 Their 1H, 13C NMR and IR spectra were identical to those 
reported: 3-(t-butoxycarbonylamino)propanoic acid 111 (96%); 4-(t-
| b u to x y c a rb o n y la m in o )b u ta n o ic  ac id  112 (85% ); 5 -(t-
butoxycarbonylamino)pentanoic acid 113 (90%); /V -e th y l-4 -(t- 
b u toxycarb on ylam in o )b u tanam ide 114 (43%); A /-e th y l-5 -(t-  
b u to x yca rb o n y lam in o )p en tan a m id e  115 (66%); /V -e th y l-4 -  
aminobutanamide hydrochloride 116 (95%); A/-ethyl-5-aminopentanamide 
h y d r o c h l o r i d e  117 ( 9 2 %) ;  A / - e t h y l - 4 - [ 3 - ( t -
butoxycarbonylamino)propanamido]butanamide 119 (41%); A/-ethyl-5-[3- 
(t-butoxycarbonylamino)propanamido]pentanamide 120 (50%); A/-ethyl-4- 
[4-(t-butoxycarbonylamino)butanamido]butanamide 121 (32%); A/-ethyl-4- 
(3-aminopropanamido)butanamide hydrochloride 122 (99%); A/-ethyl-5-(3- 
aminopropanamido)pentanamide hydrochloride 123 (95%); A/-ethyl-4-(4- 
aminobutanamido)butanamide hydrochloride 124 (90%); A/'-(3- 
aminopropyl)-A/-ethyl-1,4-diaminobutane trihydrochloride 125 (52%); N'- 
(3-aminopropyl)-A/-ethyl-1,5-diaminopentane trihydrochloride 126 (62%); 
A/,-(4-aminobutyl)-A/-ethyl-1,4-diaminobutane trihydrochloride 127 (65%).
A/-(7-Chloroquinolin-4-yl)-1-aminopropan-3-ol 176143
3 1
H N '^ V ^ O H
3'
ci' ^T9'T
4,7-Dichloroquinoline (5 g, 25 mmol) was stirred in 1-aminopropan-3-ol 
(3.82 ml, 50 mmol) at 150-160 °C for 18 h. The solution was cooled to rt 
and then excess 1-aminopropan-3-ol removed by reduced pressure
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distillation (0.35 mmHg, 44 °C). After cooling to rt the amber residue was 
triturated in 1 mol dm-3 NaOH to give a cream solid which was collected by 
filtration to yield 176 (5.0240 g, 21.25 mmol, 85%), mp 134.9-137.1 °C (lit. 
148-148.5 °C); IR, 1H and 13C NMR spectra were consistent with published 
data. New data: m/z (El) 238 (M+, 25.4%), 236 (M+, 76%), 205 (3), 191 
(100), 178 (12), 164 (9.8), 156 (61.4), 128 (5.8), 99 (9.8), 75 (5.1) and 63 
(3.5), (Found: M+, 238.0697. C i2 H i3 N2 0 37CI requires 238.0686; Found: 
M+, 236.0719. C i2 H1 3N20 35CI requires 236.0716).
W-(7-Chloroquinolin-4-yl)-1-aminopropan-3-bromide 177143
To a solution of 48 % HBr (4.6 ml, 10 equiv) was added c. H2 SO4  (2.3 ml, 
10 equiv) dropwise with T<0 °C (ice-bath). To this stirred orange solution 
was added the aminoalcohol (176) (1.01 g, 4.2 mmol), slowly, and with 
T<0 °C. The solution was heated at reflux until turbidity occurred (5 min) 
and then for a further 2 h. The aqueus layer was decanted and the residue 
was triturated with 2 mol dm’ 3 NaOH to give a white solid, collected by 
filtration, and recrystallized from EtOH-Et2 0  to yield 177 as a cream solid 
(0.479 g, 1.59 mmol, 38 %), mp >250 °C (lit. 159-160 °C); IR, 1H and 13C 
NMR spectra were consistent with published data. New data: m/z (El) 301.9 
(M+, 7.2%), 299.9 (M+, 27.9%), 297 (M+,24.4%), 219 (23.1), 191 (100), 164
(7.3), 156 (77), 135 (3.6), 99 (15.3) and 78 (12.7), (Found: M+, 301.9804. 
C 1 2 H-|2 N 2 81 B r37CI requires 301.9823; Found: M+, 299.9841.
C i 2 H i 3 N 2 7 9 Br37CI and C i 2 H 1 3 N 2 8 1 Br3 5CI, requires 299.9852 and 
299.9843. Found: M+, 297.9862. C i2 H1 2N2 79Br35CI, requires 297.9873).
3
179
A/-(7-Chloroquinolin-4-yl)-A/'-(4-diethylaminobutyl)-1,3- 
propanediamine Trihydrochloride 179
3CI
177 (0.2293 g, 0.75 mmol) was stirred in acetonitrile (5 ml) with KF on 
Celite (0.8 g, 10 equiv) and diamine 145 (1.0590 g, 10 equiv) was added. 
Stirring was continued at 40 °C for 2  h before the solution was filtered and 
concentrated in vacuo to give a yellow oil. The oil was distilled using a 
Kugelrohr to give the free base 178 as a clear oil (0.2098 g, 0.58 mmol, 77 
%), 8 h (200MHz, MeOD) 0.55 (6 H, t, J6.9, 9-H3), 1.04 (4H, m, 5,6-H2), 1.34 
(2 H, bt, J6.1, 2-H2), 2.35 (1 0 H, m, 1,4,7,8-H2), 2.90 (2H, t, J 6.0, 3-H2), 5.95 
(1 H, d, J5.5, 3'-H), 6.60 (1H, d, J 8 .8 , 6 '-H), 7.15 (1H, s, 8 '-H), 7.66 (1H, d, J
8 .8 , 5'-H), 7.75 (1H, d, J 5.1, 2 '-H); 5c (50MHz, MeOD) 10.1 (CH3 -9), 23.9 
(CH2-5 or -6 ), 26.5 (CH2-5 or -6 ), 27.0 (CH2 -2 ), 41.1 (CH2-7 or -8 ), 47.0 
(CH2-7 o r-8 ), 47.3 (CH2 -4), 47.8 (CH2 -1), 52.7 (CH2 -3), 98.9 (CH-6 '), 117.7 
(C-10'), 124.1 (CH-8 '), 125.2 (CH-3‘), 126.4 (CH-5'), 135.4 (C-7'), 148.3 (C- 
4'), 151.3 (CH-2 '), 151.5 (C-9'). The trihydrochloride salt was prepared by 
general procedure A2 to yield 179 as hygroscopic cream crystals (0.1796 
g,0.49 mmol, 85%), vmax(KBr)/cm- 1 3050 (Ar C-H), 2942 (C-H), 2868 (C-H), 
1586 (Ar C=C), 1545 (Ar C=C), 979 ((E)-C=C C-H bend), 890 (Ar C-H 
bend), 801 (Ar C-H bend); 5h (200MHz, D20 ) 1.09 (6 H, t, J7.1, 9 -H3), 1.60 
(4 H, m, 5 ,6 -H2), 1.77 (2H, m, 2-H2), 2.99 (10H, m, 1,4,7,8-H2), 3.28 (2H, t, J
6 .8 , 3-H2), 6.34 (1H, d, J7.1, 3'-H), 6.82 (1H, d, J9.4, 6 '-H), 6.84 (1H, s, 8 '- 
H), 7.25 (1H, d, J 9.5, 5 '-H), 7.81 (1 H, d, J6.9, 2'-H); 5c (50MHz, D20 ) 9.3 
(CH3 -9), 21.7 (CH2-5 or -6 ), 23.8 (CH2-5 or -6 ), 25.4 (CH2 -2), 41.5 (CH2),
46.0 (CH2), 48.0 (CH2), 48.2 (CH2), 51.7 (CH2), 99.3 (CH-6 '), 114.6 (C-10'),
118.7 (CH-8 '), 124.4 (CH-3'), 127.9 (CH-5'), 137.3 (C-7'), 139.9 (C-4'),
142.8 (CH-2'), 155.5 (C-9'); m/z (El) 364 (M+-4H, 0.2%), 362 (M+-4H, 0.5%), 
289 (15.1), 248 (9.4), 219 (13.1), 205 (46.8), 192 (100) and 112 (22.7), 
(Found: M+-4H, 364.2211. C2 0 H3 1 N4 37CI, requires 364.2208; Found: M+- 
4H, 362.2235. C2 0 H3 iN 435CI requires 362.2237).
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Attempted preparation of (E )~ /V -(7-Chloroquinolin-4-yl)-A /-(2-
cyanoethyl)-A/',A/'-diethyl-1,4-diaminobut-2-ene 180
Attempt 1: 99 (0.4279 g, 1.31 mmol) was stirred in MeOH (2 ml) and NaOH 
(0.05 g, 1 equiv) and acrylonitrile (0 . 1 0  ml, 1.1 equiv) added. The solution 
was stirred at rt for 48 h however no product was observed.
Attempt 2: 99 (0.1738 g, 0.57 mmol) was stirred in EtOH ( 2  ml) and NaOH 
(0.025 g, 1 equiv) and excess acrylonitrile (0.12 ml, 3 equiv) added. The 
solution was heated at 100 °C for 1 week, however no product was 
observed.
Attempted preparation of A /- (7 -C h lo ro q u in o lin -4 -y l) - /V -(2 -  
cyanoethyl)-A/',A/'-diethyl-1,4-diaminobutane 182
149 (0.3044 g, 1.1 equiv) was heated in phenol (0.12 g) with 4,7- 
dichloroquinoline (0.2571 g, 1 equiv) at 160-165 °C for 6  h. On cooling the 
gummy solid was partitioned between CHCI3 and 2  mol dm"3  NaOH and 
the aqueous layer was washed with CHCI3 . The organic extracts were 
concentrated in vacuo to give a brown tar. Purification was first attempted 
via silica flash chromatography hexaneane:EtOAc (1 :1 ) with the product as 
baseline material eluting in EtOH. The concentrated residue was dissolved 
in 'PrOH and precipitated with Et2 0  asnd the filtrate concentrated in vacuo
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to give a bright yellow oil. No nitrile peak in NMR or IR spectra was 
observed.
The product was identified as /V -(7 -C h lo ro q u in o lin -4 -y l)-A r,A T -  
diethyl-1 ,4-d iam inobutane 181
Cl 8' 9' ^
vmax(CHCI3 )/cm-i 3023 (Ar C-H), 2972 (-CH2-), 1579 (Ar C=C), 1532 (Ar 
C=C), 802 (Ar C-H bend); 8 h (200MHz, MeOD) 0.90 (6 H, t, J 7.2, 6 -H3),
1.50 (4H, m, 2,3-H2), 2.36 (2H, t, 4-H2), 2.41 (4H, q, J 7.2, 5-H2), 3.20 (2H, t, 
1 -H2), 6.33 (1H, d, J 5.7, 3'-H), 7.23 (1H, dd, J 9.0, 2.2, 6 '-H), 7.62 (1H, d, J
2.1, 8 '-H), 7.94 (1H, d, J 9.0, 5'-H), 8.20 (1H, d, J5 .6 , 2'-H); 8 c  (50MHz, 
D2 0 ) 11.2 (CH3 -6 ), 24.9 (CH2-2 or -3), 28.1 (CH2-2 or -3), 43.8 (CH2 -4),
47.6 (CH2 -4), 53.4 (CH2 - 1 ), 99.6 (CH-6 '), 118.7 (C -1 0 '), 124.3 (CH-8 '),
125.8 (CH-3'), 127.6 (CH-5'), 136.2 (C-7'), 149.6 (C-4'), 152.4 (CH-2'),
152.6 (C-9'); m/z (El) 307 (M+-3 H, 0.3%), 305 (M+-3H, 1.0%), 276 (5.5), 235 
(1.4), 233 (5.6), 205 (2.4), 193 (1.6), 179 (1.5) and 8 6  (57), (Found: M+-3H, 
307.1633. C i7 H2 4 N337CI requires 307.1637; Found: M+-3H, 305.1659. 
C i7 H2 4 N335CI requires 305.1659).
Af,A/'-Dibenzyl-1,4-diaminobutane 186148
Following the procedure of Lee et al. the free base was isolated as a clear 
oil in 100% yield. 1H, 13C and IR were identical to reported data, (Found: 
M+, 268.1930. C 1 8H2 4 N2 requires 268.1939).
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/V, AT-Bis-(2-cyanoethyl)-N,Ar-Dibenzyl-1,4-diaminobutane 187
186 (1.0116 g, 3.7 mmol) was stirred in neat acrylonitrile (1.5 ml, 6  equiv.) 
at 70-80 °C for 18 h before the solution was concentrated in vacuo to yield 
a yellow oil. Purification was achieved using silica chromatography with 
hexane:CHCl3 :EtOH (10:1:1) as eluent to isolate the free base as a clear oil 
(1.1383 g, 3.0 mmol, 81 %), Rf 0.35 (hexane:CHCl3 :EtOH, 10:1:1); 
Vmax(CHCI3 )/cm - 1 3065 (Ar C-H), 2942 (C-H), 2250 (CN), 1602 (Ar C=C), 
1585 (Ar C=C), 1494 (Ar C=C), 763 (Ar C-H bend), 698 (Ar C-H bend); 8 h 
(200MHz, CDCI3) 1.45 (4H, m, 2,3-H2), 2.29 (4H, t, J 6.9, 6 -H2), 2.39 (4H, 
m, 1,4-H2), 2.66 (4H, t, J 6 .8 , 5-H2), 3.53 (4H, s, 8 -H2), 7.28 (10H, m, 
10,11 ,1 2 -H); 8 c  (50MHz, CDCI3 ) 16.2 (CH2 - 2  and -3), 24.4 (CH2 -6 ), 48.9 
(CH2 -1 and -4), 53.0 (CH2 -5), 58.3 (CH2 -8 ), 119.1 (C-7), 127.1 (CH-12),
128.3 (CH-10), 128.7 (CH-11), 138.9 (C-9); m/z (El) 374 (M+, 3.2%), 283
(6.3), 213 (4.2), 173 (7.3), 123 (14.9) and 91 (100), (Found: M+, 374.2445. 
C2 4 H3 qN4  requires 374.2470).
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A/, W'-B is-(S-aminopropylJ-A^A/'-di benzyl-1,4-diaminobutane  
Tetrahydrochloride 18960
4CT
188 was prepared according to general procedure B3 reducing 187  
(1.0720 g, 2.9 mmol) in ether (50 ml). The free base was isolated as a clear 
oil2 1 4  (0.8569 g, 78%), 8 K (200MHz, CDCI3) 1.44 (4H, m, 2,3-H2), 1.53 
(4H, m, 6 -H2), 2.35 (12H, m, 1,4,5,-H2 and NH2), 2.62 (4H, t, J 6.7, 7-H2), 
3.49 (4H, s, 8 -H2), 7.29 (10H, m, 10,11,12-H). The tetrahydrochloride salt
189 was isolated as a peach solid following general procedure A1 in 100% 
yield, vmax(KBr)/cm- 1 3419 (N-H), 2930 (-CH2-), 1602 (Ar C=C), 1585 (Ar 
C=C), 1497 (Ar C=C), 746 (Ar C-H bend), 701 (Ar C-H bend); 8 h (200MHz, 
D20 ) 1.60 (4H, m, 2,3-H2), 2.03 (4H, m, 6 -H2), 2.88 (4H, t, J 7.6, 7-H2), 3.09 
(8 H, m, 1,4,5-H2), 4.21 (4H, s, 8 -H2), 7.36 (10H, m, 10,11,12-H); 5c  
(50MHz, D2 0 ) 21.3 (CH2-2 or -3), 22.5 (CH2 -7), 37.4 (CH2-1 and -4 or -5),
50.5 (CH2-1 and -4 or -5), 52.4 (CH2-1 and -4 or -5), 58.2 (CH2 -8 ), 129.5 
(C-9), 130.4 (CH-1 2 ), 131.3 (CH-10), 131.8 (CH-11); m/z (FAB) 386 (M+, 
31.8%), 295 (3), 2 2 0  (0.5), 188 (1 ) and 91 (1 0 0 ), (Found: M+ xxx, CXHXNX 
requires xxx).
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(rE^-A /,A /'-B is-(2-cyanoethyl)-A /,A /'-d ibenzyl-1,4-diam inobut-2-ene  
190
NC
190 was prepared following the general procedure B2 reacting 93 (0.4903 
g, 1.8 mmol) with acrylonitrile (0.7 ml, 6  equiv.). Purification was via silica 
chromatography with hexane:CHCl3 :EtOH (10:1:1) as eluent, folowed by 
hexane:CHCl3 :EtOH (3:1:1) to yield the free base as a clear oil (0.5441 g, 
83%), Rf 0.47 (hexane:CHCI3 :EtOH, 6:1:1); vmax(CHCI3 )/cm- 1 3022 (Ar C- 
H), 2931 (-CH2-), 2812 (N-CH2), 1602 (Ar C=C), 1494 (Ar C=C), 979 ((E)- 
C=C, C-H bend), 752 (Ar C-H bend), 722 (Ar C-H bend); 8 h (200MHz, 
CDCI3) 2.36 (4H, t, J 6.7, 6 -H2), 2.73 (4H, t, J 6.7, 5-H2), 3.10 (4H, m, 1,4- 
H2), 3.58 (4H, s, 8 -H2), 5.67 (2H, m, 2,3-H), 7.28 (10H, m, 10,11,12-H); 5c  
(50MHz, CDCI3 ) 16.4 (CH2 -6 ), 48.5 (CH2 -5), 55.4 (CH2 -1 and -4), 58.0 
(CH2 -8 ), 118.9 (C-7), 127.2 (CH - 2  and -3), 128.3 (CH-12), 128.6 (CH-10),
130.5 (CH-11), 138.5 (C-9); m/z (El) 372 (M+, 1.7%), 332 (13), 213 (5.5), 
159 (4.2), 131 (3.1) and 91 (100), (Found: M+, 372.2334. C2 4 H 2 8 N4  
requires 372.2314).
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(£)-A/,A/'-Bis-(3-aminopropyl)-W ,A/'-Dibenzyl-1,4-diaminobut-2-
ene Tetrahydrochloride 192
NH NH
191 was prepared according to general procedure B3 reducing 190  
(0.5423 g, 1.46 mmol) in ether (30 ml) with LiAIH4  ( 6  equiv.) and AICI3  ( 6  
equiv.). The free base was isolated as a clear oil (0.4332 g, 1.14 mmol, 
78%), 8 h (2 0 0 MHz, CDCI3 ) 1.58 (4H, m, 6 -H2), 1.78 (4H, s, NH2), 2.45 (4H, 
t, J6.9, 5-H2), 2.66 (4H, t, J 6 .8 , 7-H2), 3.04 (4H, m, 1,4-H2), 3.53 (4H, s, 8 - 
H2), 5.66 (2H, m, 2,3-H), 7.28 (10H, m, 10,11,12-ArH); 8 c  (50MHz, CDCI3 )
30.7 (CH2 -6 ), 40.4 (CH2 -7), 50.8 (CH2 -5), 55.5 (CH2 -8 ), 58.2 (CH2 -1 and 
-4), 126.7 (CH-2 and -3), 128.1 (CH-12), 128.7 (CH-10), 130.6 (CH-11),
139.6 (C-9). The tetrahydrochloride salt 192 was isolated following 
general procedure A1 as white crystals in 99% yield, vmax(KBr)/cnrr1 3428 
(N-H), 3065 (Ar C-H), 2934 (C-H), 1630 (C=C), 1458 (Ar C=C), 979 ((E)-C- 
H), 747 (Ar C-H), 702 (Ar C-H); 8 h (2 0 0 MHz, D20 ) 2.20 (4H, m, 6 -H2), 3.03 
(4H, t, J 7.4, 7-H2), 3.27 (4H, t, J  8.0, 5-H2), 3.93 (4H, m, 1,4-H2), 4.39 (4H, 
s, 8 -H2), 6.16 (2H, m, 2,3-H), 7.52 (10H, s, 10,11,12-H); 8 c  (50MHz, D20 )
22.7 (CH2 -6 ), 37.3 (CH2 -7), 50.5 (CH2 -5), 54.5 (CH2-1 and -4), 58.3 (CH2- 
8 ), 129.5 (C-9), 129.8 (CH- 2  and -3), 130.4 (CH-1 2 ), 131.2 (CH-10), 131.9 
(CH-11); m/z (Cl/isobutane) 382 (M+-2 H, 25.9%), 381 (M+-3 H, 70.2%), 325 
(0.35), 216 (0.28), 166 (0.43), (Found: M+-2 H 382.3052, C2 4 H 3 8 N4  
requires 382.3008; Found: M+-2H 3381.3020, C2 4 H 3 7 N4  requires 
3381.3022).
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S-Methylisothiourea 194154
4 \
S
Following the procedure of Schildneck thiourea 193 (5.9907 g, 79 mmol, 1 
equiv.) was heated at reflux with dimethylsulphate (4.1 ml, 0.5 equiv.) in 
water (3.5 ml) to isolate 194 as white crystals (8.111 g, 29 mmol, 40%), mp
240.7-242.1 °C [lit. 235 °C]
1,3-Dimethoxy-S-methylisothiourea 195155
Following the procedure of Weinhardt 194 (7.0071 g, 25 mmol, 1 equiv) 
was reacted with methylchloroformate (9.7 ml, 5 equiv.) to give 195 as 
white crystals (3.3025 g, 16 mmol, 64%), mp 102.1-104.8 °C [lit. 1 0 0 - 1 0 2  
°C]. New data: 8 h (200MHz, CDCI3) 2.34 (3H, s, 8 -H3), 3.72 (6 H, s, 5,7- 
H3), 11.75 (1H, bs, NH); 8 c  (50MHz, CDCI3) 14.3 (CH3 -8 ), 53.2 (CH3-5 or 
-7), 151.9 (C-6 ), 161.5 (C-4), 172.5 (C-2 ).
\
HN a 7
? °
187
A/,Ar-Bis-[bis(carbomethoxy)guanidinopropyl]-A/,AT-dibenzyl- 
1,4-diaminobutane 196
Following the procedure of Kumar et al. 150  1 95 (0.4878 g, 1.27 mmol) was 
stirred in EtOH (10 ml), pseudothioureacarbamate (0.48 g, 2.2 equiv.) 
added and the solution stirred at rt for 18 h. The solution was concentrated 
in vacuo to give a semi-solid. Purification was achieved using silica gel 
■ chromatography, EtOAc:hexane (1:1) increasing to EtOAc to yield the 
product 196 as a thick yellow semi-solid (0.1537 g, 0.24 mmol, 24%), 
vmax(CDCI3 )/cnr1 3342 (NH), 3020 (Ar-H), 2952 (-CH2-), 1731 (C=0), 1711 
(C=N), 1640 (C=C), 1576 (C=C), 1494 (C=C), 778 (Ar C-H), 669 (Ar C-H); 
§H (2 0 0 MHz, CDCI3) 1.37 (4H, m, 2,3-H2), 1.62 (4H, m, 6 -H2), 2.37 (8 H, m,
I ,4,5,-H2), 3.35 (4H, m, 7-H2), 3.44 (4H, s, 13-H2), 3.62 (6 H, s, 10 or 12-H3),
3.74 (6 H. s. 10 or 12-H3), 7.19 (10H, m, 15,16,17-H), 8.29 (2H, bs, NH),
II .5 9  (2H, bs, NH); (50MHz, CDCI3) 24.5 (CH2-2 and -3), 26.3 (CH2 -6 ),
39.4 (CH2 -1 and -4), 50.8 (CH2 -5), 52.5 (CH3-10 or -12), 53.1 (CH3-10 or 
-1 2 ), 53.7 (CH2 -7), 58.5 (CH2-13), 126.7 (CH-17), 128.1 (CH-15), 129.8 
(CH-16), 139.5 (C-14), 154.2 (C-9), 155.8 (C-11), 164.3 (C-8 );
16
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7.3 Experimental to Chapter 5 
General Procedure C1
A solution of 2-t-butoxycarbonyloxyimino-2-phenylacetonitrile (BOC-ON) 
(1.2 equiv.) in 1,4-dioxane (1 ml/ mmol amino acid) and water (1 ml/ mmol 
amino acid) was added to a stirred solution of the amino acid (1 equiv.) in 
distilled triethylamine (3 equiv.). The solution became homogeneous and 
was stirred at rt for 2 h. Water (1.3 ml/ mmol amino acid) and EtOAc (1.6  ml/ 
mmol amino acid) were added and the aqueous layer was washed with 
EtOAc. The aqueous layer was acidified (pH 4) using 5% citric acid and 
extracted using EtOAc (3x50 ml). The combined organic extracts were 
dried (Na2 S0 4 ) and concentrated in vacuo to give the N-BOC aminoacid.
General Procedure C2
A solution of the A/-BOC amino acid (1 equiv.) and NEt3 (1.2 equiv.) in 
acetonitrile was cooled to -5 °C (ice bath). 'Butylchloroformate (1 .2  equiv.) 
was added and the resulting brightly coloured solution was stirred for 5  min. 
The appropriate amine (5 equiv.) was added and the solution stirred at 0 °C 
for 2 h. The solvent was removed in vacuo and the residue was partitioned 
between EtOAc and water. The aqueous layer was extracted with EtOAc 
(3x50 ml) and the combined organic extracts were dried (Na2 S 0 4 ) and 
concentrated in vacuo to yield the crude product. Purification was 
achieved, where possible, through recrystallization from EtOAc.
General Procedure C3
The N-BOC amide was stirred in 3 mol dm-3 HCI/ EtOAc (1:1) for 30 min. 
The solvents were removed in vacuo to give a clear oil which solidified 
upon trituration in dry ether to give the amide as the hydrochloride salt.
General Procedure C4
A solution of the A/-BOC amino acid (1 equiv.) and NEt3 (2.4 equiv.) in 
acetonitrile ( 8  ml/ mmol amino acid) was cooled to -5 °C (ice bath). 
'Butylchloroformate (1.2 equiv.) was added and the solution was stirred for 
5 min. The amide hydrochloride salt (1.1 equiv.) was added portionwise 
and the resulting solution was stirred for 2 h. Solvent was removed in vacuo 
and the resulting solid partitioned between EtOAc and water. The organic 
phase was separated and the aqueous layer was extracted with EtOAc 
(3x50 ml). The combined organic phases were dried (Na2 S 0 4 ) and
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concentrated in vacuo to yield the crude product which was recrystallized 
from EtOAc.
General Procedure C5
To a suspension of the amino amide hydrochloride salt (1 equiv.) in dry 
THF was added a solution of BH3  in THF (1 mol dm'3 , 8  equiv.). The 
resultant mixture was heated at reflux for 24 h and then cooled to rt. 6  mol 
dm ' 3 HCI was added slowly to the solution until no more H2 was evolved 
and THF was removed by distllation at atmospheric pressure. MeOH and 
c.HCI were added to the residue and the solvents were removed in vacuo 
to yield the crude product. This was recrystallised from dry methanol to 
afford the desired polyamine hydrochloride salt.
/V-(2-Cyanoethyl)-4-(t-butoxycarbonylamino)butanamide 216
4-(t-Butoxycarbonylamino)butanoic acid 108 (3.04 g, 14.8 mmol) was 
stirred in MeCN (100 ml) and NEt3 (4 ml, 2  equiv.). 'BuOCOCI (2.3 ml, 1 .2  
equiv.) was added followed by 3-aminopropionitrile (4 ml, 4 equiv.) 
according to general procedure C 1 and gave a cherry pink solution. After 
work up a thick yellow oil was isolated which crystallized overnight. 
Recrystallization from EtOAc-hexaneane yielded 216 as pale cream 
crystals (2.4540 g, 9.6 mmol, 65 %), mp96.4-98.5 °C; Rf 0.51 (EtOAc); 
Vmax(KBr)/crrr1 3343 (N-H), 3300 (N-H), 2873 (-CH2-), 2247 (CN), 1699 
(C=0), 1644 (C=0), 1549 (C=0); 8 h (200 MHz, CDCI3 ) 1.45 (9H, s, 7-H3), 
1.61 (2 H, m, 3-H2), 2.27 (2 H, t, J7 .0, 2-H2), 2.65 (2 H, t, J 6.4, 9-H2), 3.18 
(2 H, q, J 6.3, 4-H2), 3.50 (2 H, m, 8 -H2), 4.97 (1 H, bt, J 5.6, NH), 7.28 (1 H, 
bs, NH); 8 C (50 MHz, CDCI3 ) 19.6 (CH2 -3), 19.4 (CH3 -7), 26.4 (CH2 -2),
28.4 (CH2 -9), 33.3 (CH2 -4), 35.5 (C-6 ), 39.5 (CH2 -8 ), 116.4 (C-10), 157.6 
(C-5), 173.0 (C-1); m/z (El) 256 (M+, 2 . 2  %), 199 (60), 182 (33), 154 (33), 
139 (21), 112 (100), 84 (23) and 57 (40), (Found: M+, 256.1649. 
C 1 2H2 2 N3 O3 requires 256.1636).
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A/-(2-Cyanoethyl)-4-aminobutanamide Hydrochloride 218
4 2 M 7
H 3 N  Y  6 f N
Cl o
216 (2 . 0 0 2  g, 7.8 mmol) was stirred in 3 mol drrr3 HCI (15 ml) and EtOAc 
(15 ml) according to general procedure C3. The hydrochloride salt 218 
was isolated as a hygroscopic solid and was used without purification, $h 
(200 MHz, CDCI3) 1.70 (2H, m, 3-H2>), 2 . 1 2  (2H, t, J7A,  2-H3), 2.36 (2 H, t, J 
6 .6 , 7-H2), 2.76 (2H, t, J 7.4, 4-H2), 3.19 (2 H, t, J 6.5, 6 -H2); 8 c  (50 MHz, 
CDCI3 ) 23.8 (CH2 -3), 33.2 (CH2 -2 ), 35.3 (CH2 -7), 36.5 (CH2 -4), 39.6 (CH2- 
6 ), 1 2 0 . 2  (C-8 ), 170.2 (C-1 ).
A tte m p te d  p re p a ra t io n  of N  - (2  - C y a n o e t h y I ) - 4 - 
benzylaminobutanamide 220
8
Crude nitrile 218 (1.49 g, 7.8 mmol) and benzaldehyde (0.8 ml, 1 equiv) 
were heated at relux in MeOH (20 ml) for 2 h. NaBH4  (0.36 g, 1.2 equiv) 
was added portionwise and the mixture was heated at reflux for 2  h before 
leaving at rt overnight. The solution was concentrated in vacuo to give a 
cream solid which was dissolved in H20  (10 ml) and made basic pH 12 
using NaOH (s). The aqueous layer was extracted with CHCI3  (3x10 ml) 
and the combined organic extracts dried (Na2 S 0 4 ), filtered and 
concentrated in vacuo to yield a yellow oil which contained a complex 
mixture of products.
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N-Benzyl-1,4-diaminobutane 225174
8
225 was prepared as a colourless oil according to the procedure of 
Bergeron et al. in 90 % yield. 1H, 13C and IR were identical with literature 
values. (Found: M+, 178.1462. C1 1H1 6N2 requires 178.1454)
A/-(2-Cyanoethyl)-1,4-diaminobutane 226128
226 was prepared according to the procedure of Israel et al. to yield a clear 
oil in 60 % yield. IR and bp [lit 84-87 °C, 0.7 mmHg] were consistent with 
published data.
Attempted preparation of /V -B e n zy l-A /'- (2 -c y a n o e th y l)-1 ,4 -  
diaminobutane 223
11
Attempt 1: 226 (0.7784 g, 5.52 mmol) was heated at reflux in CHCI3 (100 
ml) with benzaldehyde (0.56 ml, 1 equiv.). After 2 h the solution was 
concentrated in vacuo and dissolved in MeOH (100 ml). NaBH4  (0.3 g, 1.2 
equiv.) was added portionwise and the mixture left at rt overnight. Work up 
was as for 166 and gave a complex mixture of products.
Attempt 2: To a stirred solution of 225 (0.51 g, 286 mmol) was added 
acrylonitrile (0.19 ml, 1 equiv.) dropwise at 0  °C. The solution was stirred at 
rt for 18 h and concentrated in vacuo to give a thick oil which by TLC 
contained inseparable products.
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Attem pted syntyhesis of N -B enzy l-N -tr if luoroacety l-1 ,4 -  
diaminobutane 227
Following the procedure of Barrett et al.175> 176 225 (0.5200 g, 2.92 mmol) 
was stirred in MeCN (15 ml) and p-toluenesulphonic acid (0.5557 g, 1 
equiv.) was added. The solution was concentrated in vacuo to give a clear 
oil which was dissolved in DCM (15 ml) and 18-C-6 (0.78 g, 1 equiv.) 
added. The solution was again concentrated in vacuo, dissolved in DCM 
(25 ml) and cooled to 0  °C. NEt3 (0.45 ml, 1.1 equiv.) was added followed 
rapidly by TFAA (0.44 ml, 1.06 equiv.) and the solution was stirred at rt 
overnight. The solution was concentrated in vacuo and purification 
attempted by silica gel chromatography, eluent DCM:MeOH:NH4 0  H 
(17:2:1). Further purification was attempted however the desired product 
was difficult to obtain without contamination.
/V-Benzyl-AT-(t-butoxycarbor»ylamino)-1,4-diaminobutane 228174
228 was prepared according to the procedure of Bergeron and co-workers 
on a 2.2 mmol scale in 55% yield. 1H data was identical to published 
results. Vmax(KBr)/crrr1 3426 (N-H), 3335 (N-H), 2930 (-CH2-), 1707 (C=0), 
1686 (C=0), 1542 (Ar C=C), 1470 (Ar C=C), 1390 (C(CH3)3), 754 (Ar C-H), 
700 (Ar C-H); 6 c  (50 MHz, CDCI3) 23.4 (CH2), 26.9 (CH2), 28.2 (CH3), 48.5 
(CH2), 51.4 (CH2), 128.9 (CH), 129.0 (CH), 129.6 (CH), 131.7 (C); m/z (El) 
278 (M++1, 3%), 221 (28), 205 (14), 187 (12), 176 (1), 160 (10), 120 (46), 
106 (31) and 91 (100), (Found: (CI/NH3 ) M++1, 279.2079 C i6 H2 7 N2 0 2 
requires 279.2086).
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/V-Benzyl-AMrifluroacetyl-AT-(t-butoxycarbonylamino)-1,4- 
diaminobutane 229
228 (0.2556 g, 0.91 mmol, 1 equiv.) was stirred in MeOH (1 ml) and 
ethyltrifluroacetate (0.14 ml, 1.1 equiv.) added and the resulting solution 
was stirred for 48 h at rt before concentrating in vacuo to give a thick yellow 
oil. Purification was acheived by silica chromatography, eluent EtOAc, to 
yield 229 as a thick yellow oil (0.1814 g, 0.48 mmol, 53%), Rf 0.8 (EtOAc); 
Vmax(CDCI3 )/cm - 1 3456 (N-H), 3035 (Ar-H), 2979 (-CH2-), 1688 (C=0), 
1573 (Ar C=C), 1508 (Ar C=C), 735 (Ar C-H), 678 (Ar C-H); Sh (200 MHz, 
CDCI3) 1.35 (9H, s, -H3), 1.39-1.66 (4H, bm, -H2), 2.29 (2H, m, -H2), 3.24 
(2 H, m, -H2), 4.54 (2H, d, J 6.5, -H2), 4.60 (1 H, bt, NH), 7.20 (5H, m, -H); Sc 
(50 MHz, CDCI3) 23.6 (CH2-), 25.3 (CH2-), 27.1 (CH2-), 28.2 (CH3-), 45.9 
(CH2-), 48.1 (CH2-), 50.5 (CH2-), 127.1 (CH), 127.9 (CH), 128.1 (CH), 128.8 
(CH), 128.9 (CH), 134.7 (C), 155.9 (C); m/z (CINH3) 392 (M++NH4, 3%), 
336 (100), 320 (98), 301 (1), 276 (12), 246 (1), 2 2 1  (1 ), and 96 (6 ), (Found: 
M++NH4, 392.2175 C-|8H2 gN3 0 3 F3 requires 279.2086).
/V-Benzyl-AMrifluroacetyl-1,4-diaminobutane 230
229 (0.1776 g, 0.47 mmol) was stirred in EtOAc (1 ml) and 3 moldm-3 HCI 
(1 ml) for 1 h. The solution was concentrated in vacuo to giuve a thick oil 
which was triturated with Et20  to give a white powdery solid (0.0590 g, 
65%), vmax(CDCI3 )/cm-i 3427 (NH3+), 3032 (Ar-H), 2950 (-CH2-), 1680 
(C=0), 1605 (Ar C=C), 1560 (Ar C=C), 1497 (Ar C=C), 755 (Ar C-H), 701 (Ar 
C-H); 5h (200 MHz, D2 0 ) 1.27 (4H, bm, -H2), 2.62 (2H, m, -H2), 3.06 (1H, 
bm, -H2), 3.22 (1H, t, J 7.1, -H2), 4.38 (2H, s, -H2), 7.00 (2H, m, -H), 7.14 
(3 H, m, -H); Sc (50 MHz, CDCI3) 23.7 (CH2-), 24.6 (CH2-), 24.8 (CH2-),
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25.5 (CH2-), 39.8 (CH2-), 47.3 (CH2-), 48.4 (CH2-), 50.9 (CH2-), 51.8 (CH2- 
), 114.5 (C), 120.1 (C), 128.2 (CH), 128.8 (CH), 129.0 (CH), 129.6 (CH),
135.7 (CH), 136.1 (CH); m/z (El) 274 (M+-1, 4.8%), 273 (M+-2, 0.9%), 257 
(12), 244 (4), 231 (2), 218 (6 ), 205 (15), 202 (8 ), 177 (11), 166 (16) and 91 
(100), (Found: M+-1, 274.1291. C 1 3 H1 7 N2 OF3 requires 274.1289; M+-2, 
273.1222. C i3 H1 6N2OF3 requires 273.1229.
/V-Benzoyl-A/'-(2-cyanoethyl)-1,4-diaminobutane 234
A/,/V'-Carbonyldiimidazole (0.57 g, 1 equiv) was stirred in dry DCM with 
benzoic acid (0.43 g, 1 equiv) for 1 h. 226 (0.51 g, 3.55 mmol) was added 
and the solution was stirred overnight. DCM (10 ml) was added and the 
solution washed with 1 mol dm_3 NaOH and H20  before drying (Na2C 0 3), 
filtering and concentrating in vacuo to yield a glassy solid. Purification was 
achieved via silica chromatography, eluent EtOH, to yield a white solid 
(0.2908 g, 1.27 mmol, 33 %), vmax(KBr)/cnr1 3050 (Ar C-H), 2937 (-CH2-), 
2858 (N-CH2), 1603 (Ar C=C), 1579 (Ar C=C), 1524 (Ar C=C), 766 (Ar C-H 
bend), 6 8 8  (Ar C-H bend); 8 h (200 MHz, CDCI3) 1.49-1.62 (4H, m, 2,3-H2), 
2.45 (2H, t, J 6 .6 , 4-H2), 2.61 (2H, t, J 6 .6 , 6 -H2), 2.84 (2H, t, J 6 .6 , 5-H2), 
2.77 (1 H, s, NH), 3.39 (2H, q, J6 .4, 1-H2), 7.31 (4H, m, 11,12-H), 7.78 (2 H, 
m, 10-H); 8 c  (50 MHz, D20 ) 18.3 (CH2 -3), 26.9 (CH2 -2), 27.1 (CH2 -4), 39.6 
(CH2 -6 ), 44.7 (CH2 -5), 48.4 (CH2 - 1 ), 118.8 (C-7), 126.9 (CH-10), 128.4 
(CH-1 1 ), 131.2 (CH-12), 134.5 (C-9), 167.0 (C-8 ); m/z (El) 245 (M+, 91%), 
218 (10), 205 (35), 176 (8 ), 163 (28), 134 (37), 105 (100) and 77 (60), 
(Found: M+, 245.1526. C i4 HigN3 0  requires 245.1523).
Attempted preparation of A/-(2-Amidinoethyl)-A/'-benzoyl-1,4- 
diaminobutane Dihydrochloride 233
195
Following the procedure of Moss et a / . 180  2 mol dirr^ MesAI in toluene 
(1.01ml, 3.4 equiv) was added dropwise to a solution of NH4 CI (0.12 g, 3.6 
equiv) in toluene (2 ml), under N2 , and stirred for 2 h. The nitrile (0.3210 g, 
1 . 8 6  mmol) in toluene (1 ml) was added dropwise and stirred at 70-80 °C 
overnight. The mixture was poured onto a slurry of silica gel (0.7 g) in 
CHCI3 ( 2  ml) and stirred for 5 min before filtering. The silica was washed 
with MeOH and the filtrate concentrated in vacuo. The residue was 
redissolved in MeOH (1 ml) and filtered to remove NH4 CI. To the MeOH 
solutionwas added c.HCI (5 drops) and the solution concentrated in vacuo 
to give a complex mixture of products.
A/-(2-Dimethylaminoethyl)-4- 
(t-butoxycarbonylamino)butanamide 217
108 (3.02 g, 14.7 mmol) was stirred in MeCN (100 ml) and NEt3 (4 ml, 2  
equiv). iBuOCOCI (2.3 ml, 1 . 2  equiv) was added followed by N,N- 
dimethylethylenediamine (6.4 ml, 5 equiv) according to general procedure 
C1 and gave a orange solution. After work up a thick yellow oil was 
isolated, however no crystallization occurred. Purification was achieved 
using alumina chromatography, eluent hexaneane:EtOAc (4:1) (0.5735 g,
2 .1  mmol, 14 %), vmax(KBr)/cm- 1 3452 (N-H), 2980 (-CH2-), 2779 (N-CH2), 
1706 (C=0), 1659 (C=0), 1508 (C=0); 8 h (200 MHz, CDCI3 ) 1.36 (9H, s, 7- 
H3), 1.74 (2 H, m, 3-H2), 2.10 (2 H, t, 2 -H2), 2.17 (6 H, s, IO-H3 ), 2.36 (2 H, t, J
6.2, 9-H2), 3.06 (2H, q, J6.1, 4-H2), 3.26 (2H, q, 8 -H2), 5.62 (1H, bs, NH), 
7.28 (1H, bs, NH); 8 c  (50 MHz, CDCI3 ) 26.0 (CH2 -3), 28.4 (CH3 -7), 33.6 
(CH2 -2 ), 36.6 (CH2 -9), 39.7 (CH2 -4), 39.9 (CH2 -8 ), 45.1 (CH3 -IO), 156.3 
(C-5), 172.8 (C-1); m/z (Cl isobutane) 274 (M+H+, 20%), 218 (8 ), 200 (6 ), 
173 (0.5), 147 (6 ), 130 (5.5), 71 (26) and 58 (70), (Found: M+H+, 274.2128. 
C i3 H2 8 N3 0 3  requires 274.2125).
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A/-(2-Dimethylaminoethyl)-4-aminobutanamide 219
"'v ir
4 2 H 6 7
h 2n
o
217 (0.5735 g, 2 .1  mmol) was stirred in 3 mol dm-3  HCI (7 ml) and EtOAc (7 
ml) according to general procedure C3. The hydrochloride salt was taken 
up in water (10 ml), made basic with NaOH (s) (pH14) and extracted with 
DCM (2x10 ml). The combined organic extracts were dried (K2 C O 3 ), 
filtered and concentrated in vacuo to yield 219 as a clear oil (0.2754 g, 
1.75 mmol, 83 %), vmax(CHCI3 )/cn r1 3444 (N-H), 2979 (-CH2-), 2493 
(NH2), 1657 (C=0), 1511 (C=0); 5h ( 2 0 0  MHz, CDCI3 ) 1.40-1.60 (4H, m, 3- 
H2> NH2), 1.93 (6 H, s, 7 -H3 ), 2.00 (2H, t, J 7.2, 2-H2), 2.10 (2H, t, J 6.3, 4- 
H2), 2.43 (2H, 4-H2| J 6 .8 , 6 -H2), 2.99 (2H, m, 5-H2), 6.67 (0.65 H, bs, NH), 
7.33 (0.35H, bs, NH); §C (50 MHz, CDCI3 ) 29.6 (CH2 -3), 33.7 (CH2 -2 ), 36.9 
(C H 2 -4), 41.5 (CH2 -6 ), 45.2 (CH3 -7), 58.0 (CH2 -5), 173.0 (C-1 ); m /z  
decomposes.
Attempted preparation of A / - (2 -d im e th y l -a m in o e th y l ) -4 -  
benzylaminobutanamide 221
219 (0.27 g, 1.72 mmol) and benzaldehyde (0.17 ml, 1 equiv) were heated 
at relux in MeOH ( 6  ml) for 2 h. NaBH4  (0.066 g, 1.1 equiv) was added 
portionwise and the mixture was heated at relux for 2  h before leaving 
overnight. Work up was according to the procedure for 220 to yield a 
complex mixture of products.
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/VjN'-Bis-fS-amidinopropylJ-A/jAr-dibenzyl-l^-diaminobutane  
Tetrahydrochloride 235
NH
NH
NH
NH
4CI
Following the general procedure of Moss et a / . 180  2 mol dm"3 Me3AI in 
toluene (3.2 ml, 3.4 equiv) was added dropwise to a solution of NH4 CI (0.36 
g, 3.6 equiv) in toluene (3 ml), under N2 , and stirred for 2 h. The nitrile 187 
(0.6937 g, 1.86 mmol) in toluene (1 ml) was added dropwise and stirred at 
70-80 °C overnight. The mixture was poured onto a slurry of silica gel (1 g) 
in CHCI3 (2  ml) and stirred for 5 min before filtering. The silica was washed 
with MeOH and the filtrate concentrated in vacuo. The residue was 
redissolved in MeOH (1 ml) and filtered to remove NH4 CI. To the MeOH 
solution was added c.HCI (5 drops) and the solution was concentrated in 
vacuo to yield the hydrochloride salt as a yellow powder (0.2770 g, 0.67 
mmol, 40 %), mp >200 °C; vmax(KBr)/cm- 1 3060 (Ar C-H), 1689 (C=N), 
1624 (Ar C=C), 1496 (Ar C=C), 746 (Ar C-H bend), 700 (Ar C-H bend); 5h 
(200 MHz, D20 ) 1.58 (4H, bm, 2,3-H2), 2.72-3.40 (12H, m, 1,4,5,6-H2), 4.24 
(4H, s, 8 -H2), 7.33 (10H, m, 10,11,12-H); 6 c  (50 MHz, D2 0 ) 21.1 (CH2-2 
and -3), 28.0 (CH2-), 50.0 (CH2-). 52.3 (CH2-), 58.4 (CH2-), 129.1 (C-9),
130.3 (CH-), 131.2 (CH-), 131.7 (CH-), 167.0 (C-7).
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/V,Ar-Bis-(2-hydroxyethyl)-A/,A/'-dibenzyl-1,4-diaminobutane
238148
238 was prepared according to the procedure of Lee et al. to yield the 
desired alcohol in 60% yield. 1H and 13C NMR spectra were identical with 
literature values and 238 was used without further purification.
JV,Ar-Bis-(2-phthalimidoethyl)-A/,Ar-dibenzyl-1,4-diaminobutane
239
To a stirred solution of 238 (0.7487 g, 2.1 mmol) in THF (15 ml) was added 
triphenylphosphine (1 . 1 0  g, 2 . 2  equiv) and phthalimide (0.62 g, 2 . 2  equiv). 
DEAD (0.79 ml, 2.2 equiv) was added dropwise to produce a yellow 
solution which was stirred at rt for 12 h. The solution was concentrated in 
vacuo and the resulting oil triturated in Et2 0 :hexaneane (1:1). After filtration 
the filtrate was concentrated in vacuo and the oil purified by silica column 
chromatography, eluent hexaneane:EtOAc (3:1) (0.1513 g, 0.25 mmol, 15
10
O
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%), Rf 0.63 (hexaneane:EtOAc); vmax(KBr)/cm- 1 2982 (-CH2 -), 2872 (N- 
CH2), 1773 (C=0), 1707 (0=0), 1613 (ArC=C), 1494 (ArC=C), 1466 (-CH2- 
), 739 (Ar C-H bend), 697 (Ar C-H bend); 8 h (200 MHz, CDCI3 ) 1.27 (4H, 
m, 2,3-H2), 2.32 (4H, m, 1,4-H2), 2.55 (4H, t, J6 .2 , 5-H2), 3.41 (4H, s, 11- 
H2), 3.62 (4H, t, J 6.2, 6 -H2), 7.04 (10H, m, 13,14,15-H), 7.58 (4H, m), 7.67 
(4H, m); 8 c  (50 MHz, CDCI3 ) 24.6 (CH2 - 2  and -3), 36.0 (CH2 -1 and -4),
51.1 (CH2 -6 ). 53.7 (CH2 -5), 58.2 (CH2 - 1 1 ), 123.0 (CH-15), 126.6 (CH-13),
127.9 (CH-9), 128.8 (CH-14), 132.2 (C-8 ), 133.6 (CH-10), 139.5 (C-1 2 ),
168.1 (C-7); m/z (El) 614 (M+, 11.8 %), 523 (36), 454 (42), 333 (46), 319 
(8 ), 174 (55), 160 (19) and 91 (100), (Found: M+, 614.2868. C3 8 H3 8 N4 O4 
requires 614.2843).
A/,A/'-Bis-(2-dimethylaminoethyl)-succinyldiamide 
Dihydrochloride 237
NH
Succinyl dichloride (1 g, 6.45 mmol) was stirred in dry ether (20 ml) at 0 °C 
and /V,/V-dimethylethylenediamine (1.6 ml, 2.2 equiv) was added slowly. 
The resulting precipitate was filtered and recrystallised from EtOH:MeOH 
(4:1) to yield 237 as white crystals (2.42 g, 5.67 mmol, 8 8  %), mp >200 °C; 
Vmax(KBr)/cnr1 3433 (N-H), 3263 (N-H), 2944 (-CH2-), 1657 (C=0), 1535 
(C=0), 961 ((E)-C=C, C-H bend); 8 h (200 MHz, D2 0 ) 2.39 (4H, s, 2,3-H2),
2.74 (12H, s, 7 -H3 ), 3.12 (4H, t, J 5.8, 6 -H2), 3.41 (4H, t, J 5.8, 5-H2); 8c  (50 
MHz, D20 ) 31.1 (CH2-2 and -3), 35.3 (CH2 -6 ), 43.0 (CH3 -7). 57.4 (CH2 -5); 
m/z (El) 258 (M+ -2H, 2.6 %), 215 (1), 200 (2), 188 (37), 171 (1.3), 144 (0.6), 
117 (2.3), 98 (1.4), 71 (15) and 58 (100), (Found; M+-2 H, 258.2042. 
C i2 H2 6 N4 <D2 requires 258.2028).
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A/,A/'-Bis-(2-dimethylaminoethyl)-1,4-diaminobutane 236
Attempt 1: 237 was heated at reflux in THF with 1 mol dnrr3 BH3 in THF 
according to general procedure C5. The product isolated was extremly 
impure and difficult to purify.
Attempt 2 : 1,4-Dibromobutane (5.0 g, 23.16 mmol) was stirred in MeCN (20 
ml) and NEt3 (15 ml, 6  equiv.) followed by N,N-dimethylethylenediamine 
(5.3 ml, 2.2 equiv.) were addded. The solution was stirred at rt for 18 h and 
then filtered and the filtrate concentrated in vacuo. A number of methods of 
purification were attempted however Kugelrohr distillation was only 
successful on a small scale to yield 236 as a clear oil (3.33 g, 12.743 mmol, 
55%), bp 60-65 °C (1mm); Vmax(CDCI3 )/cn r1 3263 (N-H), 2955 (-CH2-); 5h
1 ,4,5,6-H2); Sc (50 MHz, CDCI3 ) 23.0 (CH2 - 2  and -3), 45.5 (CH3 -7), 54.0 
(CH2 -I and -4). 54.1 (CH2 -6 ), 58.3 (CH2 -5); m/z (El) 262 (M+, 5.0 %), 218 
(1 ), 174 (6 .2 ), 146 (0 .8 ), 118 (4.3), 84 (2 0 ) and 58 (100), (Found: M+, 
262.4868. C-|2 H3oN4 0 2 requires 262.4870).
Af,A/'-Bis-(cyanomethyl)-A/,A/'-dibenzyl-1,4-diaminobutane 241
240 (0.5446 g, 1.60 mmol) was stirred in CHCI3  (15 ml) and Hunigs base 
(1.22 ml, 4.4 equiv.) was added. Bromoacetonitrile (0.49 ml, 2.2 equiv.) 
was added dropwise and the solution stirred at rt for 18 h. The solution was 
washed with water (2x40 ml) and the organic extracts were dried (K2C0 3 ),
(200 MHz, CDCI3 ) 1.37 (4H, m, 2,3-H2), 1.84 (12H, s, 7-H3), 2 . 1 2  (1 2 H, m,
10
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filtered and concentrated in vacuo to give a cream solid which was 
recrystallized from EtOAc-hexaneane to yield 241 as fine cream needles 
(0.3887 g, 1.12 mmol, 70 %), mp 81.9-83.6 °C; vmax(KBr)/cm-1 3030 (Ar-H), 
2948 (-CH2-), 2780 (N-CH2), 2230 (CN), 1601 (Ar C=C), 1492 (Ar C=C), 
748 (Ar-H bend), 697 (Ar C-H bend); 8 h (200 MHz, CDCI3) 1.50 (4H, m,
2,3-H2), 2.51 (4H, m, 1,4-H2), 3.31 (4H, s, 5-H2), 3.41 (4H, s, 7-H2), 3.62 
(4H, t, J 6.2, 6 -H2), 7.14 (4H, m, 9-H), 7.23 (6 H, m, 10,11-H); 8 c  (50 MHz, 
CDCI3 ) 24.5 (CH2-2 and -3), 41.2 (CH2 -1 and -4), 53.4 (CH2 -5). 58.4 (CH2- 
6 ), 114.8 (C-6 ), 127.7 (CH-1 1 ), 128.6 (CH-9), 128.9 (CH-10), 137.2 (CH-8 ); 
m/z (El) 346 (M+, 70.9%), 319 (5), 306 (4), 280 (2), 255 (3), 228 (7), 160 
(18), 138 (7) and 91 (100), (Found: M+ 346.2161; C, 76.35; H, 7.37; N, 
16.21. C2 2 H2 6 N4  requires 346.2165; C, 76.25; H, 7.57; N, 16.18).
N ,/V'-Bis-(2-aminoethyl)-A/,W '-dibenzyl-1,4-diaminobutane 242
11
Following general procedure B3 241 (0.4487 g, 1.29 mmol) was reduced 
using UAIH4 (0.30 g, 6  equiv.) and AICI3 (1.03 g, 6  equiv.) to yield the 
tetraamine as a clear oil (0.3629 g, 1.03 mmol, 80 %), vmax(CDCl3 )/cnr1 
3019 (Ar-H), 2400 (N-H), 1522 (Ar C=C), 744 (Ar C-H), 670 (Ar C-H); 8 h 
(200 MHz, CDCI3 ) 1.20 (4H, m, 2,3-H2), 1.35 (4H, m, 1,4-H2), 2.32 (8 H, m, 
5-H2 and NH2), 2.57 (4H, t, J5 .8 , 6 -H2), 3.42 (4H, s, 7-H2), 7.19 (10H, m, 
9,10,11-H); 8c (50 MHz, CDCI3 ) 24.8 (CH2-2 and -3), 39.7 (CH2-1 and -4),
53.7 (CH2 -5). 57.0 (CH2 -6 ), 58.8 (CH2 -7), 126.7 (CH-11), 128.1 (CH-9),
128.7 (CH-10), 139.7 (CH-8 ); m/z (CI/NH3 ) 355 (MH+, 100%), 325 (0 .1 ), 
313 (0.5), 267 (0.4), 222 (0.2), 203 (0.4), (Found: MH+ 355.2854, 
C2 2 H3 5 N4  requires 355.2847).
202
A/,A/'-Dibenzyl-/\/,A/'-bis-(2-dimethylaminoethyl)-1,4-
diaminobutane Tetrahydrochloride 243
11
10
g
j)JH
+
Attempt 1: Following the procedure of Wright182 236 (0.2677 g, 1.16 mmol) 
in THF ( 6  ml) was added to a stirred solution of UAIH4  (0.22 g, 5 equiv.) in 
THF ( 6  ml) and stirring continued for 30 min. Ethyl benzoate (1 ml, 6  equiv.) 
was added dropwise and the solution heated at reflux for 18 h. H2 O (0 . 2  
ml), 6  mol dm*3 (0 . 6  ml) and H2 O (0 . 6  ml) were added and the residue 
filtered and washed with THF. THF was removed by distillation at 
atmospheric pressure and the residue converted into the hydrochloride salt 
by general procedure A2 . NMR analysis showed starting material only.
Attempt 2: To a stirred solution of 236 (0.1599 g, 0.69 mmol) in methanol 
was added PhCHO (0.16 ml, 2 . 2  equiv.) with stirring. The reaction was 
monitored by TLC and no imine formation was observed.
Attempt 3: To a stirred solution of 236 (0.3426 g, 1.5 mmol) in MeCN (10 
ml) was added Hunigs base (0.55 ml, 2.2 equiv.) and benzyl bromide (0.37 
ml, 2.2 equiv.). A number of inseparable products were observed by TLC.
Attempt 4: Following the procedure of Kim192  et al. 242 (0.3547 g, 1.00 
mmol) was stirred in MeOH and 37 % aqueous formaldehyde (5.0 ml, 6.4 
equiv.) added. A solution of NaCNBH3 (0.1260 g, 2 equiv.) and ZnCl2 
(0.136 g, 1 equiv.) in MeOH ( 6  ml) was added and a white emulsion 
appeared after addition was complete. The solution was stirred at rt for 4 h 
before addition of 0.1 mol dm"3 NaOH (15 ml) and concentrating in vacuo. 
The residue was partitioned between H2 O (10 ml) and EtOAc (10 ml) and 
extracted with EtOAc (3x20 ml). The organic extracts were washed with 
H2 O (10 ml) and brine (10 ml) then dried (K2 CO3 ), filtered and concentrated
203
in vacuo to yield a yellow oil 214 (0.2511 g, 0.61 mmol, 61 %), §h (200 
MHz, CDCI3) 1.37 (4H, m, 2,3-H2), 2.01 (1 2 H, s, 7-H3), 2.14-2.28 (8 H, m, 
1 ,4,6-H2), 2.45 (4H, m, 5-H2), 3.47 (4H, s, 7-H2), 7.20 (1 0 H, m, 9,10,11-H); 
5c (50 MHz, CDCI3 ) 24.7 (CH2 - 2  and -3), 45.9 (CH3 -7), 51.9 (CH2 -1 and 
-4), 54.1 (CH2 -5), 57.6 (CH2 -6 ), 59.0 (CH2 -7), 126.7 (CH-1 2 ), 128.0 (CH-9 ),
128.7 (CH-10), 139.8 (CH-8 ). The tetrahydrochloride salt was prepared 
according to general procedure A2 to yield 243 as a white powder, 
Vmax(KBr)/cnrr1 3423 (N-H), 2955 (-CH2-), 1618 (Ar C=C), 1496 (Ar C=C), 
748 (Ar C-H deform.), 702 (Ar C-H deform); 5h (200 MHz, D2 0 ) 1.75 (4H, 
m, 2,3-H2), 2.87 (1 2 H, s, 7-H3), 3.23 (4H, m, 5-H2), 3.58 (8 H, m, 1,4,6-H2), 
4.41 (4H, s, 7-H2), 7.48 (10H, m, 9,10,11-H); 5c (50 MHz, D2 0 ) 21.0 (CH2- 
2  and -3), 43.9 (CH3 -7), 47.5 (CH2 -1 and -4), 51.5 (CH2 -5), 53.0 (CH2 -6 ),
58.7 (CH2 -7), 126.7 (CH-1 2 ), 128.0 (CH-9), 128.7 (CH-10), 139.8 (CH-8 ); 
m/z (Cl/ isobutane) 412 (M+-2 H, 30.4%), 411 (M+-3, 100%), 352 (2 .5 ), 307 
(0.5), 262 (0.2), 233 (0.4) and 179 (1.8), (Found: M+-2H 412.3522, 
C 26 H 4 4 N 4  requires 412.3478; Found: M+-3H 411.3491, C2 6 H4 3 N4  
requires 411.3488).
N , N , N N '-Tetraethyl-4,4l-biphenyldicarboxamide 246
4,4'-Biphenyldicarboxylic acid (2 g, 8.26 mmol) was stirred in MeCN (35 ml) 
with diethylamine ( 1 0  ml, 1 0  equiv) according to general procedure C2  to 
give an orange oil which solidified on standing. Purification was achieved 
using alumina chromatography with EtOAc as eluent to give 246 as fine 
white crystals (1.00 g, 2.89 mmol, 35 %), Rf 0.66 (EtOAc); mp 137.4-138.7 
°C; Vmax(CDCI3 )/cm - 1 3054 (C-H), 2976 (C-H), 2935 (-CH2-), 1622 (C=0 
amide), 1503 (Ar C=C), 845 (Ar C-H bend); 5h (2 0 0 MHz, CDCI3 ) 1.18 
(12H, bs, J 7.3, 7,7'-H3), 3.55 (8 H, bd, 6 ,6 '-H2), 7.31 (4H, d, J 8.0, 2,2'-H), 
7.47 (4H, d, J 8.0, 3,3 -H); 5c (50MHz, CDCI3 ) 12.8 (CH3 -7), 14.1 (CH3 -7'),
39.1 (CH2 -6 ), 43.2 (CH2 -6 '), 126.8 (CH- 2  and 2 '), 126.9 (CH-3 and 3'),
136.3 (C-4 and 4'), 140.9 (C-1 and 1'), 170.8 (C-5 and 5'); m/z (El) 352 
(M+, 40%), 280 (100), 251 (9.4), 180 (55), 152 (41) and 91 (32), (Found:
204
M+, 352.2168; C 74.84; H 8.02; N 7.87. C2 2 H2 8 N2 O2  requires 352.2151; 
C 74.95; H 8.01; N 7.95; O 9.08).
Bis-(diethylaminomethyl)-4,4'-biphenyl Dihydrochloride 248
1 Mol dm-3 BH3  in THF (5.6 ml, 8  equiv) was added dropwise to a solution 
of 246 (0.2452 g, 0.69 mmol) in THF (3 ml) under N2 and heated at reflux 
for 24 h following general procedure C5. The resulting solid was 
recrystallized from ethanol-ether to give the dihydrochloride as cream 
crystals (0.1789 g, 0.45 mmol, 65 %), mp 244.0-244.9 °C; vmax(KBr)/cm"1 
3487 (O-H), 3027 (Ar-H), 2934 (-CH2-), 2756 (N-CH2), 1614 (Ar C=C), 1503 
(Ar C=C), 764 (Ar C-H bend), 695 (Ar C-H bend); 8 h (200MHz, MeOD) 0.96 
(1 2 H, t, J 7.3, 7,7'-H3), 2.81 (8 H, q, J7 .2 , 6 ,6 '-H2), 3.99 (4H, s, J 8.3, 5,5'- 
H2), 7.28 (4H, d, J 8.3, 3,3'-H), 7.35 (4H, d, J 8.4, 2,2'-H); 8 c  (50MHz, 
MeOD) 7.1 (CH3 - 7  and 7'), 45.9 (CH2 - 6  and 6 '), 54.7 (CH2-5 and 5'), 126.8 
(CH- 2  and 2'), 128.6 (C-1 and 1'), 130.9 (CH-3 and 3'), 140.7 (C-4 and 4'); 
m/z (El) 324 (M+-2H, 19.5%), 252 (100), 180 (42.6), 118 (20) and 8 6  (14), 
(Found: M+-2H, 324.2562. C2 2 H3 2 N2 O2 requires 324.2565).
205
/V,A/,-Bis-(4,4-diethoxybutyl)-4,4'-biphenyldicarboxamide 250
Following general procedure C3 4,4'-biphenyldicarboxylicacid (0.9632 g,
4.13 mimol) was stirred with 4-aminobutyraldehyde diethylacetal (3.6 ml, 5 
equiv.). The white solid was recrystallised from EtOH-EtOAc to yield 250 
as a spongy white solid (0.85 g, 1.66 mmol, 40 %), mp 158.1-159.4 °C; 
Vmax(CHCI3)/cm-i 3457 (N-H), 2978 (Ar C-H), 2957 (-CH2-), 1627 (Ar C=C), 
1560 (C=0), 1420 (Ar C=C), 863 (C-H Ar deform.); 8 h (2 0 0 MHz, CHCI3)
I . 2 0  (12H, t, J 7.0, 1 2 ,1 2 '-H3), 1.74 (8 H, m, S , ^ ^ - ^ ) ,  3.51 (8 H, m,
I I ,1 1 '-H 2), 3.70 (4H, m, 7,7'-H2), 7.36 (4H, d, J 8.2, 2,2'-H), 7.55 (4H, d, J 
8 .2 , 3,3'-H); 5c (50MHz, CHCI3) 15.4 (CH3-12 and 12'), 24.5 (CH2 - 8  and 
-8 ' or -9 and -9'), 31.1 (CH2 - 8  and -8 ' or -9 and -9'), 39.8 (CH2-11 and -11'),
61.5 (CH2-7 and -7'), 102.7 (CH-10 and -10'), 127.1 (CH-2 and -2 '), 127.6 
(CH-3 and -3'), 128.2 (C-4 and -4'), 142.7 (-1 and 1'C), 167.1 (C-5 and -5'); 
m/z (El) 348 (M+-40Et, 3%), 322 (44), 276 (1 0 0 ), 180 (87), 152 (44) 104 
(37), 90 (17) and 76 (21) (Found: M+-40Et, 348.1798. C2 2 H2 4 N2 0 2 
requires 348.1803).
206
A tte m p te d  p rep ara tio n  of N , A/’ -B i s - ( 4 - o x o b u t y  I ) - 4 , 4 1 - 
biphenyld icarboxam ide 251
Attempt 1 : 250 (0.20 g, 0.38 mmol) was stirred in CHCI3 at 0 °C and 99 % 
TFA (0.15 ml) in H2 O (0.15 ml) added dropwise. Stirring continued for 1 h 
and the solution was then made basic, NaOH(s), and extracted with DCM. 
No product was observed by NMR spectra.
Attempt 2: Water (11 drops) was added to a suspension of silica gel (3 g) in 
DCM ( 8  ml). After 2min 250 (0.3008 g, 0.57 mmol) was added with stirring 
and left for 1 h. Silica was filtered and washed well with DCM and the 
organic layer was concentrated in vacuo. No product was observed by 
NMR spectra.
H
O
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N,N  -Bis-(4-diethylaminobutyl)-4,4,-biphenyldicarboxamide 254
11
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4,4'-Biphenyldicarboxylic acid (0.5g, 2.06 mmol) was stirred at reflux in 
thionyl chloride ( 8  ml) for 1 h and the solution was concentrated in vacuo. 
The residue was taken up in dry ether (10 ml) and stirred at 0 °C before the 
careful addition of 145 (1.2 g, 4 equiv) in dry ether (5 ml). 3 Mol dm-3 HCI 
(10 ml) was added and the aqueous layer washed with ether. The aqueous 
was made basic with NaOH (s) (pH14) and extracted with CHCI3 (3x10 ml). 
The organic extracts were combined, dried (Na2 S 0 4 ), filtered and 
concentrated in vacuo to give a grey/cream solid which was recrystallized 
from CHCl3 /hexaneane to yield 254 (0.4887 g, 1.06 mmol, 51 %), 8 h 
(2 0 0 MHz, CDCI3 ) 0.98 (1 2 H, t, J7.1, 11,11"-H3), 1.64 (8 H, m, 7,7',8,8'-H2), 
2.49 (1 2 H, m, 9,9\10,10'-H2), 3.45 (4H, m, 6 ,6 ’-H2), 7.50 (2 H, d, J 8 .2 , 2 ,2 '- 
H), 7.81 (4H, d, J 8.2, 3,3'-H), 7.84 (2H, t, J 5 .3, NH); 8 c  (50MHz, CDCI3 )
11 .2 (CH3 -1 1 and 11'), 24.9 (CH2-7 and 7' or 8  and 8 '), 27.6 (CH2-7 and T  
or 8  and 8 '), 40.1 (CH2-9 and 9'), 46.6 (CH2-10 and 10'), 52.3 (CH2-7 and 
7 '), 126.8 (CH- 2  and 2'), 127.7 (CH-3 and 3'), 134.2 (C-4 and 4'), 142.4 (C- 
1 andl'), 167.4 (C-5 and 5'); m/z (El) 494 (M+, 1.4%), 351 (5), 276 (3.7), 
180 (9.7), 152 (4.9) and 8 6  (100), (Found: M+, 494.3628. C3 0 H4 6 N4 O 2 
requires 494.3636).
208
A/;/V',-Bis-(4-diethylaminobutylaminomethyl)-4,4l-biphenyl
Tetrahydrochloride 252
u
NH)
11
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31 2’
4CI
Following general procedure C5 254 (0.4887 g, 1 mmol) in THF (5 ml) and 
1 mol dm-3 BH3  in THF (8  ml, 8  equiv) yielded 252 (0.34 g, 0.64 mmol, 64 
%), mp >247.6-249.1 °C decomp.; vmax(KBr)/cnr1 3420 (N-H), 3030 (Ar C- 
H), 2940 (-CH2 -), 1502 (Ar C=C), 840 (C-H Ar bend); 5h (2 0 0 MHz, D2 0 )  
1.06 (12H, t, J 7.3, 1 1 ,ir -H 3), 1.58 (8 H, m, 7,7',8,8'-H2), 2.98 (16H, m, 
e ^ '^ ^ 'J O J O '-H ^ , 4.08 (4H, s , 5,5'-H2), 7.36 (4H, d, J 8.2, 3,3'-H), 7.55 
(4H, d, J 8.2, 2,2'-H); 8 c  (50MHz, D2 0 ) 9.0 (CH3-11 and 11'), 21.5 (CH2-7 
and 7' or 8  and 8 '), 23.6 (CH2-7 and 7' or 8  and 8 '), 47.1 (CH2-9 and 9'),
48.1 (CH2-10 and 10'), 51.5 (CH2 - 6  and 6 '), 51.6 (CH2-5 and 5'), 128.5 
(CH- 2  and 2 '), 131.0 (C-1 and 1'), 131.3 (CH-3 and 3'), 141.6 (C-4 and 4'); 
m/z (El) 466 (M+-4H, 0.4%), 322 (12), 180 (63), 144 (100) 1 1 2  (54), and 99 
(26), (Found: M+-4H, 466.4031. C3 0 H5 0 N4  requires 466.4027).
209
A/,A/,-B is-(2-dim ethylam inoethyl)-4,4'-biphenyldicarboxam ide
255
\  /  8 
N
This was prepared as for 254 using 4,4'-biphenyldicarboxylic acid (1.0g,
4.13 mmol) and heated at reflux in thionyl chloride (15 ml) for 1h and the 
solution was concentrated in vacuo. The residue was taken up in dry ether 
( 1 0  ml) and stirred at 0  °C before the careful addition of N ,N -  
dimethylethylenediamine (1.8 ml, 4 equiv) in dry ether (5 ml). Work up was 
as for 254 to yield 255 as peach crystals (0.7936 g, 2.10 mmol, 51 %), mp 
221.2-222.5 °C; vmax(KBr)/cnrr1 3315 (N-H), 3067 (N-H), 3018 (Ar-H), 2941 
(-CH2-), 2795 (N-CH2), 1635 (C=0), 1610 (Ar C=C), 1556 (C=0), 1490 (Ar 
C=C), 841 (ArC-H bend); 8 h (2 0 0 MHz, CDCI3) 2.29 (1 2 H, s, 8 ,8 '-H3), 2.55 
(4H, t, J 7.2, 7,7'-H2), 3.54 (4H, dt, J7.1, 5.3, 6 ,6 '-H2), 7.00 (2H, t J5.4, NH), 
7.65 (4H, d, J 8.05, 2,2'-H), 7.89 (4H, d, J 8.05, 3,3'-H); 5c (50MHz, CDCI3)
37.2 (CH2 -7), 45.2 (CH3 -8 ), 57.7 (CH2 -6 ), 127.2 (CH-2 ), 127.7 (CH-3),
133.7 (C-4), 142.9 (C-1), 167.0 (C-5); m/z (Cl) 383 (MH+, 100%), 377 
(0.05), 300 (0.4), 279 (0.15), 223 (0.1), 177 (0.15) and 157 (0.32), (Found: 
MH+, 383.2442. C2 2 H3 1 N4 0 2 requires 383.2437).
210
A/,A/',-Bis-[2-(dimethylaminoethylaminomethyl)]-4,4,-biphenyl
Tetrahydrochloride 256
\  /  8 
+ NH
Following general procedure C5 255 (0.5311 g, 1.40 mmol) in THF (10 ml) 
and 1 mol dm-3 BH3 in THF ( 1 2  ml, 8  equiv) yielded 256 (0.3857 g, mmol, 
%), mp 250.5-252.1 °C; vmax(KBr)/cm- 1 3337 (O-H), 2953 (-CH2-), 2671 (- 
NH+), 1605 (Ar C=C), 1563 (Ar C=C), 1498 (Ar C=C), 831 (Ar C-H bend); 
§H (200MHz, D2 0 ) 2.90 (12H, s, 8 ,8 '-H3), 3.41 (8 H, s, 6,6',7,7'-H2), 4.20 
(4H, s, 5,5'-H2), 7.41 (4H, d, J 7.6, 2,2'-H), 7.89 (4H, d, J 7.5, 3,3'-H); 8 q  
(50MHz, D2 0 ) 42.0 (CH3 - 8  and -8 '), 44.2 (CH2 - 6  and -6 '), 52.2 (CH2 - 8  and 
-8 ’), 53.3 (CH2-7 and -7'), 128.7 (CH-3 and -3'), 130.5 (C-1 and -1'), 131.5 
(CH-2 and -2'), 141.7 (C-4 and -4'); m/z (CI/NH3 ) 356 (M+-2H), 355 (M+- 
3 H), 309 (0.5), 280 (0.8), 267 (0.3) and 208 (0.1), (Found: M+-2H, 
356.2891. C22H 3 6 N4  requires 356.2842; Found: M+-3H, 353.2704. 
C2 2 H3 3 N4  requires 353.2703).
211
N,N'-Dibenzyl-4,4'-biphenyIdicarboxamide 247
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4,4-Biphenyldicarboxylic acid (1.06 g, 4.36 mmol) was stirred at reflux in 
thionyl chloride (15 ml) for 1h as for 254 and benzylamine (2.7 ml, 6  equiv) 
was added to the residue in dry ether. The precipitate was filtered and 
washed with ether to yield 247 as a white solid (1.6152 g, 8 8  %), however 
crystallisation failed due to the insoluble nature of this compound, mp >250 
°C; vmax(KBr)/cm-1 3305 (N-H), 3060 (Ar C-H), 3020 (Ar C-H), 2920 (-CH2), 
1635 (Ar C=C), 1635 (C=0), 1605 (Ar C=C), 1560 (C=0), 1490 (Ar C=C), 
840 (Ar C-H bend); 8 h (200MHz, D6 -DMSO) 4.56 (4H, d, J 5.3, 6 ,6 "-H2), 
7.38 (1 0 H, m, 8,8',9,9',10,10'-H), 7.90 (4H, d, J 7.7, 2,2'-H2), 8.09 (4H, d, J 
7.7, 3,3'-H2), 9.26 (2H, t, J  5.4, NH); 8 c  (50MHz, D6 -DMSO) 42.7 (CH2 - 6  
and 6 '), 126.7 (CH-10 and 10'), 127.3 (CH- 8  and 8 '), 128.1 (CH - 2  and 2'),
128.4 (CH-3 and 3'), 128.7 (CH-9 and 9'), 133.7 (C-4 and 4'), 139.8 (C-7 
and 7‘), 141.8 (C-1 and 1'), 165.8 (C-5 and 5'); m/z (El) 421 (M+1 , 33%), 
420 (M+, 100%), 419 (M+-1, 20%), 316 (85), 210 (4), 180 (27), 152 (14) and 
91 (2 2 ), (Found; M+1 421.1892, C2 8 H25 N2 0 2 requires 421.1868; Found: 
M+ 420.1830; C, 79.79; H, 5.82; N, 6.76. C2 8 H2 4 N2 0 2 requires 420.1822; 
C, 79.96; H, 5.75; N, 6 .6 6 . Found: M+-1 419.1757, C2 8 H2 3 N2 0 2 requires 
419.1754).
212
Attem pted preparation of A/,y\Z,-D ib e n z y la m in o m e th y l-4 ,4 l- 
biphenyl Dihydrochloride 249
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Due to the extremely insoluble nature of the diamide 247 attempts to 
reduce it using borane/THF as in general procedure C5 failed.
A/-Benzoyl-A/'-(3-benzoylam inopropyl)-1,4-diam inobutane
25716  0
This was prepared according to the procedure of Moss et at. in 50 % yield. 
1H, 13C and IR spectra were identical with published data, mp 129.1-131.0 
°C [lit. 129.5-130.5 °C]; (Found: M+, 353.2108; C, 65.82; H, 4.68; N, 11.25. 
C2 1H27N3O3 requires 353.2113; C, 65.98; H, 4.70; N, 11.42).
213
A/,A/'-Bis-(4-benzoylaminobutyl)-Bis-(3-benzoylaminopropyl)-
1,4-xylylenediamine 258
22
o
NH
N
HN
13
HN
14
a.oc'-Dibromo-p-xylene (0.2065 g, 0.78 mmol) was heated at reflux in DMF 
(10 ml) with 257 (0.6448 g, 2.2 equivl) and Na2 0 O3 (0.2 g, 2.2 equiv) for 24 
h. The solution was concentrated in vacuo, 2  mol dm-3 NaOH (10 ml) 
added and the solution extracted into EtOAc (3x10 ml). The combined 
organic extracts were dried (K2 CO 3 ), filtered and concentrated in vacuo 
and the product was recrystallised form EtOAc to yield 258 as a cream 
solid (0.2950 g, 0.37 mmol, 21  %), mp 126.5-128.5 °C; vmax(KBr)/cm- 1 
3315 (N-H), 3060 (N-H), 2940 (-CH2), 2858 (-CH2-), 1637 (C=0), 1602 (Ar 
C=C), 1578 (Ar C=C), 1541 (C=0), 1489 (Ar C=C), 849 (Ar C-H bend), 766 
(Ar C-H bend), 695 (Ar C-H bend); 8 h (200MHz, CDCI3 ) 1.57 (12H, bm, 
7,8,16-H2), 2.45 (8 H, bt, 6,15-H2), 3.38 (4H, bm, 9,17-H2), 3.44 (4H, s, 5- 
H2), 6.93 (2H, t, J 5.2, NH), 7.12 (4H, s, 2,3-H), 7.38 (1 2 H, m, 13,14,21,22- 
H), 7.56 (2H, t, J5.3, NH), 7.74 (8 H, m, 12,20-H); 8 c  (50MHz, CDCI3 ) 24.5 
(CH2-7 or - 8  or -16), 26.6 (CH2-7 or - 8  or -16), 27.3 (CH2-7 or - 8  or -16),
39.5 (CH2 - 6  or -15), 39.8 (CH2 - 6  or -15), 52.4 (CH2-9 or -17), 53.4 (CH2-9 
or -17), 58.9 (CH2 -5) , 127.0 (CH-2  and -3), 128.3 (CH-12 and -20), 128.4 
(CH-13 and -2 1 ), 129.2 (CH-14 and -2 2 ), 134.8 (C-1 and -4), 138.2 (C-11
214
and -19), 167.6 (C-10 and -18); m/z (FAB) 810 (MH+, 10%), 646 (1.7), 499 
(0.7), 455 (47), 352 (5), 169 (2 2 ), 121  (8 ), 105 (100) and 77 (29), (Found: 
MH+, 809.4717. C5oH6 iN 6 0 4  requires 809.4680).
N, /V,-B is -(4 -ben zy la m in o b u ty l)-B is -(3 -b en zy lam in o p ro p y l)-1 ,4- 
xylylenediam ine Hexahydrochloride 259
22
NH
+ 4
NH
This was prepared following general procedure C5 heating at reflux 258 
(0.3004 g, 0.37 mmol) and 1 mol dm-3 BH3 in THF ( 6  ml, 16 equiv) in THF (4 
ml) to yield 259 hexaneahydrochloride as a white powder (0.1970 g, 0.22 
mmol, 57%), mp>200 °C; vmax(KBr)/cnr1 3423 (N-H), 2948 (-CH2), 2746 (- 
CH2-), 1629 (Ar C=C), 1584 (Ar C=C), 1498 (Ar C=C), 766 (Ar C-H bend), 
695 (Ar C-H bend); 8 h (200MHz, CDCI3 ) 1.58 (8 H, bm, 7,8-H2), 1.99 (4H, 
bm, 16-H2), 2.91-3.02 (16H, bm, 6,9,15,17-H2), 4.04 (8 H, ds, 10,18-H2), 
4.24 (4H, s, 5-H2), 7.28 (20H, s, 12,13,14,20,21,22-H), 7.41 (4H, s, 2 ,3 -H); 
8 c  (50MHz, CDCI3 ) 21.4 (CH2-7 or - 8  or -16), 23.5 (CH2-7 or - 8  or -16),
44.6 (CH2-7 or - 8  or -16), 47.0 (CH2-9 or -17), 50.1 (CH2-9 or -17), 51.9 
(CH2 - 6  or -15), 52.1 (CH2 - 6  or -15), 52.7 (CH2-10 and -18), 57.4 (CH2 -5),
130.2 (CH), 130.6 (CH), 131.2 (CH), 131.5 (C), 131.6 (C), 132.9 (CH); m/z
215
(FAB) 753 (M+-5H, 6 6 %), 663 (15), 389 (0.5), and 326 (34), (Found: M+- 
5H, 753.5636. C5 0 H6 8 N6 requires 753.5686).
7.4 Experimental for Chapter 6
Pyridine-2,6-dicarboxamide 265199
HoN
O O
NH,
265 was prepared on a 1.0034 g, 6.0 mmol scale following the procedure 
of McKendrickto yield the product in 0.666 g, 67 % yield. 1H, 13C and IR 
spectra were identical with those reported, (Found M+, 165.0539. 
C7H7N3O2 requires 165.0541).
Pyridine-2,6-dinitrile 266199
NC N CN
266 was prepared on a 0.6654 g, 4.04 mmol scale following the procedure 
of McKendrick to yield the product in 0.1377 g, 27 % yield. 1H, 13C and IR 
spectra were identical with those reported, mp 129.5-131 °C [lit 128-131 
°C]; (Found M+, 129.0327. C7 H3 N3 requires 129.0330).
Pyridine-2,6-ditetrazole 2 6 7 1 "
N N N
N' N N- N
267 was prepared on a 0.5100 g, 3.88 mmol scale following the procedure 
of McKendrick to yield the product in 0.7551 g, 90 % yield. 1H, 13C and IR
216
spectra were identical with those reported, mp >300 °C [lit. >300 °C]; 
(Found M+, 215.0670. C7 H5 N9 requires 215.0669).
1,4-Bis(2'form ylphenyl)-1,4-dioxabutane 270203
/  \
270 was prepared according to the procedure of Armstrong and Lindoy on
a 200 mmol scale in 57% yield. 1H, 13C and IR spectra were consistent with
I published data, mp 126.1-127.7 °C [lit. 129 °C], (Found M+, 270.0889.
C1 6H14O4  requires 270.0886).
j
5,6 ,7 ,8 ,9 ,10,16,17O ctahydrodibenzo[e,m ][1,4]dioxa[8,11]diazac  
I yclotetradecine 271201
i
HN NH 
\  /
271 was prepared according to the procedure of Grimsley and co-workers 
on a 3.7 mmol scale in 32% yield. 1H, 13C and IR spectra were consistent 
with published data, mp 151.3-152.8 °C [lit. 169 °C], (Found M+, 298.1680. 
C1 8 H2 2 N2 O2 requires 298.1679).
217
7,8,16,17-Tetrahydrodibenzo[e,m ][1,4 ,8 ,11]dioxadiaza  
cyclotetradecine-6,9[5H,10H]dipropanam ide 272202
/  \
272 was prepared according to the procedure of Chia and co-workers on a
1.34 mmol scale in 37% yield, mp 149-151 °C [lit. 151-153 °C]. 1H, 13C 
and IR spectra were consistent with published data.
A t t e m p t e d  p r e p a r a t i o n  of  7 , 8 , 1 6 , 1 7 -
Tetrahydrodibenzo[e,m ][1,4 ,8 ,11]dioxadiaza  
cyclotetradecine-6,9[5H ,10H]bis(3-am inopropyiam ine)273
/  NH?
H2N
272 (0.22 g, 0.5 mmol) was refluxed in 1 mol dnrr3 BH3/THF (4 ml, 8  equiv.) 
according to general procedure C5 however only black residue was 
recovered with a large amount of aliphatic residues present by NMR. 
Purification was unsuccessful.
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